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SCOPE OF THE THESIS 
The majority of patients with cystic fibrosis (CF) suffer from chronic infections of Pseudomonas 
aeruginosa that are hardly eradicated from lungs. Its long persistence is associated with sophisticated 
mechanisms of adaptation, including biofilm formation, resistance to antibiotics, hypermutability and 
customized virulence factors expression. One of the hallmarks of P. aeruginosa adaptation to CF lungs is 
its diversification in an extensive number of phenotypes specially adapted to CF environment, called as 
clonal diversification, ensuring bacteria survival and infection persistence. By this reason, P. aeruginosa 
infections in CF disease are associated with poor patient outcomes.  
The gold standard of CF disease management is the eradication of P. aeruginosa from airways as soon 
as detected in order to avoid or, at least, to retard the establishment of chronic infections preserving lung 
function. To achieve a successful eradication, it is need understanding the adaptation mechanisms used 
by P. aeruginosa for antimicrobial agents target them. Otherwise, re-infection and antibiotic resistance 
episodes will continue occur. A lot of studies have been conducted over years about the genomic and 
phenotypic adaptations undergone by P. aeruginosa during chronic infections, in contrast to the less 
significant amount of studies concerning P. aeruginosa early adaptations. However, the early adaptations 
could be the key to considerably reduce the mortality and morbidity rates. Understanding the P. 
aeruginosa early adaptations in CF lungs it will be possible to design effective antimicrobial strategies and 
so to prevent antibiotic resistance, re-infection episodes and progression to chronic stages. As so, this 
project was designed and developed to respond to the central research question: which are the early 
adaptations undergone by P. aeruginosa after CF lungs colonization. P. aeruginosa during its residence 
in CF lungs can experience several environmental stresses and this question is quite complex and difficult 
to answer without considering several clinical scenarios. Therefore, this central research question was 
decomposed in several smaller research questions: what are the early adaptations undergone by P. 
aeruginosa 1) grown in CF lungs without antibiotic treatment; 2) grown in CF lungs and exposure to an 
early antibiotic treatment; 3) grown in CF lungs and exposure to a delayed antibiotic treatment; 4) are 
there disease markers indicators of P. aeruginosa early adaptation to CF lungs. The answers to these 
questions will introduce great improvements in CF disease management, in particular, helping to design 
an effective antimicrobial strategy to early eradicate P. aeruginosa infections and thus to prevent chronic 
infections development. 
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OBJECTIVES OF THE THESIS 
Microbiological studies have been focused on to determine the mechanisms underlying P. aeruginosa 
persistence and the development of chronic infections. In fact, antibiotic therapies are currently adequate 
according the gained information about chronic infections, but episodes of antibiotic and multidrug 
resistance and re-infection continue occurring. Therefore, attentions must be directed to early P. 
aeruginosa adaptation in order to block bacteria evolution and adaptation to cystic fibrosis (CF) lungs and 
consequently to avoid the development of chronic infections.  
Isolates of P. aeruginosa with differing colony morphology characteristics have been cultured from CF 
patients and considered a sign of clonal diversification. Some morphological traits, including colony size, 
texture and consistency, are indeed indicators of virulence factors expression, antibiotic resistance and 
even of the infection severity. Therefore, it was detected an opportunity to macroscopically monitor the 
clonal diversification of P. aeruginosa inside CF environment. The main goal of this PhD thesis was 
determine the evolutionary pathway followed by P. aeruginosa after CF lungs colonization in order to to 
find out the adaptation mechanisms underlying P. aeruginosa early adaptation and their driven forces. 
Moreover, it was aimed to verify the existence of disease markers of P. aeruginosa adaptations. 
Biomarkers discovery could have great impact on early P. aeruginosa infection diagnosis. To achieve 
these goals, eight key aims were established to draw the early P. aeruginosa adaptation: 
1) Standardize the experimental parameters that impact on colony morphology characterisation.  
2) Organize the vocabulary and update the concepts used to describe colony morphologies. 
3) Explore a molecular method in the detection and identification of P. aeruginosa colony 
morphology variants; 
4) Identify the specific colony-biofilm variants to further detect biofilm growth in CF environment; 
5) Identify the early adaptations undergone by P. aeruginosa and the driven forces; 
6) Determine the impact of antibiotic treatment timings and antibiotic concentrations in early P. 
aeruginosa eradication and the response of population against the different treatments;  
7) Identify the biomarkers associated with early P. aeruginosa adaptations.  
8) Construct a public database fully dedicate to bacterial colony morphologies and their phenotypic-
associated data.  
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OUTLINE OF THE THESIS 
The present thesis includes research work at Centre of Biological Engineering, University of Minho, 
Braga, Portugal and at BIOSCOPE group, University of Vigo, Ourense, Spain, under the supervision of 
Doctor Maria Olívia Pereira and Doctor Jose Luis Capelo, respectively. 
This thesis is organized into five chapters. Chapter 1 is a general introduction of cystic fibrosis (CF) 
airway disease and their microbial-associated infections. A particular description of the impact of P. 
aeruginosa infections in the context of CF, the in-use antibiotic therapies to eradicate these infections and 
the strategies used by P. aeruginosa to ensure its long-persistence in CF lungs is provided. In Chapter 2, 
some improvements introduced in colony morphology characterisation method at experimental procedure 
and lexicon levels are reported in order to overcome some limitations of this method. Chapter 3 focuses 
on the study of P. aeruginosa biofilm populations, in particular, it is reported the diversity and functionality 
of the sub-populations detected inside biofilms. In Chapter 4 some important research questions are 
answered: which are the early adaptation undergone by P. aeruginosa after CF lungs colonisation, the 
impact of antibiotic treatments on P. aeruginosa adaptation and the identification of early CF disease 
biomarkers. Chapter 5 describes the MorphoCol, a new ontology-based knowledgebase for the 
standardised, consistent and machine-interpretable description of the morphology of colonies formed by 
human pathogenic bacteria. The last chapter, Chapter 6, contains the major conclusions of this thesis 
and some suggestions of relevant research lines that should be addressed in near future in order to 
construct the overall picture of P. aeruginosa adaptation in CF lungs since colonization to the 
development of chronic infections. 
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ABSTRACT 
Pseudomonas aeruginosa infections are the major cause of high morbidity and mortality in cystic fibrosis 
(CF) patients. Despite the long and aggressive antibiotic treatments, P. aeruginosa still persists causing 
chronic infections. Its long-persistence is due to sophisticated mechanisms of adaptation, including clonal 
diversification into specialized CF-adapted phenotypes. While CF community awaits the development of 
effective therapies targeting conductance regulator mutations, the gold standard of CF disease 
management is the eradication of P. aeruginosa from CF lungs as soon as detected. Early eradication of 
P. aeruginosa avoids or, at least, retards the development of chronic infections preserving lung function. 
But to achieve a successful eradication, it is need understanding the early adaptations mechanisms used 
by P. aeruginosa for antimicrobial agents target them. Up to now these mechanisms are unclear. Being 
so, this project aimed to determine the early adaptations undergone by P. aeruginosa after CF lungs 
colonization and their driven forces in several clinical scenarios. 
Alterations in colony morphology are one of the indicators of clonal diversification of bacteria in CF lungs 
and are also associated with different virulence factors expression and antibiotic resistance. Therefore, it 
was take the advantage of this macroscopic feature of P. aeruginosa to monitor its evolution in CF 
environment after in vitro initial colonization. Despite its potential, colony morphology characterisation 
method exhibit has some restrictions, such as the unclear impact of the experimental parameters in 
colony morphogenesis and detection of colony diversity, variability of vocabulary and inconsistent 
concepts about morphological traits and the time to return results. Therefore, before analysing P. 
aeruginosa clonal diversification in CF environment, it was attempted to introduce some improvements on 
this method related to standardisation of the experimental parameters and vocabulary and speed up 
colony analysis in three different studies. The results of the first study demonstrated that all experimental 
parameters analysed, including colony growth time, colony density per plate, culture media, bacterial 
mode of growth and bacterial genetic background influenced colony morphogenesis and the detection of 
bacterial diversity. Therefore, a set of guidelines was created and proposed to clinical community in order 
to standardise the experimental parameters. Further, a morphological classification system to 
unambiguously characterise and describe bacterial colonies was constructed based on literature. The 
system was deeply tested and demonstrated to be accurate for bacterial colonies characterisation. The 
third study, it was aimed to introduce some quickness and high-throughput features to colony morphology 
characterisation verifying whether MALDI-TOF MS could distinguished morphotypes. MALDI-TOF MS 
colony classification did not totally match with manual colony characterisation, leading to conclude that 
MALDI-TOF MS provided additional information about colony variants not visible at naked eye. MALDI-
TOF MS cannot thus “replace” colony morphology method but rather complement it. 
The data obtained in the first study demonstrated that colony morphology characterisation could be used 
as a reliable method to detect biofilm-derived colony morphotypes. So, it was tried to find out a colony 
morphology variant characteristic of biofilm lifestyle, which could be used as a marker of P. aeruginosa 
biofilm growth and the development of chronic infections. The results revealed that biofilm population 
diversity was highly strain-dependent, hindering the unambiguous establishment of a colony variant 
marker of P. aeruginosa biofilms. Nonetheless, small colony variants (SCV) demonstrated to be a strong 
hint of biofilm growth. 
In order to investigate the early adaptations undergone by P. aeruginosa after CF lungs colonisation, 
bacteria grow in artificial sputum medium during ten days in the presence and absence of ciprofloxacin, 
an antibiotic often used in CF context. Data revealed that substantial phenotypic diversity is likely to be 
present in P. aeruginosa populations shortly after CF lungs colonization. Ciprofloxacin concentrations at 
this simulated early stage of disease demonstrated to play dose-dependent role. Inhibitory concentrations 
of ciprofloxacin, established based on the MIC of biofilm cell, were effective in bacterial eradication, in 
contrast to the sub-inhibitory doses that triggered P. aeruginosa diversification into new “fitter” variants. 
Impaired swimming motility was one of the first signs of adaptation noticed in all P. aeruginosa clonal 
variants, either in the presence or absence of ciprofloxacin. It was speculated that this adaptation was 
triggered by the environmental CF conditions due to the absence of mutators.  Being so, impaired 
swimming motility was considered a potential disease marker for early P. aeruginosa adaptation and 
infection development. It was also found that some colony morphology traits, including sheath, size and 
colour, could be useful indicators of antimicrobial resistance towards some antibiotics and of some 
virulence factors expression. 
During the development of this project the comparison of morphological traits and phenotypic data among 
colony morphotypes was a hard task.  So, to easily perform this kind of analyses it was created a new 
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ontology-based tool for the description of colony morphologies formed by bacteria, called MorphoCol. 
MorphoCol establishes and standardises in consistent way the minimum information necessary to 
describe colony morphotypes and also the phenotypic data related to the colony-forming bacteria. In near 
future, this knowledgebase will transform the findings of this project and upcoming results related to 
colony morphology variation into valuable information for clinical decision making. 
The overall data will have great impact on CF disease management because relevant improvements were 
introduced in the colony morphology characterisation method that will strengthen clinical diagnosis. Clonal 
diversification in CF lungs and other host sites could be now better monitored and accurately described. 
Moreover, the identification of a putative CF disease marker of early P. aeruginosa adaptation and 
infection development will also assist in the design of tailored effective antimicrobial therapies. 
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RESUMO 
Pseudomonas aeruginosa é a maior causa das elevadas taxas de morbidez e mortalidade associada a 
pacientes com fibrose cística (FC). Apesar dos longos e agressivos tratamentos com antibióticos, a P. 
aeruginosa persiste originando infecções crónicas. A sua longa persistência deve-se a sofisticados 
mecanismos de adaptação, designadamente a diversificação clonal em fenótipos altamente adaptados 
às condições de FC. Enquanto a comunidade médica aguarda pelo desenvolvimento de terapias eficazes 
direcionadas ao regulador mutacional de condutância, o standard terapêutico seguido é a erradicação da 
P. aeruginosa logo que detetada. A erradicação atempada da P. aeruginosa evita ou, pelo menos 
retarda, o desenvolvimento de infecções crónicas, preservando assim a função respiratória. Contudo, 
para obter a erradicação bacteriana é necessário perceber os mecanismos iniciais de adaptação da P. 
aeruginosa para que os agentes antimicrobianos os possam bloquear. Assim sendo, este projeto 
pretendeu determinar quais as adaptações iniciais da P. aeruginosa após colonização das vias 
respiratórias de pacientes com FC e as suas respetivas forças impulsionadoras para diversas situações 
clínicas.  
As alterações na morfologia de colónia é um dos indicadores de diversificação clonal das bactérias em 
ambiente de FC. Estas alterações estão igualmente associadas à expressão diferencial de factores de 
virulência e à resistência a antibióticos. Assim, utilizou-se esta característica macroscópica da P. 
aeruginosa para monitorizar a sua evolução e adaptação em ambiente FC. Apesar do seu potencial, a 
caracterização de morfologia de colónias apresenta algumas restrições, tais como o impacto incerto dos 
parâmetros experimentais na morfogénese das colónias e na detecção de diversidade de colónias, a 
variabilidade de vocabulário e conceitos inconsistentes sobre os traços morfológicos, e o tempo de 
obtenção de resultados. Assim, antes da análise da diversidade clonal da P. aeruginosa em ambiente 
FC, tentou-se introduzir alguns melhoramentos neste método em três diferentes estudos, nomeadamente 
na estandardização dos parâmetros experimentais e vocabulário, bem como acelerar a obtenção de 
resultados. Os resultados do primeiro estudo demonstraram que todos os parâmetros experimentais 
analisados (tempo de crescimento das colónias, densidade de colónias por placa de cultura, meio de 
cultura, modo de crescimento bacteriano e os antecedentes genéticos) influenciaram a morfogénese das 
colónias e na detecção de diversidade bacteriana. Assim sendo, foi elaborado e proposto um conjunto de 
linhas de orientação para estandardização dos parâmetros experimentais. Posteriormente, foi construído 
um sistema de classificação para inequivocamente caracterizar a morfologia de colónias com base na 
literatura. Este sistema foi amplamente testado e demonstrou-se adequado para a caracterização de 
colónias bacterianas. No terceiro estudo tentou-se introduzir alguma celeridade e aumento do débito de 
resultados verificando se MALDI-TOF MS seria capaz de distinguir os morfótipos. Esta técnica forneceu 
uma classificação dos morfótipos ligeiramente diferente comparativamente à classificação manual. Tal, 
leva a concluir que MALDI-TOF MS fornece informação adicional sobre os morfótipos que não foi 
observável macroscopicamente. Assim, o MALDI-TOF MS não pode assim “substituir” o método de 
caracterização manual de morfologia de colónias mas pode ser um método complementar. 
Os dados obtidos com o primeiro estudo demonstraram que a caracterização de morfologia de colónias 
pode ser usado na detecção de morfótipos derivados de biofilmes. Assim, tentou-se identificar um 
variante morfológico característico do crescimento em biofilmes que possa ser posteriormente usado 
para detectar este modo de crescimento e, consequentemente o desenvolvimento de infecções crónicas. 
Os resultados revelaram que diversidade população dos biofilmes foi dependente da estirpe, dificultando 
assim a identificação do variante morfológico característico de biofilme. Ainda assim, verificou-se que as 
small colony variants (SCV) são um forte indicador do crescimento séssil.   
De forma a investigar as adaptações iniciais da P. aeruginosa após colonização de vias respiratórias com 
FC, as bactérias foram crescidas em muco artificial (MA) na presença e ausência de ciprofloxacina 
durante 10 dias. Os resultados deste estudo revelaram que é provável a existência de diversidade 
fenotípica logo após a colonização das vias respiratórias. As diferentes concentrações de ciprofloxacina 
testadas demonstraram desempenhar uma ação dose-dependente. Concentrações inibitórias, 
estabelecidas com base na MIC de células de biofilme, foram eficazes na erradicação da P. aeruginosa 
em MA, contrariamente às concentrações sub-inibitórias. Estas concentrações “acionaram” a 
diversificação fenotípica em variantes melhor adaptados ao ambiente FC. A limitada capacidade de 
swimming foi um dos sinais de adaptação inicial da P. aeruginosa verificada em todos os variantes 
fenótipicos. Foi assim especulado que esta adaptação foi promovida pelas condições típicas de FC 
devido à ausência de mutators. Como tal, a capacidade limitada de swimming foi considerada um 
potencial marcador dos estágios iniciais do desenvolvimento de infecções em FC. Foi igualmente 
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verificado que alguns traço morfológicos de colónias, nomeadamente a bainha, tamanho e cor, foram 
indicadores de alterações na expressão de fatores de virulência e resistência a antibióticos.  
Durante o desenvolvimento deste projeto a comparação de traços morfológicos das colónias, bem como 
de dados fenótipos foi uma tarefa árdua. Neste sentido, foi desenvolvida uma base de dados, designada 
por MorphoCol, para a descrição de morfologia de colónias formadas por bactérias. MorphoCol 
estabelece e uniformiza a informação mínima necessária de uma forma estruturada e consistente. Num 
futuro próximo, esta base de dados transformará os resultados deste projeto e  outros subsequentes em 
informação relevante para a tomada de decisão clínica. 
O conjunto de resultados obtidos neste projeto terá um impacto considerável na gestão clínica da FC 
devido aos consideráveis melhoramentos introduzidos no método de caracterização de colónias pois 
fortalecerão o diagnóstico clínico. A diversificação clonal nas vias respiratórias de FC e nos outros locais 
pode ser assim melhor monitorizada e descrita adequadamente. Para além disso, a identificação de 
possíveis marcadores para estágios iniciais de adaptação de P. aeruginosa em FC ajudarão na definição 
de terapias antimicrobianas eficazes.  
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1.1. Cystic Fibrosis 
Cystic fibrosis (CF) is an autosomal recessive disease caused by a defect in the cystic fibrosis 
conductance regulator (CFTR) gene located in humans on chromosome 7. The CFTR depletion or 
malfunctioning affects mainly lungs, digestive and reproductive systems, but also secretory glands, such 
as the endocrine and sweat glands  [1, 2]. CF is thus a multi-system disorder causing several 
complications on the human body, but its effects on lungs are the best studied so far due to the severe 
symptoms that patients suffer and the high mortality rate associated to poor lung function  [3, 4].  
It is generally accepted that CFTR acts as a channel that pumps chloride from the intracellular to 
extracellular space through the membrane of the epithelial cells that produce sputum (Figure 1.1A). 
Several hypotheses have been formulated attempting to explain the relationship between CFTR deficiency 
and sputum accumulation. It has been considered that the transport of chloride partially controls water 
movement and consequently influences the production of thin and flowing sputum, fundamental to 
maintain the lungs protected  [1, 5]. The CFTR lack causes, thus, a defective chloride secretion creating 
an osmotic gradient that, consequently, provokes water hyper-reabsorption and abnormal thick and sticky 
sputum (Figure 1.1B)  [1, 6]. This sputum with altered pH interferes, reducing or even inhibiting, the 
activity of epithelial antimicrobial molecules of the innate immune system and the ciliary function, both 
crucial for homeostasis  [2]. 
Other functions are also associated with CTFR including inhibition of sodium absorption, which loss 
causes excessive sodium (and water) absorption, regulation of HCO3- and some proteins transport 
through epithelial cell membranes  [6, 7]. The relevance of the latter mechanisms in CF airways is unclear, 
however it is believed that reduced chloride secretion or sodium hyper-absorption can occur. Both 
mechanisms lead to airway-surface-liquid depletion and sputum viscosity increase causing impaired cilia 
beats and accumulation of thick dehydrated airway sputum, which profoundly accounts for the typical 
symptoms suffered by CF patients  [7, 8].  
Sputum retention leads to infection and consequently to inflammation, and this circle perpetuates itself 
since inflammatory products, such as elastase released by neutrophils, stimulate sputum secretion and 
breakdown  [6, 9]. In addition, CFTR mutation leads to dysregulation of various components of the innate 
immune system. In effect, CFTR has been considered a relevant receptor for internalization and further 
elimination of some bacteria, for instance Pseudomonas aeruginosa. Thus, its absence compromised the 
immune response  [2, 10]. The defective mucociliary transport and the compromised immune defences 
predispose CF patients to the establishment of recurrent bronchopulmonary infections. 
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Figure 1.1. Schematic model of transport of ions in normal and CF epithelia. (A) Normal expression of CFTR maintains the constant 
depth of periciliary liquid layer on top of the airway epithelia leading to efficient mucociliary clearance, at a rate of approximately 60 
µm s-1 (denoted by vector), by the ciliated cells. A normal rate of epithelial O2 consumption produces no O2 gradients within this thin 
airway surface liquid (denoted by white bar); (B) In the absence of CFTR, water, Na+ and Cl- are reabsorbed, removing the periciliary 
liquid layer. The globet cells underneath the epithelia hypersecreted sputum that becomes highly thickened due to the depletion of 
the periciliary liquid layer. This thick sputum adheres to the epithelium and reduce or stop sputum clearance (0 µm s-1). The 
ineffective mucociliary clearance and raised O2 consumption by CF epithelia result in hypoxic gradients within the sputum masses. 
The colour bars to the right of each diagram represent the O2 pressure, with increasing red colour presenting a progressively more 
anaerobic environment (Adapted from Hassett et al. (2009)  [11] and Worlitzsch et al. (2002)  [12]). 
 
1.2. Bacterial infections 
Bacterial infections pose a serious challenge in the care of CF patients. The accumulated sputum has 
nutrients being, thus, a good environment for microbial colonization  [13, 14]. CF lungs are infected with a 
complex microbial flora, mainly composed by bacteria, provoking acute and chronic infections that result in 
decline of the lung function, respiratory failure and premature death of patients  [15, 16]. Once bacterial 
infections are established, their eradication by antibiotic treatment is hardly achieved  [10, 15].  
For many decades, the microbiome of CF airways has been determined by culture methods focusing on 
the most commonly isolated organisms including P. aeruginosa, Staphylococcus aureus and Haemophilus 
influenzae. Advances in microbial diagnosis techniques have revealed that CF lungs are an environment 
much more richer than previously estimated and, most important, that many other opportunistic organisms 
are associated with the evolution of the airway disease in CF individuals  [17, 18]. Over the last decades, 
culture independent approaches, such as sequencing of bacterial 16S rRNA gene, have been identified 
more than 100 distinct genera, including commensal genera, gram negative such as Burkholderia cepacia 
complex (mostly B. multivorans and B. cenocepacia), Stenotrophomonas maltophilia, Achromobacter 
spp., and Inquilinus limosus; non-tuberculous mycobacteria; and fungal organisms, such as Aspergillus 
fumigatus  [17, 19, 20]. Viruses have been also detected, although their specific role in CF lung disease is 
still unclear  [21, 22]. 
The diversity of the CF microbiome varies over time. During childhood microbial diversity reaches its peak 
falling during the second decade of life when it is more frequently dominated by P. aeruginosa  [23, 24, 
25]. S. aureus and non-typeable H. influenza are prevalent in infections occurring during childhood and 
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then colonization by P. aeruginosa progressively increases as CF patients grow older  [19, 26, 27]. It has 
been proposed that S. aureus may somewhat prepare the CF environment to promote P. aeruginosa 
colonization and, by this reason, S. aureus pre-colonization has been considered a risk factor  [2, 28]. The 
end-stage (or the chronic stage) of CF airway disease is generally associated with reduced community 
diversity and dominance by a few antibiotic resistant pathogens such as P. aeruginosa and B. cepacia 
complex (Bcc)  [29]. Among the panoply of opportunistic bacteria that may colonize and infect CF lungs, 
P. aeruginosa is considered the most significant as it has evidently been linked to worsening of the lung 
and respiratory status  [30]. 
It is now clear that the different bacterial species coexisting in CF airways establish interactions, 
contributing to the pathogenesis of the disease and in driving a response to therapy  [16, 31]. Despite the 
documentation about this coexistence, very little is known about the interactions among species and their 
impact on severity and progression of infections. More studies are needed to understand how these 
microbial interactions are establish, how they affect the ecological balance of multispecies communities 
and the progression of disease. 
 
1.2.1. Pseudomonas aeruginosa 
As aforementioned, the microbial community resident in CF lungs is known to be complex and it has 
considerably changed mainly due to alterations in antibiotic regimens. Nevertheless, P. aeruginosa is still 
the most common pathogen isolated from CF sputum  [5, 15, 32].  
P. aeruginosa is a versatile microorganism, ubiquitously distributed in different environments, including 
terrestrial, aquatic, animal, human and plant  [33]. It is a Gram-negative opportunist pathogen in 
hospitalized or immune-compromised patients causing infections such as pneumonia, burn, wound, 
urinary tract and gastrointestinal infections, otitis media and keratitis  [32, 34, 35]. Its versatility arises from 
its largest genome with nearly 6000 genes that encloses, for instance, genes associated with diverse 
metabolic pathways, virulence factors, transport, efflux and chemotaxis conferring to P. aeruginosa great 
adaptive ability  [33, 34]. This human pathogen is intrinsically resistant to a wide range of antibiotics and 
frequently displays intrinsic multidrug resistance  [36, 37]. Moreover, this bacterium is able to coordinate 
metabolic pathways, optimize nutritional and reproductive potential according to the surrounding 
conditions and resources and, thus, it can survive, grow and cause infection in different environments  [34, 
38].  
The presence of P. aeruginosa in CF airways is highly associated with poor lung function, morbidity and 
mortality of patients. The longer a patient remains free of colonization with P. aeruginosa, the longer his 
life expectancy will be. The incidence of P. aeruginosa infections varies widely among CF centers but 
there is common increase of prevalence with age, being more prevalent in adults  [5, 32]. In the last years, 
P. aeruginosa was detected in 20-25 % of infants, 25-50 % of children aged 2-10 years and almost 80 % 
of young adults  [19, 26, 27]. 
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Despite the inflammatory response and the long-term and intensive antibiotic treatments, infections 
caused by P. aeruginosa persist in CF lungs. Once entering in CF airways, this bacterium is virtually 
impossible to eradicate due to its remarkable genome plasticity that allows rapid adaptation to the 
stressful CF environment  [5, 39, 40]. After P. aeruginosa colonization, patients may suffer of successive 
episodes of re-colonization until resulting in a chronic infection that can persist from years to decades or 
even never been eradicated  [40, 41].  
Several factors can influence the P. aeruginosa infection course in CF airways and, unfortunately, there is 
limited knowledge about the characteristics of this microorganism that have impact on the severity of 
infection. Until now, it is just known that during CF infection development P. aeruginosa switches from an 
acute environmental virulent pathogen, characteristic from early infection stages, to a CF-adapted 
pathogen typical from chronic infection stages  [9, 38, 42]. This switching is one of the most striking 
adaptive mechanisms used by P. aeruginosa to survive and grow in such complex environment as CF 
lungs. CF environment is a complex ecosystem due to the different conditions that bacteria may found, for 
instance, different oxygen concentrations, nutrient availability, other microbial species, oxidative stress, 
antibiotic treatments and immune defences. P. aeruginosa is able to generate progressively multiple 
phenotypes highly adapted to changing CF environment and their emergence and coexistence is the key 
factor for persisting in CF lungs for several decades or even an entire life  [42]. This intense diversification 
of the bacterial population is named of clonal diversification and supports the ‘Insurance Hypothesis’ which 
states that (more) diversity within a population maintains or enhances its functioning against a wide range 
of adverse environmental fluctuations  [43]. P. aeruginosa clonal diversification provides thus 
subpopulations resistant to the range of different CF stresses and able to colonize a variety of CF airways 
niches  [44, 45]. The role of each subpopulation generated by P. aeruginosa in CF airway is discussed in 
section 1.5. 
 
1.3. Antibiotic treatments 
Some treatment progresses were made in order to extend the life expectancy of CF patients, however it 
remains very reduced, around 38 years, mainly because of bacterial infections  [26, 27]. In the last 
decades, new therapies have emerged based on the knowledge of CFTR dysfunction and airway CF 
microbiome, such as targeting CFTR replacement, stimulation of alternative chloride channels, inhibition 
of sodium absorption and airway rehydration, in order to avoid sputum accumulation and, consequently, 
the establishment of bacterial infections  [6, 7, 8, 46]. None of those strategies has sufficient potential to 
stop CF infections development so far.  
The best strategy is certainly to prevent infection as late as possible mainly from acquisition of P. 
aeruginosa. The preventive procedures may include avoiding person-to-person contact and contacting 
with contaminated surfaces, which may lead to transmission and acquisition of microorganisms. As P. 
aeruginosa may survive in abiotic (or inanimate) surfaces for months [47, 48], cleaning and disinfection of 
the clinical settings, including rooms, clinical equipment and medical devices are thus important. Health 
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workers should practice hand hygiene and during hospitalization CF patients should be isolated to prevent 
transmission and acquisition of pathogens in particular P. aeruginosa and multi-resistant strains  [48].  
Although the prophylactic efforts, infections can still occur and the actual and more effective approach to 
fight CF-associated infections relies on antimicrobial treatment. Currently, there is not a consensual 
antimicrobial treatment to eradicate bacterial infections from CF lungs as treatments vary among clinics, 
countries and even continents  [49, 50]. Numerous strategies have been used varying in route of antibiotic 
administration (systemic, oral, inhaled antibiotics or route combination), classes of antibiotics and 
treatment duration (reviewed by Schelstraete et al. (2013)  [41]). Inhaled antibiotics, mainly 
aminoglycosides, have high successful rates in bacteria eradication, in particular against P. aeruginosa, 
due to the direct delivery of high-dose of antibiotic to the bronchial lumen space with limited systemic 
toxicity. A tobramycin inhalation solution has been used to treat long-term and chronic bacterial infections 
with significant benefits for lung function delaying re-infection and reducing mortality  [51, 52, 53]. Other 
inhaled antibiotics have been studied and have demonstrated efficacy against microbial infections, 
including colistin, gentamicin, ceftazidime, cephaloridine, aztreonam lysine, taurolidine, and a 
gentamicin/carbenicillin combination  [51].  
It is very common the treatment of CF-associated infections with combination of oral and inhaled therapies 
using two antibiotics with distinct modes of action. The quinolones, in particular ciprofloxacin and 
levofloxacin, are the most used as oral agents combined with inhaled tobramycin, aztreonam or colistin. 
Oral and intravenous antibiotics have also attracted interest, including the intravenous regimes of anti-
pseudomonal antibiotics β-lactams (pipercillin or ticarcillin), third- and fourth-generation cephalosporins 
(ceftazidime and cefepime), carbapenems (meropenem or imipenem), or monobactams (aztreonam), 
combined with an oral aminoglycoside (amikacin, gentamicin or tobramycin)  [49, 54, 55, 56].  
Even so, treatment of bacterial infections in CF lungs remains a challenge. Multiple factors may disturb the 
antibiotic action, including the nature of the drug, the microbial population resident in CF airways, host 
characteristics, patient adherence to the treatment and the timing of antibiotic treatment  [50, 57]. CF 
environment conditions represent as well a challenge to treat bacterial infections. Mucin and extracellular 
deoxyribonucleic acid (DNA), which are present in sputum, can interfere in antibiotic action. Biofilms are 
as well of special concern as the extracellular matrices restrict seriously the action of the majority of the 
antimicrobial agents (discussed later in section 1.4). Due to these limitations, other antibiotics have been 
introduced and used as alternative agents, such as inhaled amikacin, aerosolised levofloxacin (both have 
completed phase 3 trial) and the combination of fosfomycin and tobramycin (in phase 2 clinical trial)  [4, 
46, 49, 50].  
Regardless the antibiotic agent used, it is consensual that soon as infection is detected, an antibiotic 
treatment must be initiated. Some studies suggest a window of opportunity for successful eradication of 12 
weeks since primary detection of infection, however this period is not well defined  [58, 59]. At this stage, it 
is important to verify if patients are colonised by P. aeruginosa. If not, it is of upmost importance to delay 
the acquisition of P. aeruginosa since it is associated with worsening patient prognosis. Anti-pseudomonal 
antibiotic treatments could still be administrated to prevent P. aeruginosa acquisition but a prospective 3-
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year study demonstrated no differences in P. aeruginosa rate acquisition between a control and treatment 
group with oral ciprofloxacin and inhaled colistin  [60]. Therefore, the current status of antibiotic treatments 
does not recommend the prophylactic treatment with antipseudomonal antibiotics to prevent P. aeruginosa 
acquisition in CF individuals  [41, 50, 61]. For the cases of P. aeruginosa early colonization, it is 
recommended aggressive antibiotic treatments at early infection stage in order to eradicate bacteria from 
lungs and thus retard the establishment of chronic infection preserving lung function  [62, 63, 64]. The 
antibiotic treatment administrated to these CF patients early colonised with P. aeruginosa typically follows 
the scheme represented in Figure 1.2.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. Antibiotic treatment scheme after first detection (Adapted from Doring et al. (2012)  [50]). 
 
In general, it is prescribed a 3-week antibiotic treatment. In cases of treatment failure, the treatment is 
prolonged for more 28 days, however, there is no consensual treatment for P. aeruginosa infections  [41, 
50, 63]. In attempt to standardize early antibiotic treatments, it was performed two large multicentre 
studies, the Early Pseudomonas Infection Control (EPIC) program in the United States and the Early 
Inhaled Tobramycin for Eradication (ELITE) study in Europe. The EPIC trial consisted in randomized 
patients in four different antibiotic eradication strategies during 18 months: 1) tobramycin inhalation 
solution (TIS) combined with oral ciprofloxacin every 3 months; 2) TIS combined with oral placebo every 3 
months; 3) TIS combined with oral ciprofloxacin only when quarterly respiratory cultures were found 
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positive for P aeruginosa; 4) TIS combined with oral placebo only when quarterly respiratory cultures were 
found positive for P aeruginosa. The results published by the EPIC trial demonstrated that all patients 
groups exhibited similar successful eradication rates  [65].  
The ELITE study treated patients as well with twice-daily inhaled tobramycin 300 mg for 28 and 56 days 
and similar results were obtained for both patients groups. 93 % of patients were P. aeruginosa-free after 
one month and 63 % of patients were P. aeruginosa-free after 2 years.  [53]. From both studies it was 
concluded that adding ciprofloxacin to antibiotic regimes did not produce benefits in P. aeruginosa 
eradication rates. However, the Copenhagen CF center performed a long study during 20 years in which 
CF patients were treated with inhaled colistin and intravenous ciprofloxacin for 3 months. 80 % of the 
treated patients were P. aeruginosa-free for up 15 years and the bacterial isolates recovered showed 
reduced antibiotic resistance  [58, 66]. Other European CF center performed a similar study and obtained 
the same results  [62]. Although these controversial results, the main clinical practice is the combination of 
inhaled colistin and oral ciprofloxacin for 3-week to 3-month, which has demonstrated to be a successful 
approach  [66]. As inhaled colistin for 3 months with inhaled tobramycin for 1 month revealed results quite 
similar to the colistin/ciprofloxacin treatment, colistin/tobramycin is also a common treatment in 
hospitals  [67].  
The current European status of antibiotic eradication treatments does not recommend a particular strategy 
due to the limited number of comparative treatment studies available  [50]. 
Despite early antibiotic treatments have demonstrated high rate of success, there are some patients for 
whom early treatments fail (Figure 1.2). In those cases, i.e. in the presence of persistent infections, it is 
crucial the maintenance of the therapy for extended periods of time  [50]. After a successful eradication, 
re-infection episodes can occur mainly due to the original site and source of infection be the sinonasal 
cavities that inhaled antibiotics can not reach  [68, 69]. 
Finally, culture negativity following an antibiotic treatment does not absolutely mean that bacteria were 
eradicated. Culture negativity may mean that bacterial load is in fact significantly reduced but some 
pathogens may persist in CF lungs. Moreover, some pathogens may be metabolic inactive or unculturable 
and, thus undetectable by culturing methods  [41, 50]. Therefore, patients who had a successful 
eradication of bacteria from CF lungs, as well as those who had never been infected, should be routinely 
monitored to detect as early as possible the infection in order to treat it with high success rates.  
 
1.4. Clonal diversification of P. aeruginosa in cystic fibrosis lungs 
The long-term persistence of P. aeruginosa infections in CF lung is associated with clonal diversification, 
or expansion, into specialized phenotypes (Figure 1.3). Driven by the challenging selective pressures 
imposed by the typical CF conditions, e.g. interspecies competition, deficient oxygen availability, biofilm 
growth, the immune system action, oxidative stress and antibiotic treatment, P. aeruginosa progressively 
generates phenotypes specially adapted to CF airways conditions  [5, 10, 70, 71].  
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Figure 1.3. Time course of P. aeruginosa infection development. (a) Sputum colonization stage - P. aeruginosa equipped with full 
virulence factors enter in CF sputum; (b) Early infection stage – P. aeruginosa, which exhibit the environmental or wild-phenotypes 
species characteristics, starts its adaptation to CF environmental conditions; (c) Chronic infection stage – P. aeruginosa is full 
adapted to CF environment. At this stage, there is high phenotypic and genotypic diversity and formation of biofilms. 
The CF selection forces are evident when clinical isolates of P. aeruginosa are frequently mucoid. Indeed 
mucoid variants are rarely isolated from non-CF environments supporting the existence of specific CF 
selective pressure  [5, 40]. By this reason, P. aeruginosa conversion from non- to mucoid form is 
considered the hallmark of CF airway.  
However, other phenotypic features of clonal variants adapted to CF airways have been frequently 
observed, including small colony variants (SCV), non-pigmented variants, increased antibiotic resistance, 
excellent ability to form biofilms, increased mutation frequencies, altered metabolic pathways and 
attenuated virulence potential  [6, 39, 71]. The repeated occurrence of these particular phenotypic features 
and/or gene expression in chronic isolates sampled from different patients and clinical settings suggests 
the existence of a parallel evolution of P. aeruginosa in CF airways  [72, 73].  
 
Biofilm formation 
The biofilm lifestyle represents a reservoir of high phenotypic diversity and it is considered one of the most 
important adaptive mechanisms of P. aeruginosa within CF sputum (Figure 1.3)  [11, 39, 74]. Biofilms are 
microbial communities bound to a surface and/or to each other encased in a self-produced matrix 
composed of exopolysaccharides, proteins and DNA  [75, 76, 77]. Worlitzsch et al. (2002)  [12] have 
shown that in the conductive zone, region from the trachea to the terminal bronchiolus, P. aeruginosa 
grows mainly in biofilms, whereas very few bacteria are localized at the epithelial surface of the bronchi. 
Other studies have provided as well evidence of biofilm growth through inspection of sputum samples and 
lung tissue sections  [39, 74, 78]. There are evidences that biofilm strategy is used as well by Burkholderia 
spp., A. xylosoxidans and Stenotrophomonas species  [79]. 
Nowadays, biofilms are recognized as an important issue in human disease management due to their 
remarkable resistance achieving 10 to 1000-fold higher tolerance to antimicrobial agents than 
corresponding planktonic bacteria  [77, 80]. This biofilm resistance has multifactorial nature resulting from 
the combination of several mechanisms, including restricted penetration of antimicrobials through the 
exopolysaccharide matrix, slow growth of bacteria within biofilms caused by nutrient and oxygen 
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restriction and accumulated metabolic wastes, and quorum-sensing (QS) molecules  [81, 82, 83, 84]. The 
limited penetration of antibiotics and immune defences through the exopolysaccharide matrix is definitely 
one of the major contributors for their ineffective action and thus P. aeruginosa persistence. Alginate is the 
major component of CF biofilm matrix providing structure and protection to bacteria from the stressful 
environmental conditions of CF lungs. Augmented levels of alginate are generally observed in CF patients 
chronically infected and it is associated with poor prognosis because alginate triggers a significant 
antibody response  [85, 86].  
Airway CF biofilms are genetic, proteomic and physiologic different of surface-attached biofilms formed 
on, for instance, indwelling devices (catheters, prostheses, pacemakers, stents) and medical and clinical 
equipment. Instead of the direct surface colonization, clearly observed in device-associated infections, 
bacteria in the CF lungs preferentially form multicellular clusters or macrocolonies within the sputum and 
not on the epithelium surface of the bronchi and non-respiratory bronchioles as initially supposed  [12, 74, 
87, 88]. Additionally, the environment in which CF-associated biofilms are formed is considered to be 
microaerophilic or anaerobic. Bacteria enter and colonize CF sputum, consume oxygen via respiration and 
generate steep oxygen gradients within the sputum  [10, 11, 88]. The limited oxygen availability to 
anaerobic environments in CF sputum was confirmed by direct in situ oxygen measurements using a 
microelectrode  [12]. The oxygen-limited and anaerobic growth conditions significantly increase antibiotic 
resistance of biofilm-forming bacteria  [89].  
Until now, it is not clear when bacteria after CF airway colonization switch to sessile lifestyle, but it is 
known that biofilm formation enables bacteria to successfully establish chronic infections. Presumably, P. 
aeruginosa form biofilms in response to stressful conditions including microaerobiosis and/or antibiotic 
treatments  [40, 90].  
The great variability or heterogeneity of phenotypes included and developed within biofilms is certainly 
one of the major contributors for sessile bacteria recalcitrance that it is not observed in planktonic 
state  [44, 91, 92]. To switch from planktonic to biofilm mode of growth, bacteria undergo a number of 
complex physiological, metabolic and phenotypic differentiations. For instance, biofilm-growing bacteria 
undertake specific changes in protein regulation, especially those related with proteins involved in 
resistance to oxidative damage, exopolysaccharide production, phospholipid synthesis and membrane 
transport  [93, 94, 95]. Global gene expression analyses of mature P. aeruginosa biofilms have revealed 1 
% of differential gene expression between the planktonic and biofilm mode of growth, with 0.5 % of the 
genes being activated and about 0.5 % being repressed  [96]. Among the transcription factors, repression 
of flagellar and pili genes and stress response regulator genes, such as rpoS, hyperexpression of genes 
for ribosomal proteins and metabolism and transport functions were the most identified.  
Gene expression varies during biofilm development, which means that there are stage-specific temporal 
and spatial gene expression patterns leading to temporal and spatial phenotypic diversity. This is 
particular relevant concerning the resistance of mature biofilms to antimicrobial treatment. The biofilm-
specific phenotype can trigger mechanisms responsible for antimicrobial resistance and persistence and 
consequently enhance pathogenicity. P. aeruginosa genome sequencing has revealed that a mature 
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biofilm can express several cluster genes encoding efflux pump involved in resistance to some 
antibiotics  [96].  
Within biofilms, various heterogeneous environments exist as a result of the distinct levels of nutrients and 
oxygen availability and accumulated metabolic wastes that bacteria have to face and adapt in a process 
similar to CF airway adaptation  [97]. This diversification profits the whole biofilm population with diverse 
abilities to face environmental challenges as long as bacteria coordinate with each other. Bacterial 
cooperation and differentiation are facilitated through the production and perception of QS small signalling 
molecules called autoinducers. QS is a cell-cell communication system used by bacteria to regulate gene 
expression in response to fluctuations in cell-population density and it has being reported to play a role in 
early and later stages of biofilm development  [98, 99]. QS allows bacteria to “sense the quorum”, which 
means the relative density of the population, and coordinate their behaviour according to that sense of 
“quorum”. Bacteria produce and secreted small molecules (the QS signal) that when are sufficiently high 
the QS signal binds to an intracellular receptor that activates (or represses) a sub-set of genes  [98, 100, 
101]. Because biofilms are in general high dense amount of bacteria, QS play a key role in gene and 
protein expression during biofilm formation  [98, 102, 103]. P. aeruginosa has at least three distinct QS 
systems, termed las, rhl and Pseudomonas quinolone signal (pqs)  [101, 104, 105]. The lack of las QS 
system allowed the formation of biofilms, however does not allow them to achieve the mature stage. The 
rhl QS system has been reported as active in the early stages of biofilm development and its blockage 
may prevent biofilm formation  [93, 106]. The interbacterial communication is mediated by two types of 
molecules, N-acylhomoserine lactones (AHL) and 4-quinolones, allowing bacteria to percept their density 
and regulates their gene expression properly. For instance, up-regulating genes encoding virulence 
factors, such as those related to the production of enzymes or toxins, optimize the metabolic and 
behavioural activities of bacteria within the community  [107, 108]. The role of QS is also evidenced in 
interspecies communication where the secreted AHL is perceived by other adjacent microbial species that 
may respond to establish new biofilms  [109]. There are evidences of cross-communication mediated by 
QS between P. aeruginosa and Bcc within biofilms  [110]. 
Biofilm heterogeneity is also reflected in distinct antibiotic susceptibility profiles. Due to the different biofilm 
cell physiological states, biofilms have typically a top-to-bottom decreasing susceptibility profile. Antibiotics 
are effective against the cells located in the top of the biofilm, generally in active state, in contrast to the 
middle and bottom zones where cells are intermediate resistant or resistant to antibiotics. Even when 
antibiotics reach the middle and/or bottom biofilm zones, the majority of them has no activity against 
dormant cells (cells with reduced or even absence of metabolic activity) and, thus, are unsuccessful in 
biofilm eradication  [83, 97, 111].  
Planktonic P. aeruginosa cells are also found in CF sputum  [74]. Due to alterations in CF environment, 
such as pH and oxygen and nutrients availability, biofilm-cells dispersion may occur  [112]. The dispersal 
of biofilm population provides to P. aeruginosa an opportunity to colonize new zones or niches in CF 
sputum and, thus, perpetuating infection. In fact, dispersal events can be responsible for the acute 
exacerbations observed in chronic infections  [90, 92, 113].  
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Hypermutability 
The whole adaptation process to CF airways can be accelerated by the emergence of mutator phenotypes 
(or hypermutable phenotypes) which have high mutation rates up to 1000–fold than non mutator 
phenotypes  [114, 115, 116]. In extreme selective conditions, as those occurring in CF airways, this 
sophisticated mechanism improves the microevolution of P. aeruginosa accelerating its intraclonal 
diversification. The emergence of phenotypic variants and mutators can be intrinsic, relying on mutations 
(or recombinations) caused by defects on one of the several DNA repair or error avoidance systems, 
combined or not with extrinsic or environmental factors, such as competition for different niches in a 
spatially heterogeneous environment as CF airways, and/or selection that favours mutants better “fitter” to 
CF airways  [115, 117, 118]. Mutators can also be stimulated by environmental factors as the presence of 
reactive oxygen species (ROS) generated from inflammatory responses  [119]. ROS can trigger the 
generation of phenotypic variants damaging DNA and cause mutations in bacteria. Further, sub-inhibitory 
or sub-lethal concentrations of antibiotics can induce mutations and recombinations and, consequently, 
supporting the emergence of phenotypic variants and mutators  [70, 115, 120]. The genes mainly affected 
are the antimutator genes mutS, mutL, and uvrD but it can be observed defects as well in the genes mutT, 
mutM, and mutY  [114, 121, 122]. 
The amount of mutators in biofilms is significantly higher than in planktonic state. This condition may 
explain the enhanced antibiotic resistance, and frequently multidrug resistance of biofilm-associated 
bacteria, and the high genetic and phenotypic diversity observed within biofilms  [123, 124]. 
The generation of several clonal variants represents a huge biological advantage because it prepares P. 
aeruginosa population for extreme and unpredictable stresses (‘Insurance Hypothesis’) supporting the 
long-term survival of this pathogen  [43, 44]. Mutators achieve more quickly CF adaptation due to the 
expression of virulence traits, antibiotic resistance, increased ability to form biofilms and alternative 
metabolic functions representing thus a serious clinical problem  [115, 125, 126]. In effect, mutators can 
increase the transcription of genes involved in the metabolism of fatty acids and amino acids crucial for 
obtaining energy in CF ecological niches where aerobic respiration is not possible  [127].  
Although all the biological advantages, mutators may have a reduced ability to survive in other distinct 
environments indicating they can reach high levels of habitat- or niche-specialization spending its 
biological fitness  [40, 115]. During infection development non- and mutators coexist in CF airways, 
however mutators prevail at chronic stage, which may be indicative that they have in fact adaptive 
advantage.  
Through the combined action of these sources of clonal diversification, including phenotypic switching, 
biofilms and hypermutability, P. aeruginosa may achieve impressive levels of diversification, adaptation 
and evolution promoting the persistence of the bacterial populations in CF airways. Therefore, these 
sources should be intensively studied in order to understand the underlying mechanisms to further block 
them and combat the recalcitrant infections. 
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1.5. P. aeruginosa evolution and adaptation during infection 
development 
The regular sampling of CF sputum has allowed performing a detailed characterization of P. aeruginosa 
over infection development through transcriptomic, metabolomics and proteomic techniques. Therefore, it 
is now possible to start drawing an evolutionary trajectory of P. aeruginosa within CF airways. 
During infection development, genotypes and phenotypes differ markedly from those that initially 
colonized CF airways (Figure 1.4). Microbiological studies have reported changes in P. aeruginosa 
phenotypic and genetic traits, relevant in the context of bacterial pathogenesis, and different antibiotic 
resistance patterns along infection development, as well as after antibiotic treatments  [128, 129, 130]. 
Moreover, similar evolution and adaptation profiles were observed in distinct clonal lineages of CF-
adapted strains suggesting that in fact there is a similar selective pressure in CF airways. This evolution 
and adaptation processes lead to the generation of several phenotypes varying in characteristics such as 
colony morphology with distinct consistency, size, texture and colour, inactivation of QS, hypermutation, 
loss of the O-antigen components of the lipopolysaccharide (LPS), loss of motility, resistance to 
antibiotics, changes in nutritional requirements and other virulence-associated traits  [5, 70, 129, 130]. In 
fact, some of those factors have been considered the hallmark of CF disease and even can indicate the 
infection stage, such as the conversion of P. aeruginosa to mucoid phenotype, loss of motility and the 
emergence of SCV, characteristics indicative of chronic infection. However, many other characteristics 
have been described across all phenotypes isolated so far and it is unknown their role in bacterial 
adaptation and persistence and in infection progression. 
 
 
 
 
 
 
 
Figure 1.4. Representation of P. aeruginosa microevolution during infection in CF airways. At early stage of infection, P. aeruginosa 
is full equipped with cell-associated virulence factors, including flagella, pili, type III secretion systems (T3SS) and secreted virulence 
factors (e.g., proteases, pyoverdine and rhamnolipid) and exhibit antibiotic sensitivity. At the chronic stage of infection, P. aeruginosa 
is fully adapted to CF environment and exhibits a variety of adaptations, including overproduction of alginate, loss of the implicated 
virulence factors for initial infection establishment, resistance to antibiotics (expression of efflux pumps) and adapted metabolism. 
This microevolution occurs by the repeated interplay of mutation and selection. 
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Antibiotics have provided significant control of bacterial infections in CF airways, however the occurrence 
of antibiotic resistance and the lack of new drugs or therapeutic strategies make imperative the 
identification of alternative targets for treatment. For understanding the mechanisms underlying bacterial 
adaptation to CF environment and the resistance to antibiotic treatments, it is need an overall picture of 
the actual knowledge about P. aeruginosa populations resident in CF lungs.  
The compilation of the phenotypic traits exhibited by bacteria according to the infection stage is a hard 
task due to the lack of agreement on the definitions of early, intermediate and chronic colonization and 
infection stages. Next, the evolution, adaptation and diversification profiles of P. aeruginosa are reviewed 
and compared agreed by the “European Consensus” that just considers two infection stages, early and 
chronic stages, according to the presence of P. aeruginosa be lower or higher than 6 months, 
respectively  [131].  
 
1.5.1. Early infection stage 
Most CF patients acquired pathogens mainly from their surrounding environment, especially from clinical 
settings where patients remain for long periods of time. Therefore, early CF isolates exhibited identical 
microbial characteristics of their environmental or wild-phenotypes species (Figure 1.4)  [38, 132, 133]. At 
the first colonization of CF airways, P. aeruginosa have to regulate properly its gene expression to quickly 
adapt to this challenging environment, including host immune defences, antibiotics and different substrate 
composition.  
The bacterial characteristics among acute CF isolates significantly vary, however there is a trend towards 
high virulence potential and cytotoxicity and lower frequency of mutators strains  [60]. The expression of 
virulence factors, including cell-associated and secreted virulence factors, is considered to be fundamental 
at early stage for the success of infection establishment. These virulence factors include, for instance, i) 
the increased production of pyoverdine, hemolysin and phospholipase C, ii) the augmented production of 
rhamnolipid regulated by QS, which helps biofilm formation that protects cells against oxidative stress, 
decreases liquid surface tension, due to its biosurfactant feature, and facilitates the access to nutrients 
within biofilms; iii) the increased production of total protease seemed to promote mucoidy essential for 
long-term bacterial persistence; iv) swimming and twitching motilities; and iv) the expression of the T3SS 
that augments cell cytotoxicity potential and facilitates infection development  [40, 132, 133, 134, 135, 
136].  
Typically, P. aeruginosa exhibit a non-mucoid phenotype, sensibility to antibiotics and have low bacterial 
density in lungs, in contrast to chronic infections  [41, 133]. Acute CF isolates produce AHL suggesting 
that QS circuit plays a role for P. aeruginosa pathogenesis at this stage of infection. Afterwards, QS 
seems be no longer needed and lasR mutants are frequently isolated. Mutator strains are not prevalent at 
this stage because they are not efficient to establish a primary infection  [137, 138]. 
At the early stage, eradication is still possible whether an antibiotic treatment was started as soon as 
possible. Otherwise, approximately 20 % of those first P. aeruginosa colonisations could become directly 
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chronic infections and may persist up to the end of patient life  [41, 133]. Following P. aeruginosa 
eradication, it is common a new acquisition event with a different genotype or a re-colonization with the 
same genotype. Re-colonization with the same genotype may occur due to the persistence of the 
environmental source or due to the colonization of the upper airways, such as the paranasal sinuses  [68, 
139]. Upper airways can function as reservoirs of pathogens and interchange of P. aeruginosa can be 
possible. A recent study revealed that biofilms in fact can be found in sinuses of CF patients with 
intermittent lung colonization  [140]. 
Colonisation of the CF airways with mucoid strains is associated with an accelerated rate of decline in 
pulmonary function, however, there are some evidences that early acquisition of mucoid strains could be 
successfully achieved  [41, 141]. 
In summary, although the virulence potential of early CF isolates is higher than chronic isolates, they 
exhibited increased antibiotic sensitivity. Therefore, P. aeruginosa early detection and eradication are 
currently the main goal to avoid infection progression to chronic stage. Early infections are intensively 
treated with antimicrobial therapy resulting in the majority of the cases in P. aeruginosa eradication, at 
least temporal eradication [41]. In cases of antimicrobial therapy failure, infection can shortly evolve to 
chronic infection. Identification of the CF patients who may evolve to chronic infections based on the acute 
bacterial characteristics is still not possible because of factors related to host-pathogen and pathogen-
pathogen interactions may play a role that is unknown so far  [60, 142].  
 
1.5.2. Chronic infection stage 
The continuous and selective pressure over the population leads to the emergence of diverse phenotypic 
and genetic variants specially adapted to CF airways. It has been observed among chronic P. aeruginosa 
isolates alterations in colony morphology, namely the conversion to the mucoid morphotype, to SCV and 
non-pigmented variants, changes in surface antigens, reduce virulence potential, increased antibiotic 
resistance, overproduction of exopolysaccharides and modulation of microaerobic and anaerobic 
metabolic pathways (Figure 1.4). These alterations suggest a survival strategy to save or, at least, to 
reduce energy costs with virulence factors expression in favour of the use of alternative metabolic 
pathways crucial at this stage. 
The repeated occurrence of the described phenotypic features in chronic isolates of P. aeruginosa 
indicates that they may be a result of parallel evolution, which means that related microorganisms develop 
the same adaptive features in identical but independent environments  [72]. Several studies have profiled 
isolates of P. aeruginosa in attempt to find the common route towards the chronic phenotype and the 
mechanisms underlying such route. Among them, longitudinal studies using transcriptomic approaches 
have provided relevant information about the genetic changes undergo by P. aeruginosa and allowed 
comparing the expression of specific set of genes among patients in different periods of time. It has been 
identified gene expression changes in multidrug efflux pumps and regulators of QS and alginate 
biosynthesis, being these two latter the hotspots of mutations  [38, 72, 143, 144].  
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In the scope of genomic evolution in chronic CF lung infection, it should be highlighted the work performed 
by the Copenhagen and Hanover clinics. They have regularly collected P. aeruginosa from all their CF 
patients in the 1970s and 1980s and performed the genome sequencing of all the isolates. They started 
their investigation with the most prevalent clones, the C and PA14, and observed that both clones convert 
their phenotypes becoming deficient in the LPS O-antigen, with impaired motility and decreased 
siderophores secretion, as well as in other virulence factors expression, and remaining non-mucoid  [145]. 
The isolates later collected just exhibited impaired competitive growth. These cases demonstrated that the 
evolutionary transition might be through additive effects of various mutations. However, a single loss-of-
function mutation can induce dramatic changes in P. aeruginosa as those observed through the mucoid 
variant due to the pleiotropic effects of mucA mutation  [5, 38]. 
Mucoid colony morphology results from alginate overproduction, absence of flagellin and pilin and 
expression of other virulence factors. Within the mucoid form, P. aeruginosa is more difficult to eradicate 
because its highly resistance to antibiotics and to the action of host immune defences, for instance, to 
phagocytosis mediated by macrophages and neutrophils and to antibodies oponization  [6, 11, 146]. 
Alginate promotes P. aeruginosa encapsulation and biofilm formation protecting sessile bacteria from the 
action of ROS, antibiotics and host immune defences persisting in CF lungs  [39, 40]. In particular, 
alginate has been shown to retard the penetration of aminoglycosides antibiotics, for instance tobramycin, 
through P. aeruginosa biofilms achieving a minimum inhibitory concentration (MIC) 50 times higher than 
the planktonic bacteria  [14, 147]. The presence of biofilms is thus a key factor for the persistence of 
infection in CF airways  [148]. Biofilm cell differentiation contributes to the generation of higher diversity 
that consequently increases the ability of P. aeruginosa to colonize new niches in CF airways, and thus 
perpetuating infection  [44, 90, 92, 113].  
Because mucoid P. aeruginosa raise a vigorous antibody response, its presence contributes to tissue 
damages, decreased lung function and a decline in health  [85, 86]. The genetic mechanisms underlying 
P. aeruginosa transition to the mucoid form have been intensively studied and conversion is mainly 
caused by mutational inactivation of the mucA gene and more rarely of mucB or mucD genes  [149, 150]. 
mucA gene encodes a cytoplasmatic membrane bound protein that acts as anti-σ-factor, σ22, limiting the 
expression of the algD operon required for alginate synthesis. MucA binds to AlgT (also termed AlgU) that 
negatively controls the transcription of the algD gene. Inactivation of mucA results in upregulation of AlgT 
and production of alginate  [5, 151, 152]. It is believed that the constant oxidative stress found in the CF 
airways induces the mucA gene mutations  [39, 153]. In fact, σ22 can also activate the transcription of 
several other genes related to virulence factors expression and to stress response, including heat shock, 
osmotic and oxidative stress  [38, 154]. Additionally, it can repress the expression of T3SS genes through 
activation of AlgU that in turn activates the regulatory genes algP, algQ, algB, and algR. AlgR, a global 
regulator, affects the expression of multiple genes including T3SS  [155]. This suggests an impressive 
coordination of two high-cost energy systems in order to bacteria persist in CF airways.  
Although mucoid phenotype is very successful at chronic infection stage, non- and mucoid phenotypes 
can coexist  [74]. Non-mucoid isolates can occur due to persistence of P. aeruginosa wild-type or re-
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conversion of mucoid phenotypes (revertants). Mucoid phenotypes can revert to non-mucoid form in the 
absence of in vitro selective pressure or through secondary mutations. Non-mucoid phenotypes can carry 
as well mucA mutation suggesting that mutation occurred when selective pressure occurs and when it 
vanished secondary mutation takes place  [38, 156]. This suggests that the production of alginate 
represents high-energy costs and thus its unstable feature. At this stage, non-mucoid phenotypes 
revertants have its alginate production at minimal levels  [104]. 
Several other mutations may appear in CF chronic isolates, mainly in genes associated with acute toxicity, 
for instance lipopolysaccharide biosynthesis, twitching motility, regulation of exotoxin A, pyoverdine 
synthesis, and QS factors  [143]. Another P. aeruginosa variant frequently isolated from chronic CF lung 
infections and clinically relevant is the SCV, so designated because of their small-colony size, typically 1-3 
mm after 24-48 h of growth on agar media  [157]. SCV are normally hyperpiliated, hyperadherent, 
excellent biofilm formers and exhibit autoaggregative behaviour and increased twitching motility  [158, 
159, 160, 161]. In addition, SCV display augmented resistance to several classes of antibiotics, notably to 
aminoglycosides, contributing to P. aeruginosa persistence in CF airways and poorer lung function. SCV 
are generally selected after prolonged antibiotic treatments  [157, 162]. In contrast with mucoid phenotype, 
the mutations that arise in SCV appear to be very diverse and a challenge for understanding the 
underlying molecular mechanisms  [163]. This phenotype may arise from the increased expression of the 
pel and psl polysaccharide gene loci and elevated intracellular c-di-GMP levels that enhance the ability to 
form biofilms, motility and the expression of the T3SS persisting thus more efficiently in the CF 
airways  [161, 163]. Until now, SCV were mostly studied regarding S. aureus but currently it has been 
equally assumed that P. aeruginosa SCV is as well a cause for infection persistence  [77, 164, 165, 166]. 
Other colony morphologies have been isolated from CF airways typically exhibiting rough texture due to 
alteration of the lipid A moiety of LPS. Those variants contain few, short, or no O side chains and exhibit 
augmented proinflammatory activity  [40]. Alterations in the Toll-like receptor ligand reduce the affinity of 
P. aeruginosa lipid A for polymyxin and for cationic antimicrobial peptides improving P. aeruginosa 
persistence in CF lungs  [167, 168]. 
In chronic infections, P. aeruginosa lives in biofilm-growth mode as abovementioned in which cells 
downregulate flagellum and type IV pili since they are no longer needed to move across sputum and along 
epithelial cell surfaces  [99]. Nonpiliation may arise from mutations of pilB, encoding an ATPase needed 
for the extension and retraction of pili, or defects in pilQ gene, required to extrude the pilus through the 
bacterial outer membrane  [169]. Lacking flagella (e.g. fliC mutant), P. aeruginosa isolates are hardly 
phagocytosed by alveolar macrophages and neutrophils helping bacteria to evade the host immune 
defences and allowing its persistence in CF airways  [40, 104]. Nevertheless, the majority of CF isolates 
exhibited rpoN mutations that provoke the loss of both pili and flagella  [170]. Biofilm phenotypes reduce 
thus their immune recognition factors leading to diminished immune detection of these antigens. Through 
sputum and lung samples, it was observed neutrophils surrounding P. aeruginosa biofilms and rarely it is 
observed neutrophils inside of biofilms  [39, 74]. Moreover, it has been shown that the lysis of spent 
neutrophils add viscosity and volume to biofilms because of the release of DNA and protein  [171, 172]. 
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Chronic CF isolates show other attenuated virulence factors such as reduced production of AHL, 
proteases, phospholipase C, loss of pyoverdine, pyocyanin, and elastase and decreased cytotoxicity 
potential, due to the switch off the T3SS  [173]. These alterations also reduce the efficacy of the immune 
system to recognize P. aeruginosa helping thus its persistence in CF airways  [40, 104]. This decrease in 
virulence potential may be associated with some downregulated genes such as oprG, lasB, rsaL and 
lecB  [174]. 
Chronic P. aeruginosa isolates are commonly lasR mutants. lasR gene encodes QS transcriptional 
regulator LasR and its downregulation may explain the reduced or absent production of AHL at this 
infection stage, the autolysis and the iridescent gloss of P. aeruginosa colonies, the growth advantage on 
amino acids and decreased virulence potential  [143, 175]. In addition, lasR mutants can use nitrate (NO3-) 
and nitrite (NO2-) as the terminal acceptor of electrons allowing P. aeruginosa growth in anaerobic niches 
and confering resistance against ciprofloxacin and tobramycin. The loss of social and cooperative 
behaviour may confer an adaptive advantage since the production of QS signal molecules, such as N-(3-
oxo-dodecanoyl)-L-homoserine lactone (3-oxo-C12-HSL), N-butanoyl-L-homoserine lactone (C4-HSL), 2-
heptyl-4(1H)-quinolone (C7-HHQ), and 2-heptyl-3-hydroxy-4(1H)-quinolone (PQS), are costly. Avoiding 
these costs, P. aeruginosa can ensure its persistence for long-term  [104, 129]. QS seems just contribute 
to P. aeruginosa pathogenesis at colonization or acute stages  [129, 176].  
To survive and adapt to CF airways, P. aeruginosa has as well to adapt its metabolic pathways. In fact, 
those metabolic alterations are also considered a marker of the chronic stage. The generation of energy is 
mainly based on oxidative substrate catabolism, however P. aeruginosa is able to use alternative electron 
acceptors. The carbon metabolism of P. aeruginosa is mediated by catabolite repression control, which 
determines the catabolism of substrates in a preferred order. Short-chain fatty acids, amino acids and 
polyamines are generally the preferred carbon sources and sugars the less favoured  [177]. CF sputum 
contains high amount of mucin, DNA, lipids, amino acids and proteins that P. aeruginosa can uptake. 
Several studies have reported that peptides, amino acids and fatty acids belonging to host defences, such 
as prostaglandins and phosphatidylcholine, supports P. aeruginosa growth in CF airways  [13, 127]. The 
increased availability of those components is highlighted by the frequent isolation of auxotrophic variants 
for different amino acids, however the adaptive advantage of those variants in CF airways is unclear so 
far  [178, 179]. Arginine and methionine are the most common auxotrophisms detected among CF 
isolates  [179, 180, 181, 182]. Auxotrophic variants may be more common than actually reported because 
those variants may be less cultivable in vitro and consequently underestimated.  
Another nutritional key factor for P. aeruginosa survival and persistence in CF lungs is the acquisition of 
iron. This bacterium uses several strategies to obtain iron, including siderophore mediated uptake, heme 
and ferrous iron uptake  [183, 184]. 
As aforementioned, the distinct oxygen availability in CF sputum represents a challenge for P. aeruginosa 
that undergo metabolic and physiologic changes with high impact on antibiotic treatments. Along chronic 
infection progress, P. aeruginosa can face aerobic, microaerophilic and anaerobic zones within the CF 
sputum and different enzymes, transporters and regulators for different metabolic pathways are up-
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regulated to achieve this adaptation and grow in these environments  [60]. P. aeruginosa preferentially 
uses oxygen as terminal electron acceptor to obtain maximum energy. Under anaerobic conditions, P. 
aeruginosa can obtain energy to grow from denitrification or fermentation of arginine  [11, 127]. 
Denitrification or anaerobic respiration allows detoxification of NO generated during infection development. 
The outer membrane protein OprF represents a crucial factor in anaerobic metabolism since it allows the 
permeation of the ions NO3-/NO2- fundamental to perform denitrification  [11, 88, 127]. In niches where 
oxygen and N-oxides are unavailable but amino acids are in high amounts, P. aeruginosa can use 
fermentation of arginine converting it into ornithine  [127]. In cases of arginine limitation, P. aeruginosa can 
still convert pyruvate into acetate and thus obtain energy. By this way, anaerobic biofilms can be formed 
and support P. aeruginosa survival, growth and persistence in CF airways. Anaerobic environments 
increase P. aeruginosa antibiotic tolerance and the robustness of biofilms through the increased 
production of alginate, typically via mutation in algT/algU  [89, 185, 186, 187]. Consequently, CF mucoid 
strains, that are alginate producers, are selected at this chronic stage.   
Despite all these findings about the metabolic pathways used by P. aeruginosa during chronic infections, it 
is still scarce the information about the regulation and the mechanisms underlying each metabolic 
pathway and the specific effects on virulence, antibiotic resistance and persistence in CF lungs. Certainly, 
the understanding of those mechanisms could help to new therapeutic solutions arise. 
The presence of mutators within the populations is characteristic of chronic infections and considered a 
virulence determinant of P. aeruginosa often associated with parallel occurrence of subpopulations with 
distinct phenotypic characteristics  [114]. Mutators ensure P. aeruginosa survival against various CF 
stress conditions and other unpredictable stress factors being, moreover, a key factor in the development 
of multi-antimicrobial resistance  [121]. At chronic stage, hypermutability increases also due to the 
presence of biofilms in which the frequency of mutators is higher than the free-living mode of growth  [45, 
123].  
Chronic infections are usually punctuated with worsening of symptoms (acute pulmonary exacerbations), 
in which P. aeruginosa may regain the increased levels of acute virulence of early stages, suggesting that 
the expression of some virulence factors can be reversible  [113, 188]. It is believed that biofilm cells 
dispersion events are one of the underlying mechanisms of a pulmonary exacerbations  [92, 113, 189]. 
Because the definition of exacerbation is under debate, some authors have proposed other implications 
such as altered antibiotic treatment  [190] or alterations of bacterial load or the emergence of a virulent 
subpopulation  [181, 191, 192]. The first hypothesis seems to be supported by other studies that 
demonstrated increased levels of P. aeruginosa exoenzyme S, exotoxin A, elastase, and alkaline protease 
during exacerbations episodes  [193, 194]. In addition, high-doses of antibiotics are used to treat 
exacerbations decreasing the bacterial load and resulting in attenuation of the symptoms  [188, 193, 195]. 
Besides improving lung function, antibiotic treatment is used to extend the period of time between acute 
exacerbations  [50]. Because P. aeruginosa is the most common bacteria isolated from CF patients with 
exacerbations, in general, the choice of the antibiotic agent is an antipseudomonal agent  [3]. So far, there 
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is not a successful antimicrobial regime able to totally eradicate P. aeruginosa in chronic infections, but it 
can be achieved one or two log reduction of bacterial load  [57]. 
Despite the intensive and long antibiotic treatment, chronic infections of P. aeruginosa are rarely 
eradicated due to the occurrence of antibiotic resistance. It is frequently observed β-lactam-resistant P. 
aeruginosa phenotypes  [196], as well as ciprofloxacin  [197], colistin  [198] and tobramycin resistant 
phenotypes and even multi-drug resistance  [199]. The main reasons for such increased antibiotic 
resistance is the biofilm-growth style, the presence of mutators and increased production of resistance 
factors, for instance, the antibiotic efflux pumps (e.g. MexCD-OprJ) and the production of β-
lactamases  [121, 200, 201, 202, 203, 204, 205]. P. aeruginosa is equipped with a two-component 
regulatory system ParR-ParS that regulates resistance against, at least, four classes of antibiotics 
throughout activation of the efflux pump MexXY-OprM and modification of LPS operon and downregulation 
of oprD porin expression  [59]. Mutations in cbrA gene coding a sensor kinase of the cbrAB two-
component regulatory system conferred resistance against polymyxin B, ciprofloxacin and tobramycin. In 
addition, it enhances the ability to form biofilms  [206]. CF isolates can accumulate mutations in antibiotic 
resistance genes that combined with biofilm antibiotic resistance mechanisms results in an impressive 
expression and activity against antibiotics.  
In summary, the exhibition of certain characteristics, including alginate overproduction (mucoid 
phenotype), slow growth (SCV), alternative metabolic pathways, antibiotic resistance and loss of virulence 
factors expression, is currently considered a chronic phenotypic profile and the end-point result of P. 
aeruginosa evolution in CF airways. P. aeruginosa clearly adopts a strategy aiming to reduce its energy 
costs in favour of activation of other biological pathways that ensure its long-term persistence. The actual 
evolutionary “model” of P. aeruginosa within CF airways consists in an initial and rapid adaptation period 
dominated by positive selection and adaptive mutations, followed by a period with minor phenotypic 
changes dominated by negative selection and fewer adaptive mutations  [5]. This evolutionary process 
ends with an advent of a lineage of highly adapted bacteria with impressive ability to persist in CF lungs 
for long-term. Despite the assumption of parallel evolution to CF-well adapted phenotypes and the limited 
number of adaptive features, it is important to highlight that the actual evolutionary route towards a 
common profile among different patients is still not well understood. In fact, genomic and transcriptomic 
studies have just begun tracking P. aeruginosa evolution. 
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2 
Advances in detection of bacterial diversity  
using colony morphology characterisation 
 
 
Abstract 
Colony morphology may be an indicator of clonal diversification of bacteria in CF lungs which alterations in the colony 
aspect may reflect increased pathogenic potential. Despite the relevance of using colony morphological 
characterisation to inspect the virulence and antimicrobial resistance of pathogens, there is great variability in 
experimental conditions, morphological criteria and vocabulary used to characterise bacterial colonies, which hampers 
accurate clinical diagnosis. 
This chapter includes three distinct and complementary works that aimed to introduce some improvements in the 
colony morphology characterisation method in order to enhanced clinical diagnosis. First, it was intended to 
intensively study the impact of some experimental conditions, including colony growth time, number of colonies per 
plate, solid culture medium, bacterial mode of growth and genetic background on colony morphogenesis and on the 
detection of bacterial diversity. The results demonstrated that all parameters studied had impact on colony 
differentiation and on the detection of bacterial diversity. These results allowed to clearly understanding that 
morphologies just should be compared in identical plating conditions, otherwise the detected colony differentiation 
could be caused by in vitro conditions rather than bacterial adaptations in human host. Based on the results obtained, 
it was suggested some guidelines that should be followed in order to obtain the most accurate results regarding 
colony characterisation. The second study intended to construct a morphological characterisation system for bacterial 
colonies. The great variability of vocabulary, concepts and morphological criteria currently used by authors prompted 
the construction of a system that might assist clinical and research laboratories to perform accurately colony 
morphology characterisation. It is believed that this system will facilitate the comparison of morphologies across 
samples, strains, species, experiments and laboratories that significantly will advance the knowledge about infection 
and improved antimicrobial stewardship. In the last study, it was aimed to introduce speed and high-throughput to 
colony morphology characterisation method exploring MALDI-TOF MS as a tool for bacterial colony morphotyping. 
MALDI-TOF MS provided distinct colony classification in comparison with manual morphotyping. The differences 
between these two methods could arise from molecular alterations not perceptible by macroscopic observation of 
colony morphologies. These results may suggest that MALDI-TOF MS could, in some extent, be used as a significant 
complementary tool for colony morphotyping.  
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2.1. Introduction 
A timely diagnosis is the most effective approach to prevent or control bacterial infections in CF disease. 
To perform a successful diagnosis it is required an accurate (sensitive and specific) and fast identification 
of the infecting pathogens  [1]. The current issue on clinical diagnosis is the ability of generating not just 
taxonomic results, but also providing information about the pathogenic potential of the bacteria isolated 
from CF patients  [2]. According to bacterial identification and characterisation, such as antibiotic 
susceptibility profile and virulence factors expression, the best antimicrobial approach is chosen to control 
or eradicate the bacterial infection. Therefore, rapid pathogen detection, identification and characterization 
are the gold standard for clinical diagnosis. Furthermore, bacterial identification and characterization is not 
only an issue of clinical diagnosis, but it also accounts for understanding the infection development and 
persistence within the host. 
Over the years, important technological advances have occurred in bacterial identification that have 
provided a wide range of techniques to detect, identify and differentiate bacteria. Molecular methods, such 
as the enzyme-linked immunosorbent assay (ELISA), the polymerase chain reaction (PCR) and, the most 
promising one, matrix-assisted laser desorption/ionization time of flight combined with mass spectrometry 
(MALDI-TOF MS) have introduced improvements in bacterial identification as they contributed to speed up 
the analysis and the reduction of handling  [1, 2]. Microbial infecting communities of CF lungs encompass 
a wide clonal heterogeneity that these recent methods are limited to detect as the bacterial identification 
and characterisation is performed based on detection of specific molecules. However, there are just few 
identified probable active molecules contributors to the activation of phenotypic diversification. These 
molecules are highly dependent on environmental stresses that bacteria has experienced, which seriously 
limit the ability to detect such increased molecular variability. 
Isolation of specimens using bacteriological techniques, such as the culturing in non- and selective or 
differential media, is a routine procedure during clinical diagnosis  [3]. Growing on agar surfaces, bacteria 
form colonies whose appearance helps the clinicians and researchers to identify genera or even species. 
This method is called as colony morphology characterisation and is defined by Moore; V.A. (1912)  [4] as 
“The examination of plate cultures…determining the character of the different colonies, their action upon 
the medium, and the rapidity of their development...”. Colony morphology characterisation relies thus on 
the description of the phenotypic traits exhibited not by an individual microorganism but by a group of 
microorganisms, the colonies. The colony observation is performed through naked eye examination or 
using a magnifying glass and characterised using morphological criteria, such as form, surface, size and 
colour.  
Despite being described by several authors as an old-fashioned method  [1, 2], colony morphology 
characterization is a useful diagnosis method. It can provide valuable insights into diversity of the infecting 
microbial population fundamental to design an effective antimicrobial treatment customized to a particular 
infecting population  [5, 6, 7, 8, 9, 10]. Moreover, colony morphology characterization has undoubtedly 
advanced the knowledge about microbial adaptation, persistence and evolution concerning several human 
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infections and diseases. In CF airway disease P. aeruginosa adaptation was evident when it was 
spreading bacteria on agar plates and observed their different colony appearances over infection 
development, including iridescent colonies  [11], mucoid colony variants  [12, 13, 14], SCV and rough 
SCV  [15, 16, 17, 18]. The different aspect of colonies can reflect differences in virulence  [16, 19, 20, 21, 
22], antimicrobial resistance  [23, 24, 25, 26] and persistence  [25, 27], features that impact the efficacy of 
antimicrobial agents and the response of bacteria towards them. This means that any modification in 
colony morphology traits, such as colour, opacity, size and texture, may be a sign of altered expression of 
one or more bacterial traits important to antimicrobial stewardship. The correlation between pathogenic 
features, such as antimicrobial resistance, virulence factors expression, persistence ability, and colony 
morphologies is just almost unknown though extremely important. The scant knowledge regarding those 
biological/morphological relationships is partly due to the fact that colony morphotyping has some inherent 
disadvantages of being a culture-based method, but also because of other barriers related to the lack of 
standard experimental conditions, universal morphological criteria, unequivocal and common concepts 
and terms to perform colony morphology examination. Therefore, conceptual and practical advances in 
this method are urgent, considering its importance in the generation of comprehensive knowledge on 
microbial adaptation, evolution and infection development and, most important, in helping to design 
effective antimicrobial treatments for bacterial eradication from CF lungs. 
This chapter presents and discusses some improvements performed in the scope of the detection of 
bacterial diversity using the colony morphology characterisation method. It was aimed to overcome some 
technical limitations, in particular to reduce handling time, to establish more accurate colony morphology 
procedures and to standardise colony morphology data. Therefore, in a first stage, the influence of some 
important experimental parameters on colony morphology development and diversity detection was 
extensively studied. Afterwards, vocabulary, concepts and morphological criteria about bacterial colonies 
was compiled to construct, as far as it is known, the first renewed colony morphology characterisation 
system since the first publication of colony terms. Finally, the ability of the MALDI-TOF MS to discriminate 
distinct colony morphologies was assessed in order to verify the possibility of introducing some speed and 
high-throughput to colony morphology characterisation method. 
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2.2. Improvements on colony morphology identification towards 
bacterial profiling  
2.2.1. Objective  
Apart from obvious morphological differences among bacterial colonies that have been reported, the 
plating conditions in which evaluation has been performed were different among published works. This 
variety is especially significant in what concerns the medium used and the growth time allowed for colony 
development. The continuing reliance of clinical diagnosis on colony morphology characterisation 
demands understanding the role of plating conditions in colony morphogenesis and their impact in the 
detection of bacterial diversity. To obtain new insights about this issue, two P. aeruginosa strains (a 
reference strain and a clinical isolate) were used to perform a detailed evaluation of colony morphologies 
along time testing different colony growth times, number of colonies per plate, culture media and mode of 
growth, including planktonic and biofilm lifestyle. The goal was at determining the impact of these 
experimental conditions on each colony morphological features, including form, margin, texture, size and 
colour, in a systematic way.  
 
2.2.2. Materials and Methods 
Bacterial strains and culture conditions 
P. aeruginosa ATCC 10145 and a clinical isolated from medical equipment (from now on referred as PAI1) 
were used throughout this study. Bacteria were routinely cultured on tryptic soy broth (TSB) or agar (TSA) 
medium at 37 ºC. All strains were preserved in criovials (Nalgene) at – 80 ± 2 ºC. Prior to each 
experiment, bacterial cells were grown on TSA plates for 24 h at 37 ºC. The use of a reference strain and 
a PAI1 ensured the different genetic background. 
 
Planktonic cultures 
Planktonic bacteria grew overnight in TSB at 37 ºC and 120 rpm. Cell suspension of each strain was 
washed twice in phosphate buffered saline solution (PBS) by centrifugation (9000 g, 5 min) and further 
serial diluted and plated on solid media.  
 
Biofilm formation 
Biofilms were developed as previously described  [28]. Briefly, bacteria were grown overnight on TSB at 
37 ºC in air conditions. Cell suspension of each strain was diluted in TSB to obtain 107 CFU/mL as final 
concentration. Afterwards, the bacterial suspension was transferred to a 96-well polystyrene microtiter 
plate where biofilms were developed aerobically on a horizontal shaker (120 rpm) at 37 ºC for 24 h. After 
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that, biofilms were sonicated into PBS and vortexed to homogenize. Finally biofilm-cells were serial diluted 
with PBS and spread plated on solid media. 
 
Observation and classification of colony morphology. 
To assess the impact of the solid media composition on colony morphology features, bacteria were serial 
diluted and plated on different solid media in air conditions, including TSA (15 g/L, Liofilchem), 
Pseudomonas isolation agar (PIA, 45 g/L, Fluka) and Cetrimide (CET, 45,5 g/L, Merck) plus 10 mL/L of 
glycerol, at 37 ºC. It was observed that the amount of solid medium in the plate had impact on colony 
morphogenesis. However, this factor was not included in this study and the amount of solid media could 
be variable. To evaluate the influence of the lifestyle of the bacteria on their colony morphology, bacteria 
coming from biofilms and planktonic cultures were used. Plates with different colony numbers were 
observed to infer about the role of colony density per plate on morphology differentiation. Finally, different 
times of growth were used to assess the effect of growth time: after 15, 24, 30, 45 and 50 h of incubation. 
Colonies were observed by directly placing the petri plates under a magnifying glass (Olympus SZ-CTV) 
and recorded with a CCD camera (AVC, D5CE; Sony, Tokio, Japan). The identification and 
characterisation of colony morphotypes were carried out using five parameters: colony size, form, colour, 
texture and margin, according to Table 2.1. A phenotypic variant was considered when it differed in, at 
least, one of the referred morphological parameters. All experiments were performed 5 times. 
 
Table 2.1. Morphological features used to characterize P. aeruginosa colony morphologies. 
Class Sub-class 
Colony Form Circular  
 Irregular 
  
Colony Margin Entire 
 Irregular 
  
Colony Texture  Smooth  
 Rough 
 Wrinkled 
  
Colony Sizea Small  
 Large 
  
Colony Colour White 
 Brown 
 Yellow 
 Green 
a colonies were considered small if presented diameter below 3 mm and large if presented diameter above 3 mm [15]. 
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2.2.3. Results  
To describe each colony, regarding the distinct morphological characteristics, the following terms were 
used as synonymous: colony morphology, colony type, colony variant and morphotype, all meaning a 
group of bacteria grown from a single cell on agar surface exhibiting a typical colonial pattern. It must be 
remarked for further studies that this definition does not exclude the possibility that different strains or 
species exhibit the same morphotype or that a strain or species exhibits more than one morphotype. All 
morphotypes presented were observed at least in 3 of the 5 replicates. 
 
Effects of growth time on colony morphogenesis  
Planktonic and biofilm bacteria were cultured on solid media plates and colonies were examined after 15, 
24, 30, 45 and 50 h of growth at 37 ºC. These intervals of time allowed observing the sequential stages of 
colony morphological features during growth on the different solid media (data shown just addressing TSA 
plates, Figure 2.1, 2.2, 2.3 and 2.4). After 15 h of growth, heterogeneity among colony morphologies was 
only incipient. Between 15 and 45 h of growth, colonies changed their appearance (intermediate 
morphologies) could ending in totally different morphotypes. Similar 15 h colonies may still end in similar 
colonies as it happened with the planktonic P. aeruginosa ATCC (Figure 2.1) or ended in completely 
distinct colony morphotypes as occurred in the biofilm-variants of ATCC (Figure 2.3) and planktonic and 
biofilm variants of PAI1 (Figure 2.4A – 2.4H). An interesting result was that, independently of the strain or 
the type of morphotype, after 45 h, no morphological changes were observed, apart from the increase of 
the colony size, meaning that at 45 h the colony morphogenesis was complete and all morphological traits 
were well defined. This evidence was verified in all solid media tested (TSA, PIA and CET). Therefore, 
further analyses of colony morphology were performed considering the traits exhibited at 45 h of growth. 
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Figure 2.1. Morphological evolution of planktonic P. aeruginosa ATCC 10145 colonies observed on TSA. Rows A to D represent the 
colony morphology development of the variants identified after 15 h of growth. Morphotypes of the rows A and B at 15, 45 and 50 h 
of incubation were the same variant, however they showed distinct intermediate morphological stages over time (at 24 and 30 h). All 
morphotypes were observed at least 3 times of the 5 performed. White bars = 0,5 mm; black bars = 1 mm. 
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Figure 2.2. Morphological evolution of planktonic P. aeruginosa PAI1 colonies observed on TSA. Rows A to D represent the colony 
morphotypes development of the variants identified after 15 h of growth. Morphotypes of the rows A/B and C/D at 15 h of incubation 
were the same variant, but they showed distinct intermediate morphological stages (at 24 and 30 h) ending into different variants, 
B=C and A=D. All morphotypes were observed at least 3 times of the 5 performed. White bars = 0,5 mm; black bars = 1 mm. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.3. Morphological evolution of colonies derived from P. aeruginosa ATCC 10145 biofilms. Rows A to C represent the colony 
morphotypes development of the variants identified after 15 h of growth. Morphotypes of the rows A and B at 15 h of incubation were 
the same variant, but they showed over time distinct intermediate morphological stages (at 24 and 30 h) and ended as different 
variants (columns 45 and 50 h). All morphotypes were observed at least 3 times of the 5 performed. White bars = 0,5 mm; black bars 
= 1 mm. 
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Figure 2.4. Morphological evolution colonies derived from P. aeruginosa PAI1 biofilms. Rows A to J represent the colony 
morphotypes development of the variants identified after 15 h of growth. Morphotypes of the rows A to H at 15 h of incubation were 
the same variant, but they showed distinct intermediate morphological stages (at 24 and 30 h) ending into different variants. At 45 h 
a total 10 morphotypes were identified: the rows A to H were considered 8 distinct SCV (diameter below 3 mm) and I and J were 
considered 2 distinct non-SCV. All morphotypes were observed at least 3 times of the 5 performed. White bars = 0,5 mm; black bars 
= 1 mm. 
Effects of plate colony density on colony morphogenesis 
During colony evaluation, it was observed that colonies growing close to each other altered their 
development (Figure 2.5). A colony density higher than 20 colonies per agar plate resulted in close 
neighbouring growth and thus in limited colony formation when compared with more distant or isolated 
colonies. For instance, distant colonies of planktonic P. aeruginosa PAI1 that exhibited circular form, 
undulate margin, rough texture and large size (Figure 2.5C), when grown in plates with 20 to 100 colonies 
exhibited circular form, irregular margin, rough texture and small size (Figure 2.5B) and in plates with 
more than 100 colonies exhibited undistinguished form and margin, rough texture and undetermined size 
(Figure 2.5A). To ensure unbiased data, morphology characterization was performed in plates with a 
maximum of 15 colonies. 
 
A 
 
B 
 
                                  C 
 
    
Figure 2.5. Colony morphologies of planktonic P. aeruginosa PAI1 after 30 h of growth on plates with: (a) more than 100 colonies; 
colonies exhibited undistinguished form and margin due to high colonies density on the plate, rough texture and undetermined size; 
(b) approximately 30 colonies; colonies exhibited circular form, irregular margin, rough texture and small size; (c) 20 or less colonies; 
colonies exhibited circular form, undulate margin, rough texture and large size, distinct morphology in contrast to (a) and (b) These 
experiments were performed 5 times. White bars = 1 mm. 
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Effects of culture medium composition on colony morphogenesis and diversity detection 
Planktonic and biofilm-associated P. aeruginosa were plated onto different solid media (TSA, PIA and 
CET) in order to assess the role of nutritional composition of solid media on colony morphology definition 
and detection of bacterial diversity. The results showed that solid media clearly influenced colony 
morphogenesis and variants detection. Both P. aeruginosa strains, either from planktonic and biofilm 
cultures, when plated on TSA, PIA and CET exhibited distinct colony morphologies according the media 
used (Table 2.2). It was verified that the features margin, texture and colour were the most affected. The 
most relevant result was the high diversity of morphotypes detected in TSA in comparison with PIA and 
CET for both P. aeruginosa strains. This result had particular expression regarding morphotypes obtained 
from biofilms. 
 
Impact of the mode of growth on colony morphogenesis and diversity 
Based on the fact that biofilm formation is usually originated by planktonic cells, it was considered of 
utmost importance to identify the colony morphotypes of the initial population that originated the biofilms.  
As TSA was the medium where higher colony diversity was observed, thus the data analysis was just 
focused on morphotypes observed on TSA. The most relevant result was the high diversity of 
morphotypes obtained from the biofilm cultures of both strains, namely the PAI1 that originated 5-fold 
more colony morphotypes when plated onto TSA than the reference strain. ATCC biofilms encompassed 
three distinct large and circular colony morphologies: a wrinkled and concentric variant with an entire 
margin (Figure 2.3A, column 45h); a rough colony variant with irregular margin (Figure 2.3B, column 45h); 
and the third variant (Figure 2.3C, column 45h) similar to the planktonic counterpart (Figure 2.1, column 
45h). In contrast, the planktonic reference strain gave rise to a homogeneous population composed just by 
large and circular colonies, with a small marked centre, irregular margin and with a sheath (Figure 2.1, 
column 45 h). The surface showed to be predominantly rough with some small wrinkled zones. These 
colonies were yellow when plated on TSA. 
Much higher diversity was detected from the biofilm-associated bacteria developed by the PAI1. Eight 
distinct SCV, colonies with less than 3 mm of diameter (Figure 2.4A – H, column 45h), and two larger 
colony variants were observed (Figure 2.4I and 2.4J, column 45h). In turn, the planktonic PAI1 originated 
a heterogeneous population just composed by two large yellowish colony variants: smooth with entire 
margins (Figure 2.2B and 2.2C, column 45h), and by smooth variants with irregular margins (Figure 2.2A 
and 2.2D, column 45h). The observation of new colony variants in the case of biofilm-associated bacteria, 
suggests that a fraction of the planktonic cells changed phenotypically when growing as a biofilm. 
  
Table 2.2. Characteristics of the distinct colony morphologies generated by the reference and the clinical strain of P. aeruginosa on different solid media (TSA, CET and PIA) grew as planktonic cultures 
and biofilms. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a  texture should be described from out to inside; morphotypes with same types of texture but in different zones was considered as distinct colony variants. 
b colonies were considered small if presented diameter below 3 mm and large if presented diameter above 3 mm. 
 Media Form Margin Texturea Sizeb Colour 
Planktonic P. aeruginosa ATCC 10145       
 Morphotype I TSA circular irregular rough and wrinkled large yellow 
 Morphotype II PIA circular irregular wrinkled and rough large green 
 Morphotype III CET circular irregular rough large green 
 P. aeruginosa PAI1       
 Morphotype IV TSA circular entire smooth large yellow 
 Morphotype V TSA circular irregular smooth large yellow 
 Morphotype III PIA circular irregular rough large green 
 Morphotype VI CET irregular irregular rough and smooth large green 
Biofilm P. aeruginosa ATCC 10145       
 Morphotype I TSA circular irregular rough and wrinkled large yellow 
 Morphotype VII TSA circular entire wrinkled large yellow 
 Morphotype VIII TSA circular irregular rough large yellow 
 Morphotype II PIA circular irregular wrinkled and rough large green 
 Morphotype IX PIA circular entire wrinkled and rough small green 
 Morphotype III CET circular irregular rough large green 
 Morphotype X CET circular entire rough small green 
 P. aeruginosa  PAI1       
 Morphotype IV TSA circular entire smooth large yellow 
 Morphotype V TSA circular irregular smooth large yellow 
 Morphotype XI TSA irregular irregular wrinkled small yellow 
 Morphotype XII TSA circular entire Rough and wrinkled small yellow 
 Morphotype XIII TSA circular entire smooth and wrinkled small yellow 
 Morphotype XIV TSA circular irregular smooth and wrinkled small yellow 
 Morphotype XV TSA circular irregular wrinkled small yellow 
 Morphotype XVI TSA circular irregular rough and wrinkled small yellow 
 Morphotype XVII TSA circular entire smooth small yellow 
 Morphotype XVIII TSA circular entire and irregular smooth and wrinkled small yellow 
 Morphotype III PIA circular irregular rough large green 
 Morphotype IX PIA circular entire wrinkled and rough small green 
 Morphotype VI CET irregular irregular rough and smooth large green 
 Morphotype X CET circular entire rough small green 
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Effect of genetic background on colony morphogenesis 
Despite belonging to the same species, the genetic background exerted significant influence on the 
definition of colony traits as showed on Table 2.2. Colonies of both strains in the same experimental 
conditions shared some characteristics and differed in others. For instance, planktonic cultures resulted 
mostly in colonies that shared the large dimension and the circular form, but were clearly different in other 
traits, such as the texture and the margin. Another interesting result was the different ability of the two 
strains to generate colony variants: the PAI1 originating 2- and 5-fold more colony morphotypes-
planktonic and -biofilm associated when plated onto TSA than the reference strain.  
 
2.2.4. Discussion  
The recognition of typical colony morphologies is crucial for clinical diagnosis. Scientific and clinical 
laboratories frequently use the colony morphology displayed by bacteria on agar media as an auxiliary 
means to identify bacterial species because of their different and specific growth patterns. Despite the 
technological advances, colony morphology characterisation is still used for taxonomic purposes and, 
most important, to obtain information about the microbiological effect of the antibiotic courses, in 
particular, to determine the occurrence of phenotypic selection [2, 7, 31].  
Colony morphology characterisation is gaining attention because it is thought that changes in morphology 
could be the expression of bacterial adaptation to different environments and thus hampering the bacteria 
identification based on morphological traits. Distinct colony morphotypes may arise and their erroneous 
identification and/or characterization may significantly influence the clinical diagnosis.  
The actual interpretation of the function of colony morphotypes isolated from CF samples or identified in 
vitro experiments is mainly based on results comparison among reports. A detailed analysis of 
methodological procedures of these reports revealed that experimental conditions are highly variable 
among reports. For instance, P. aeruginosa colonies have been characterized and compared after being 
grown on different agar media, and also with different medium supplements, as well as after different 
growth times  [16, 29, 30]. This has also happened with other species such as S. aureus  [31, 32], 
Streptococcus pneumoniae  [33, 34] and Enterococcus faecalis  [9, 35]. The gain of knowledge about the 
mechanisms involved in bacterial adaptation and survival in CF context and in other infections and 
diseases, such as clonal diversification, biofilm resistance, bacterial persistence and other biological 
processes may be compromised since the influence of experimental conditions in colony morphology 
definition and detection is still unknown. The present study showed the impact of experimental 
parameters, including colony growth time, number of colonies per plate, solid medium, bacterial lifestyle 
and genetic background on morphological features of P. aeruginosa colonies.  
Regarding the bacterial lifestyle, it seemed important to study the impact of the planktonic and biofilm 
mode of growth on colony morphology. Biofilm formation is a relevant strategy used by P. aeruginosa to 
introduce bacterial diversity in order to face the stressful CF conditions  [36, 37, 38]. The switch of mode of 
growth from planktonic to biofilm implies cellular alterations and it was hypothesised that they could be 
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observed in colony morphology variation. Biofilms encompass a wide range of microniches with specific 
biological activities that may somewhat translate the well-known biofilm heterogeneity. Stewart and 
Franklin (2008)  [39] reported that in a mature biofilm at least three distinct physiological states can be 
anticipated: cells near the biofilm-bulk-fluid or in the more superficial layer, presenting similarities with 
planktonic cells; cells in the middle zone; and cells in the deeper zone. In fact, the present results 
demonstrated the potential of colony morphology characterization to discriminate the biofilm population 
diversity since several colony morphotypes were isolated from biofilms (Figure 2.3 and 2.4).  
The monitoring of the colony development over time demonstrated that, in case of P. aeruginosa colonies, 
morphological characterization should just be performed after, at least, 45 h of colony growth. 
Characteristic morphological features remained unchanged only after 45 h of growth for all tested solid 
media (Figure 2.1, 2.2, 2.3 and 2.4), and by this reason the assessment of P. aeruginosa colonies with 
less than 45 h of growth led to inaccurate characterizations and further misinterpretations. Several studies 
addressed observations of P. aeruginosa colonies with less than 45 h, which may raise the question 
whether the authors would achieve the same conclusions observing older colonies  [30, 40]. The diversity 
of SCV observed and described in the present study (Figure 2.4A – 2.4H) supports, as well, the need of 
colony characterization just when colonies reached the definitive and unchanged state. In literature, no 
studies reported high SCV heterogeneity besides the rough SCV possibly due to limited colony growth 
time allowed  [40, 41, 42]. The series of SCV presented in this study may play a relevant role on biofilms 
resistance or persistence against environmental stressors and antimicrobial agents. However, this role is 
unknown until now, possibly due to the improper colony characterization.  
Based on the results disclosed in the present study, a previous study of colony development before the 
main biological study is recommended in order to prevent the possible loss of data about colony 
morphology. In alternative to a prior colony development study, prolonged time of growth should be 
allowed and several subsequent colony observations should be performed until verification of 
unchangeable traits (with exception of size). This last approach is most adequate for hospital laboratories 
that generally do not have time for prior studies. Both approaches would allow determining the duration of 
complete colony morphogenesis and no morphotypes would be overlooked and mischaracterized. The 
detection of variants with slower growth rates is, for instance, particularly important for patients who are 
receiving antibiotic treatment. Morphotypes as SCV may be not detected due to their slow growth and/or 
overgrown and higher prevalence of other morphotypes as mucoid variant that can conceal SCV. Inter- 
and intra-species diversity of CF populations can be thus overlooked which represent a serious clinical 
issue. 
Another relevant factor when CF or other clinical samples are processing and plating in solid media, is the 
bacterial concentration of the sample. It is imperative the serial dilution of samples prior to plating on non- 
and selective media to facilitate detection and quantification of bacteria. Several reports exhibit images of 
colonies with various colonies surrounding each other  [17, 43, 44]. The present data showed that 
distance between colonies, an issue frequently ignored, is important. Neighbouring colonies might limit or 
alter morphogenesis possibly due to competition for nutritional resources or bacterial signalling and 
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communication. Be’er et al. (2009)  [45] reported that sibling colonies decelerate or even stop their growth 
when facing each other and stated that the production and perception of small signalling molecules may 
influence colony morphogenesis, gene expression and cell differentiation. Therefore, for colony 
morphology characterisation intermediate and low concentrations are preferred for obtaining properly 
separated colonies. 
The solid media used to grow bacterial colonies is also a condition of great discrepancy among reports. 
Regarding P. aeruginosa colonies, media such as TSA, LB agar, PIA and blood agar have been used to 
observe colony morphology variation  [16, 29, 46]. Selective media such as PIA and CET are very useful 
when clinicians suspect of P. aeruginosa infection. The selective media inhibit the growth of non-
Pseudomonas pathogens and facilitate the recovery of P. aeruginosa if it is present in the CF sample. 
Currently, there are insufficient evidences to recommend a particular type of medium to plate CF samples 
for better P. aeruginosa detection. Therefore, it is recommended to plate CF samples in both non- and 
selective media  [47]. In this study, both non- and selective media were used. 
It is well known that solid media composition influence fungal colony morphogenesis  [48], but concerning 
bacterial colonies, it was just demonstrated some colony morphology dependency on nutritional and agar 
concentration in the scope of colony pattern modelling studies  [49, 50, 51]. More recently, it was reported 
that mucoid morphotype detection might be variable among solid media  [52]. However, the real impact of 
solid medium variations on other morphological characteristics, including size, form, colour, texture and 
margin, has not been explored. The preservation of morphological features among solid media is critical in 
clinical diagnosis. The inconsistent detection of certain morphotypes such as SCV or mucoid variant 
makes the diagnosis unsure, leading to inaccurate antimicrobial treatment that may cause antimicrobial 
resistance in bacteria and contribute for infection persistence. Thus, the question of whether the detection 
of colony morphotypes is affected by the solid media used or not, i.e., dependent of nutritional composition 
of media, is of critical importance. Results obtained showed that the composition of the solid media used 
to plate P. aeruginosa, either coming from planktonic or biofilm cultures, is relevant to colony morphology 
definition. The effect of medium composition in colony patterns was clearly evident in traits as margin, 
colour and texture (Table 2.2). In addition, the present results evidenced that bacteria spread onto non-
selective medium as TSA generate more colony morphology diversity, in contrast with Pseudomonas 
selective agar such as PIA and CET. For instance, the expression of SCV morphotype from PAI1 biofilm-
cells on TSA were higher (eight SCV were detected), in contrast with just one morphotype on PIA and 
CET. This is maybe explained by the presence of irgasan in PIA and nalidixic acid and cetrimide in CET 
that may inhibit the growth of some colony variants  [53]. The perception of colony morphologies 
dependence of nutrients concentration challenges the traditional morphology-based methods to detect 
bacterial diversity and may affect the actual performance of clinical diagnosis culture dependent 
approaches. The results here obtained provided data for international centres such as those existent for 
CF disease to modify their guidelines, and expressly recommended to plate CF samples in both non- and 
selective media for detection diversity purposes. Furthermore, research laboratories should as well 
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consider which media is more adequate to obtain results, in particular, if they are testing hypothesis 
against other published studies. Comparisons should be performed in similar conditions. 
Considering all the issues previously discussed, a set of guidelines was proposed for authors, clinicians 
and technicians to implement when performing colony morphology characterization and further comparing 
results (Table 2.3). Scientific research and clinical diagnosis are the most benefited with similarity of the 
experimental procedures of the colony morphology method. This will lead to better comprehension of 
bacterial adaptation and evolution, purposes of fundamental science, with the ultimate goal of predicting 
antimicrobial resistance, expression of virulence factors and persistence ability based on morphological 
traits, relevant for supporting clinical diagnosis on bacterial profiling. 
 
Table 2.3. Guidelines to accurately perform and compare results among bacterial colony morphologies observations. 
General 
considerations 
For studies that are testing hypothesis against others studies, the conditions of colony 
observations should be as similar as possible, including solid medium, colony growth 
time and sample concentration. 
Solid media Select the solid media that most alike the human sites from which bacteria were 
isolated in order to improve detection of bacterial diversity. 
Height of solid media The height of solid media per plate should be standardized and not less than 0,5 cm 
(approximately 15 mL in 90 cm plates). 
Colony growth time A prior study should be performed before colony morphology evaluation; colony 
growth time is established for the time from which all morphological traits are constant 
over the time (with exception of size). 
For hospital laboratories, it should be allowed prolonged time of colonial growth and 
performed several subsequent colony observations until verification of unchangeable 
traits (with exception of size). 
Colony density per 
plate 
Colony morphology observation should not be performed using plates with increased 
number of colonies; there is not a general threshold because colony size is highly 
depending of the bacterial species. For instance, P. aeruginosa colonies are typically 
large and observation should be performed in plates with less than 15 colonies; in 
contrast, S. aureus colonies are typically minor, and observation can be performed in 
plates with 30 to 40 colonies. 
Bacterial strain Some reports and manuals indicate typical morphological patterns for bacterial 
species, however different genetic background and biological phenomena as 
phenotypic switching may alter the considerate typical patterns of a bacterial species. 
Therefore, previous guidelines should be always performed.  
Bacterial diversity 
detection 
To avoid losing information about diversity, clinical samples should be plated into non-
selective media. Plating in selective media should be performed only for detection of 
bacterial species in a sample. 
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2.3. Morphotyping of bacterial colonies using a renewed 
characterisation system 
2.3.1. Objectives 
Colony morphology is considered a method with great potential to detect bacterial diversity and to predict 
some bacterial features such as antimicrobial resistance and expression of virulence factors. Although the 
number of publications about this method has shown a substantial increase per year, the knowledge 
about the correlation between bacterial features and colony morphologies is inconsistent and 
unstructured. The main rationale of this work is the great variability of vocabulary, concepts and 
morphological criteria used by authors to describe colony morphologies. This inconsistency prompted the 
construction of a renewed universal characterisation system for bacterial colonies that might assist clinical 
and research laboratories to perform accurately colony morphology characterization. With the general use 
of this system, it would be possible to achieve a common lexicon for bacterial identification and 
characterization by colony morphology. Colony descriptions will become explicit, reliable and 
unambiguous and information about infecting populations will be easily shared among researchers, 
laboratories/centres, and clinicians. Through the interchange of information, clinical diagnosis may gain 
substantial and relevant knowledge about the infecting populations and disclose their mechanisms of 
adaptation and persistence and, this way, could prevent, control or even eradicate bacterial infections. 
 
2.3.2. Materials and Methods 
Revision of literature 
The process adopted to construct a characterisation system consisted the extraction and learning of terms 
and concepts used by authors in their publications (Figure 2.6). The process of document retrieval 
encompassed the screening of books, encyclopaedias and research papers. The research papers were 
compiled through PubMed keyword-based searches, combining terms related to morphological 
descriptions and bacterial colonies. Most content was harvested from the ‘Materials & Methods’ and 
‘Results & Discussion” sections, including the captions of figures and tables. 
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Figure 2.6. An overview of the literature revision for terms and concepts collection. The documents were retrieved via PubMed and 
analysed in detailed. Typically, colony morphology vocabulary was contained on “Methods & Materials” and “Results” sections and 
captions of figures. After vocabulary collection and listing, terms were organized in a structured way creating a renewed classification 
system for colony characterisation. 
Bacterial strains  
To test the constructed system based on vocabulary learning from literature for characterization of 
bacterial colony morphologies, in-house experiments were performed, including several bacterial species 
and strains to ensure colony variability. A total of 30 strains were used in this study belonging to 8 
bacterial species as described in Table 2.4, including P. aeruginosa, S. aureus, Escherichia coli, S. 
pneumonie, Klebsiella oxylota, Klebsiella pneumonie, Dolosigranulum pigrum and Proteus mirabilis. 
Bacteria were routinely cultured on TSB or TSA medium at 37 ºC. All strains were preserved in criovials 
(Nalgene) at – 80 ± 2 ºC. Prior to each experiment, bacterial cells were grown on TSA plates for 24 h at 37 
ºC. 
 
Planktonic cultures 
Planktonic bacteria grew overnight in TSB at 37 ºC, 120 rpm. Cell suspension of each strain was washed 
twice in sterile water by centrifugation (9000 g, 5 min) and, further serial diluted and plated on several 
solid media.  
 
 
 
ADVANCES IN DETECTION OF BACTERIAL DIVERSITY   
 88 
Table 2.4. List of the bacterial species and strains used in this study. 
Species Strain Description 
P. aeruginosa   
 ATCC 10145 Reference strain 
 ATCC 39324 Reference strain 
 PA01 Reference strain 
 PA14 Reference strain 
 CECT 111 Reference strain 
 PAI1 Superficial isolated 
 PAI2 Clinical isolated 
 PAI3  Clinical isolated 
   
S. aureus ATCC 25293 Reference strain 
 SAI1 Medical device isolated 
 SAI2 Clinical isolated 
 SAI3 Clinical isolated 
 SAI4 Clinical isolated 
 SAI5 Clinical isolated 
 SAI6 Clinical isolated 
 SAI7 Clinical isolated 
 SAI8 Clinical isolated 
 SAI9 Clinical isolated 
 SAI10 Clinical isolated 
 SAI11 Clinical isolated 
 SAI12 Clinical isolated 
 SAI13 Clinical isolated 
   
E. coli K12 MG1655 Reference strain 
 rpoS mutant Mutant strain 
 bolA mutant Mutant strain 
   
S. pneumonie  SPI1 Clinical isolated 
   
Klebsiella oxylota ATCC 13182 Reference strain 
   
Klebsiella pneumonie KPI1 Clinical isolated 
   
Dolosigranulum 
pigrum 
CIP 104051  Reference strain 
   
Proteus mirabilis SGSC 414 Reference strain 
 
Biofilm formation 
Biofilms were development as previously described  [28]. Briefly, bacteria grew overnight on TSB at 37 ºC, 
120 rpm. Cell suspension of each strain was diluted in TSB to obtain 107 CFU/mL as final concentration. 
Afterwards, bacterial suspensions were transferred to 96-well polystyrene microtiter plate where biofilms 
were developed aerobically on a horizontal shaker (120 rpm) at 37 ºC for 24 h. After that, biofilms were 
scrapped into sterile water, homogenized and biofilm-cells were serial diluted with sterile water and 
spread plated on several solid media. 
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Colony observation 
To assess colony morphology, bacteria were serial diluted and plated on different solid media, including 
TSA, CET, PIA, Muller Hinton agar (MHA), MacConkey agar, Klebsiella Selective Agar and Mannitol. After 
several hours  (different intervals of time were tested) at 37 ºC, colonies were observed by directly placing 
petri plates on magnifying glass (Olympus SZ-CTV) and photographed in a CCD camera (AVC, D5CE; 
Sony, Tokio, Japan). 
 
2.3.3. Results 
An extensive search in literature, including research papers, books and encyclopaedias, transversal to all 
knowledge areas was performed in order to gather terms used to describe colony morphologies formed by 
bacteria. More than one hundred terms related to colony morphology characterization were compiled. 
More than reviewing, it was attempted to organize the terms and construct a characterisation system 
based on those findings. Literature revision was filtered out, considering the exclusion criteria below: 
- terms with no clear definition (for example, “normal colony”; “atypical morphology”, “irregular 
shaped”, and “normal size”); 
- terms referring to characteristics of bacteria-forming colony, i.e. characteristics of the bacteria that 
form the colony rather than the morphological features of the colony (for example, “rod-shaped 
bacteria”); 
- derived terms (for example, “semi-fluffy”, “semi-dry”, “degree of colour”, “non-mucoid”, “slightly 
rhizoid”, “marginally convoluted”); 
- infrequent terms, i.e. those apparently used by only one author or research group. 
Then, the remaining terms were checked for definition inconsistencies and term synonyms. Typically, the 
most used term was chosen as the main descriptor of the morphological feature and the other related 
terms, but with identical meaning, were associated as synonyms to provide flexibility to the system. Based 
on these criteria, a first characterisation system was constructed (Figure 2.7). Seven categories, including 
form, margin, surface, elevation, opacity, size and colour composed the system. All seven categories 
comprised sub-categories that represented the detailed features of a colony. For instance, smooth, rough, 
wrinkled, brittle, moist, viscous, dry and mucoid are the sub-categories of surface. 
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Figure 2.7. The literature-based system of the colony morphology characterisation. The system is composed by 7 categories (form, 
margin, surface, elevation, opacity, size and colour) and 39 sub-categories, which are the detailed features of the main categories.  
 
Testing of the colony morphology characterisation system  
For the purpose of testing the feasibility of the system, several experiments were performed using 
different bacterial species in a total of 30 strains. All bacterial strains were grown in planktonic and biofilms 
state under different conditions: exposure to disinfectants, antibiotic treatments, oxygen limitation 
(anaerobiosis, microaerophilic), osmotic stress, inter- and intraspecies competition and combination of 
stresses. In addition, bacteria were collected, plated and grown under several conditions: distinct agar 
media, time of colony growth and oxygen availability (anaerobiosis, microaerophilic, aerobiosis). The 
diversity of bacterial strains, two modes of growth, panoply of stress factors and distinct plating conditions 
ensured a priori increased colony morphology diversity to intensively test the system constructed.  
Hundreds of colony morphologies were analysed and characterized. The vast colony morphologies 
obtained allowed noticing that the system based on the actual criteria was valid but pointed out some 
constrains. First, some P. aeruginosa colonies exhibit an enveloping part or structure after the margin that 
surrounds the colony (Figure 2.8A), which was not included in the system. This part of the colony was 
named as ‘sheath’. Because of the fact that some colonies exhibited sheath and others did not, it seemed 
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that this differential feature should be described and included in the system Second, colonies can exhibit 
more than one type of surface. For instance, P. aeruginosa colonies can exhibit surfaces with smooth and 
wrinkled zones (Figure 2.8B), smooth and rough zones (Figure 2.8C), or rough and wrinkled zones (Figure 
2.8D). These types of morphologies with more than one type of surface were not predicted in the system 
and should be well identified. Third, the large number of colonies examined allowed to take notice another 
relevant issue about colony surface, the difference between wrinkled and rough surfaces. It was observed 
that some colonies could present greater vertical irregularities (Figure 2.8B) and other exhibited smaller 
vertical irregularities (Figure 2.8C). As the dimension of the irregularities was different, it should be 
described as a distinct feature. In fact, there are two terms to describe colony surface irregularities, 
wrinkled and rough, but they are frequently used as synonymous and rarely as a differential feature and 
thus the system considered them as the same characteristic  [16, 40]. However, the system should 
differentiate these two types of irregularities to better typing colonies. Fourth, still regarding colony 
surfaces, features as dry or mucoid, included in surface category, were not characterized through simple 
observation as the other surface features (smooth, rough and wrinkled). Brittle, moist, viscous, dry and 
mucoid features were evaluated when colonies were taken off from agar media. By this reason, the 
inclusion of different kind of features in the same category did not seem adequate. Fifth, the definition of 
size was not adequate for all species. The presence of SCV was detected in several biofilm populations, 
however they exhibited a wide range of diameters according to the bacterial species. For instance, P. 
aeruginosa and K. pneumonie SCV exhibited typically diameters above 3 mm (Figure 2.8C and E, 
respectively), in contrast to S. aureus SCV that typically exhibited diameters above 1-2 mm (Figure 2.8F). 
Therefore, the system was improper, concerning colony size description. 
To enhance the descriptive abilities of the characterisation system, the initial structure was extended to a 
total of 10 main categories and 45 sub-categories (Figure 2.9), and some definitions of categories and 
sub-categories improved (Table 2.5 and Table S2.1 in Supplemental Material, respectively). The following 
subsections introduce all terms, explaining the semantics adopted by the system and discussing the 
semantic inconsistencies and ambiguities found in literature.  
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Figure 2.8. Colony morphologies of (A) to (D) P. aeruginosa; (E) K. pneumonie; and (F) S. aureus that exhibited traits not predicted 
by the first version of the colony morphology characterisation system. Black bars = 1 mm 
 
 
 
Table 2.5. Definitions of the terms that composed the categories of the last version of the colony morphology characterisation 
system. 
Category name Definition 
Form The external appearance or configuration of the clearly defined area of a colony. 
Margin A limit zone or area immediately adjacent to a colony. 
Sheath A structure after the margin that surrounds a colony. 
Type of Surface A morphological feature related to the superficial or outer appearance of a colony having one or more type of textures. 
Texture Appearance or physical structure or composition or organization of morphological features or irregularities present on a colony surface. 
Consistency Degree of coherence, density, firmness or viscosity of a colony. 
Elevation Appearance or configuration of a colony above the agar surface and observed from lateral perspective or side view. 
Opacity An optical quality of colony based on the amount of visible light transmitted through the colony mass. 
Size Physical dimension, extension or magnitude of a colony including sheath, if present. 
Colour Chromatic appearance of a colony. 
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Figure 2.9. Final structure of the colony morphology characterisation system. The system is composed by 10 categories (form, 
margin, sheath, type of surface, texture, consistency, elevation, opacity, size and colour) and 45 sub-categories, which are the 
detailed features of the main categories (for instance brittle, dry, moist, mucoid and viscous). Green boxes represent the new 
categories introduced in this version of the system.   
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Form 
The term form is commonly used to describe the whole configuration of a colony. For example, “…overall 
surface shape (convex, crater, lobulated, radial, radioumbilicated, radio-umbonated, peaked, rugose, 
segmented-rugose, segmented-umbilicated, umbilicated, umbilicated with irregular edge, umbilicated with 
heaped-up irregular edge, or umbonated).”  [54], or to differentiate colonies with certain characteristics, 
such as “…two distinct colony morphology variants that switched between a transparent form, facilitating 
adherence and carriage, and an opaque form that poorly adhered…”  [33]. So, in the characterisation 
system form is concerned to the geometrical configuration of the colony, for instance circular, elliptical, 
rhizoid, filamentous, fusiform and irregular. 
 
Margin 
The description of the margin of the colony, also referred to as edge or border, is typically based on the 
characteristics of the colony circumference. For example, “Colony type 2 was hard, more orange in colour, 
non-rhizoid or only slightly rhizoid, and had irregular edges and convex growth form. Colony type 3 had 
round edges, and smooth, yellowish appearance.”  [20], “ ‘fried egg’ SCVs, with translucent edges 
surrounding a smaller elevated…”  [55], “other colonies (approximately 60 % of the total) were smaller with 
somewhat rough edges”  [56]. In the characterisation system, margin represents the configuration of the 
limiting border of the colony, including entire, undulate, erose, lobulated, filamentous.  
 
Sheath 
The description of sheath is not common in colony morphology observation. However, this structure is 
often present in P. aeruginosa colonies, which are clinically recurrent, and it is quite variable (Figure 2.7). 
Based on the results obtained, this may be a valuable element in the description of colony differentiation. 
So, it was included in the characterisation system. The descriptors of sheath include sheath present, 
sheath absent. 
 
Type of Surface 
As abovementioned, some bacterial species can form colonies with more than one type of texture at the 
surface (Figure 2.7B, 2.7C and 2.7D). As such, a new category, named ‘type of surface’, was added to the 
system to describe how many types of textures or irregularities were exhibited by the colony surface. 
Notably homogeneous surface when a surface has just one type of texture and heterogeneous surface 
when the surface presents more than one type of texture. 
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Texture 
Colony texture, also referred to as surface or roughness, is a very common feature in morphological 
descriptions. Its importance arises from experimental evidence that rough colonies are often associated 
with key pathogenic phenomena, such as augmented virulence potential  [16, 57].  
In literature, it was found examples of general texture descriptions applied to colony morphology such as: 
“PA14 lasR mutant formed a flat, smooth colony as compared to the wrinkled wild-type phenotype”  [57], 
“the ST variant formed colonies that were smaller and had a rough, wrinkled, and dry surface appearance 
compared to the smooth, larger WT colonies”  [40] and “… type I (wrinkled, purple, dry and irregular giant 
cristae; n = 8), II (wrinkled, purple, dry and volcanolike; n = 6), (…) V (smooth, pale, mucoid and raised 
circles; n = 3), VI (smooth, pale, mucoid and even glistening; n = 2)…”  [58]. This feature may also be 
used to describe the form of the colonies. For instance, “… overall surface shape (convex, crater, 
lobulated, radial, radio-umbilicated, radio-umbonated, peaked, rugose, segmented-rugose, segmented-
umbilicated, umbilicated, umbilicated with irregular edge, umbilicated with heaped-up irregular edge, or 
umbonated)”  [54].  
The contents of the previous category surface were separated since they are assessed in different ways. 
The features smooth, wrinkled and rough are indeed surface features and thus remain in the category. 
However, as they particularly characterise the texture of the surface, the category was renamed as 
texture. Concerning the other elements of the category surface (Brittle, moist, viscous, dry and mucoid), 
they are not surface but consistency features and, thus, were moved to a new category (see consistency 
section). Then, the texture in this system denotes the presence or absence of irregularities on the colony 
surface. 
In addition, often enough, the types of texture rough and wrinkled are used as synonymous or as 
discriminating characteristics  [16, 40, 59]. The characterisation system addresses this conceptual 
ambiguity by defining the terms wrinkled and rough in accordance to the interpretation provided by the 
results here obtained.. When irregularities are present, their form is depicted as wrinkled or rough if the 
vertical irregularities are large or small, respectively. A surface showing no irregularities is described as 
smooth. 
 
Elevation 
Typically, the elevation describes the form of growth of the colony observed from a side perspective. For 
example, “Colony type 1 was rhizoid and flat with yellow centre. Colony type 2 was hard, more orange in 
color, non-rhizoid or only slightly rhizoid, and had irregular edges and convex growth form.”  [20]. In the 
characterisation system, elevation and form were differentiated, that is, one corresponds to the side 
perspective of colony form and the other describes the overall geometric colony configuration, 
respectively. The descriptors of elevations include flat, raised, convex, pulvinate, and umbonate. 
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Consistency 
Consistency is frequently described as a surface property. For instance, “… characterisation of two B. 
cenocepacia sequential isolates displaying different morphotypes (mucoid vs non-mucoid) isolated from a 
CF patient…”  [60], “… P. aeruginosa PDO300 showed a nonmucoid colony morphology…”  [30] and “… 
type I (wrinkled, purple, dry and irregular giant cristae; n = 8) (…) IV (wrinkled, pale, semi-dry and 
volcanolike; n = 2), V (smooth, pale, mucoid and raised circles; n = 3)…”  [58]. Similarly to what happens 
with the texture, consistency is often described as a form or surface characteristic  [54]. The examination 
of consistency is distinct of form and texture. It is needed to take off colonies from the agar plate to 
describe their consistency in contrast from form and texture whose description is just based on 
observation. By these reasons, in the characterisation system, form, texture and consistency were 
separated and consistency was defined as density, firmness, or viscosity. Colonies can be brittle, moist, 
viscous, dry and mucoid. 
 
Opacity 
Opacity has been described as an important colony feature in different pathogenic morphotypes. For 
instance, in the case of S. pneumonie colonies “…two distinct colony morphology variants that switched 
between a transparent form, facilitating adherence and carriage, and an opaque form that poorly 
adhered…”  [33] and in the case of Pseudomonas fluorescens colonies, “… The original isolate formed 
thick opaque colonies…”, “… After three days of growth in liquid KB medium, flat and translucent colonies 
were found…”  [21]. Therefore, opacity was included in the characterisation system and defined as a 
characteristic of the colony to absorb visible light. 
 
Size 
The feature size is a well-recognised trait in colony characterisation. For instance: “… strain 43895OR is 
also similar to the rdar strains of S. enterica serovar Typhimurium in characteristics such as colony 
size…”, “… E. coli strain 43895OR forms a larger colony…”  [26], “… Temperature-induced SCVs were <1 
mm in colony size …”  [61] and “… Analysing the persisting bacteria revealed a high phenotypic diversity, 
showing normal, small and very small colonies…”  [18]. 
The significance of the size description arises from the association between the appearance of small 
colonies and increased antibiotic resistance  [55, 62]. However, it has conceptual gaps. For instance, 
Haussler and colleagues (1999)  [15] considered P. aeruginosa SCV those that have 1-3 mm of diameter. 
However, several other authors study P. aeruginosa SCV without any clear assumption about the 
diameter range of the colony  [16, 63]. Additionally, this definition of size is highly taxon-dependent as 
abovementioned. For instance, the dimension of a small colony of P. aeruginosa, in general defined as 
below 3 mm, does not correspond to the dimension of a small colony of S. aureus, typically defined as 
below 1-2 mm. Therefore, in the characterisation system the sub-categories of size were defined in a 
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taxon-independent manner such that the small denotes a colony dimension nearly one-tenth less than the 
size of the wild-type colony and the large denotes colonies exceeding this threshold.  
Colony size can be reported as well in a quantitative manner. Diameter measurements are also frequently 
used to characterise the size of the colony. For instance, “… The following features of colony morphology 
were recorded: colony size (measured in mm by ruler)…”  [33] and “… cells of the rdar strains were 
reported to reach colony diameters of 6 cm…”  [26]. The inclusion of diameter into the system, the unique 
quantitative class, was due to limitations of qualitative size characterization. The characterization of a 
colony as small or large is dependent of the wild-morphotype species. The real dimension of a colony 
must be included and recorded numerically for unequivocal perception of small or large dimensions. In the 
characterisation system, diameter was thus included as a sub-category of size and defined as the 
distance between two equidistant points of the margin or sheath.  
 
Colour 
The chromogenesis or colour exhibited by bacterial colonies is very important when describing clinical 
morphotypes because it is associated with the differential production of various pigments  [64, 65]. Some 
examples of colour description applied to colony morphology are: “… certain strains of Salmonella that 
displayed a red and dry colony phenotype…”; “… the white variants do not revert back to a dry, red 
phenotype...”  [26], “… StNMSm (straw-colored, nonmucoid, and smooth) morphotypes exhibited 
decreased frequency of pyocyanin overproduction…”  [64] and “Colony type 3 had round edges, and 
smooth, yellowish appearance. Type 4 colonies were white or light yellow, smooth and spreading on the 
agar with irregular shape.”  [20]. In the characterisation system, colour was included and defined as a 
composite chromatic quality composed of hue, saturation and intensity parts. A diverse and automatic 
pallete of colours could be incorporated into colour category, but for now it was chosen to focus on the 
colours that have already been documented in the literature. Therefore, characterisation system includes 
these “basic” colours, notably white, black, grey, brown, yellow, red, orange, green, blue, pink and violet. 
 
2.3.4. Discussion 
Colony morphology variation or “dissociative behaviour”, firstly described in 1964 by Zierdt et. al  [66], is 
able to detect phenotypic diversity of bacterial populations that other methods do not easily identify. 
Through colony morphology observation, it was possible to verify, for instance, the occurrence of clonal 
diversification of bacteria in CF lungs crucial to understanding the existence of microevolutionary 
pathway  [67, 68]. Despite its importance and potential, colony morphology characterization has many 
limitations. In addition to the restrictions inherent to being a culturing-dependent method, colony 
morphology characterization presents high variability in its performance, despite having a simple 
procedure. The vocabulary, concepts and morphological criteria used by authors to characterize and 
describe the colony features are indeed one of the most important handicaps to achieve an accurate 
typing of bacteria. All of the work related to colony characterisation has been performed without common 
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lexicon for colony description, classification or even designation. Such conceptual variability makes 
comparisons among colony morphology data inadequate. Vocabulary and criteria used by community 
need to be universal, consistent, unambiguous to effectively represent, analyse and, most important, to 
interchange data among experiments, species, clinical samples, patients, infections or diseases.  
The first attempt to obtain a systematization of vocabulary about bacterial growth was in 1901 when 
Chester  [69] compiled several criteria and terms that can be used to characterize the different types of 
bacterial cultures. Some of those criteria and terms are now old-fashioned and inaccurate, considering 
current knowledge about bacterial diversification in terms of colony morphology patterns. Later, David 
Bergey modified the manual proposed by Chester and it remains today the major treatise since its first 
publication in 1926  [70]. Bergey extensively described the typical morphological patterns of colonies 
formed by the several bacterial species identified so far. However, Bergey did not state which criteria were 
chosen to characterize those bacterial colonies. Meanwhile, several different terms and criteria have 
emerged and have been used to characterise colonies. As so, a renewed and universal characterisation 
system for bacterial colonies is required. Such system will have great impact in several scientific areas, 
since colony morphology characterization has been used for different purposes in panoply of scientific 
areas and, certainly, will impact the clinical diagnosis. The novelty of this study was the organisation of the 
current terms in a structured way never performed before. 
After a careful and extensive study of all terms and criteria used since early ages to characterise bacterial 
colonies, an organised system was constructed. The literature-based system was tested with in-house 
colony morphologies and, although it has revealed to be valid, it has exhibited some limitations. According 
the detected limitations, the system was improved. In the end, the colony characterisation system 
indicated as the main morphological criteria that should be used to describe colony morphologies: form, 
margin, sheath, type of surface, texture, elevation, consistency, opacity, size and colour (Figure 2.5). Each 
of these categories has its own vocabulary, the sub-categories, allowing thus to achieve an accurate 
description of the colony morphology. Most of the terms and definitions that composed this system are 
widely used by the microbiological community to characterize and differentiate colony variants.  
This system provides to scientific and clinical communities a set of minimum information about colony 
morphologies that should be contained on descriptions, reflecting the most essential aspects of colonies. 
It should be emphasised that colonies described using a common lexicon are more easily compared 
across species, strains, patients, experiments, laboratories, infections or diseases. 
More than the organisation of the terms, this system aimed at standardising the conceptual definitions of 
each term (main categories and sub-categories), included in the system. This characterisation system 
attempted to capture the precise meaning of each term, avoiding variability, heterogeneity and ambiguity. 
Therefore, each term had an associated concept to avoid dubious understandings so that authors might 
use them unmistakably. The general understanding of the meaning and use of terms and vocabularies is 
essential to standardize colony morphology descriptions and to facilitate the comparisons between reports 
and knowledge advance about phenotypic plasticity, bacterial adaptation and evolution.  
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This characterisation system also included alternative terms or synonymous for categories or sub-
categories. Terms, either main or sub-categories, are not obligatory. Authors can use any term of their 
preference although with the commitment that term means which is stipulated in the system. The inclusion 
synonymous makes the system flexible. It is important not to break with current concepts abruptly and 
impose a radical “culture” change of colony terms and criteria. The clinicians and researches adherence to 
the system is desirable.  
This classification system of bacterial colony morphologies does not represent a static entity. The 
characterization of colony morphologies is a challenging task because bacteria are unpredictable 
organisms always changing to overcome stressor factors, such as host environment and/or fluctuations, 
immune defences and antimicrobial actions. Therefore, morphological criteria, vocabulary and concepts of 
this system should be continuously upgraded. Suggestions of new or alternative terms, as well as 
concepts are very welcome.  
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2.4. A new approach to bacterial colony morphotyping by matrix-
assisted laser desorption ionization time of flight-based mass 
spectrometry 
2.4.1. Objectives 
Over the years automated methods for bacterial identification and characterization were continuously 
demanded, attempting to respond to the clinical needs of fast and reliable diagnosis. Colony morphology 
characterisation can take days to return results because bacteria need to grow, which imposes significant 
delay to action in situations where timely intervention is urgently needed to reduce associated costs. 
MALDI-TOF MS is considered a robust and reliable tool for bacterial taxonomy identification including 
species and strain differentiation. To date MALDI-TOF MS ability to discriminate at colony morphology 
level has not been assessed yet. To enable faster response of colony morphology characterisation 
method demanded by clinical diagnosis, the present study aimed at assessing MALDI-TOF MS as a tool 
for colony morphology differentiation. To this end, a standardized sample preparation protocol for bacteria 
and a MS data analysis taken with a MALDI-based method elaborated for rapid colony morphology 
profiling was used as proof-of concept with two main human pathogenic bacteria, P. aeruginosa and S. 
aureus.  
 
2.4.2. Materials and Methods 
Materials and reagents 
All culture media used in this study were obtained from Liofilchem Diagnostic.  The following reagents 
were used to perform MALDI-TOF MS analysis: trifluoroacetic acid (TFA) 99 % (v/v) was from Riedel-de-
Haen (Seelze, Germany), α-cyano-4hydroxycinnamic acid (α-CHCA) and sinapinic acid (SA) both puriss 
were from Fluka (Buchs, Switzerland). Milli-Q water was used throughout the experiments. All the 
chemicals used were of analytical-reagent grade, unless otherwise specified. All materials were used 
without further purification. 
 
Bacterial strains and culture conditions 
The strains tested were P. aeruginosa ATCC 10145 and S. aureus ATCC 25293. These bacteria were 
routinely cultured on TSB or TSA medium at 37 ºC. All strains were preserved in criovials (Nalgene) at – 
80 ± 2 ºC. Prior to each experiment, bacterial cells were grown on solid media for 24 h at 37 ºC. S. aureus 
was included in this study to verify whether the possible MALDI-TOF MS ability to discriminate colony 
morphologies was not exclusive to one bacterial species.  
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Biofilm formation 
P. aeruginosa ATCC 10145 and S. aureus ATCC 25293 were allowed to form 24-h-old biofilms as 
described previously   [28]. Bacteria inocula were grown overnight on TSB at 37 ºC in air conditions, and 
then diluted in fresh TSB to obtain suspended cultures with 107 CFU/mL as final concentration. 
Afterwards, each bacterial suspension was transferred to 6-well polystyrene plate, where biofilms were 
developed aerobically on a horizontal shaker (120 rpm) at 37 ºC for 24 h. Then, biofilms were scrapped 
into sterile water, homogenized; being the biofilm-cells serially diluted with sterile ultrapure water and 
spread on solid media plates. 
 
Observation and classification of colony morphology 
To assess colony morphology, bacteria from planktonic and biofilm cultures were allowed to grow on solid 
plates during 72 h at 37 ºC. This step was aimed at obtaining complete and unchangeable morphotypes of 
both species. Colony morphologies were observed by directly placing the petri plates on a magnifying 
glass (Olympus SZ-CTV) and photographed in a CCD camera (AVC, D5CE; Sony, Tokio, Japan). Colony 
morphotyping was based on the proposed characterisation system of bacterial colonies (see section 2.3). 
Therefore, colonies were described using key morphological features, including form, margin, type of 
surface, texture, size, sheath, elevation, opacity, consistency and colour  [54, 58, 71]. In addition, a 
quantitative parameter, the diameter, expressed in millimetres, was also included in the characterisation.  
 
Bacterial preparation for MALDI-TOF MS 
The different colonies of each bacterium were transferred from solid media to the extraction tube with a 
plastic loop. P. aeruginosa cells were re-suspended in ultrapure water and treated following a previous 
described protocol with some minor modifications as follows  [72]. Cells were washed with 0,1 % (v/v) of 
TFA, re-suspended in 200 µL of chloroform-methanol (1:1) and vortexed for 1 min. The cell suspension 
was centrifuged at 9000 g for 8 min and the resulting pellet re-suspended in 15 µL of 0,1 % (v/v) of TFA. 
Different matrix solutions were daily prepared with α-CHCA and SA as follows: 10 mg of α-CHCA were 
dissolved in 50 % (v/v) of acetonitrile (ACN) and ultrapure water containing 0,1 % (v/v) of TFA; 20 mg of 
SA were dissolved in 30 % (v/v) of ACN and ultrapure water containing 0,3 % (v/v) of TFA. Then, each of 
the aforementioned matrices were mixed with the cellular sample (1:1), and the mixture was vortexed for 
30 s. Each mixture (cell sample and matrix solution) was spotted on the MALDI target plate and allowed to 
dry at room temperature. 
The treatment of S. aureus cells was performed according to Carbonnelle et al.  [73] with some 
alterations. 1:1 (v/v) matrix to sample ratios were investigated by changing the matrix composition to 
assess the best matrix for this bacteria. The bacteria were first spotted into the MALDI plate and then the 
bacteria were covered by the matrix. The mixture was allowed to dry at room temperature.   
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MALDI-TOF MS analysis 
An Ultraflex II MALDI-TOF/TOF instrument equipped with a nitrogen laser radiating at 337 nm from Bruker 
Daltonics was used to acquire bacteria mass spectra. 
Measurements were done using the reflector positive ion mode, with a 20 kV accelerating voltage, 75.1 % 
grid voltage, 0.002 % guide wire, and a delay time of 140 ns. Mass spectra were taken in the m/z range of 
2000-20000 and obtained in different regions of the same sample, based on the acceptance criteria of 
1000 laser shots per spot. External calibrations were performed with a Protein Calibration Standard I 
(Bruker Daltonics). 
Mass spectra were processed with FlexAnalysis software (Version 2.4), subjected to baseline correction, 
noise filtration, normalized to the base peak, smoothed using Gauss algorithm and analysed considering 
the mass interval of 2000-20000 Da (due to the good reproducibility of spectra profile at that range). In 
order to avoid the presence of noisy peaks, each sample was spotted five times in the MALDI MS, the 
resulting spectra were aligned allowing an m/z error of 750 ppm, and those peaks that did not appear in, 
at least, three of the five spectra were discarded. 
 
Clustering Analysis 
An agglomerative hierarchical clustering was employed to analyse the individual spectrum and peak 
similarities. The clustering was constructed using a custom implementation of the Unweighted Pair Group 
Method with Arithmetic Mean  [74] algorithm with Hamming distance  [75] as the distance metric. It was 
decided to choose this distance metric instead of the more common Euclidean distance since it was not 
used the peak intensity information. Therefore, the clustering was built taking into account solely the 
presence or the absence of the peaks in each spectrum. The clustering results were presented as heat 
maps using the Java Treeview software  [76].  
The peak lists used in the clustering analysis were filtered applying a Chi-squared test of independence 
corrected using Williams’ Correction, and selecting those peaks with a p-value under 0.05. That is, only 
the most discriminative peaks were used.  
 
2.4.3. Results and Discussion 
S. aureus and P. aeruginosa are the most prevalent pathogens in CF lungs in child and adults, 
respectively  [77]. One of the major concerns of the medical community related to those pathogens is the 
increasing resistance displayed by bacteria to antibiotics over infection development in CF lungs  [78, 79, 
80]. Resistance seems to be potentiated when bacteria switch from planktonic or free-living state to 
sessile lifestyle and start growing as biofilms that are more resistant and persistent to antimicrobial 
stressors than their planktonic counterparts  [81]. Therefore, it seemed important to include in this study 
colony morphotypes developed by both planktonic and biofilm-associated bacteria.  
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The success of the treatment to eradicate those infections is highly dependent on the speed and precision 
of pathogen identification and characterisation. Microbial diagnosis demands thus rapid, sensitive, 
specific, easy to perform (not labour intensive) and high-throughput methods for bacterial identification 
and characterization  [1]. MALDI-TOF MS approaches are able to perform species identification and even 
strain differentiation based on molecular signatures in a quick and simple way  [82]. Direct bacterial 
profiling by whole bacteria analysis is one of the most attractive approaches of MALDI-TOF MS, 
particularly in bacterial identification and differentiation. The direct deposition of “intact” bacteria mixed 
with matrix on the MALDI plate simplifies the laboratory procedures, thus minimising the costs and time 
taken in preparing the samples, without accuracy losses  [83].  
The fast and reliable results obtained by MALDI-TOF MS coupled with its simple procedure seemed an 
excellent method to combine with colony morphology characterisation. The high-throughput feature of 
MALDI-TOF MS could accelerate the rate of generating data on colony morphology discrimination and 
therefore morphotypes could be anticipated without culturing steps. In near future, morphotypes 
discrimination could be based on matching against constructed libraries with characteristic spectra/peaks 
for each morphotype. Researchers and clinicians could be able to automatically identify the morphotype-
associated bacteria and even the biological features of the bacteria (antibiotic resistance profiles and 
virulence factors expression). This will greatly impact the cuurent clinical diagnosis. 
 
MALDI-TOF MS analysis optimization 
For colony morphotypes fingerprint and further comparison of spectra, reproducibility plays a crucial role. 
As this study aimed intra-strain differentiation, high quality and reproducibility of spectra have even more 
significance. A total of 4 morphotypes for each species were studied and for each morphotype a total of 
three to six biological replicates were used. The range of replicates was variable because of distinct 
prevalence of each morphotype in planktonic and biofilm cultures. Each biological replicate was spotted 
into the MALDI plate five times. 
Spectra reproducibility is also highly dependent on the sample preparation method used and, for that 
reason, an extensively search about sample pre-treatments was performed. Liu et al. (2007)  [72] reported 
an extensive study of sample preparation methods for identification of Gram-negative and Gram-positive 
bacteria ensuring high quality and reproducibility of spectra obtained. Due to being simpler and faster, this 
method was chosen to test in this study. Following this optimized method, to clean bacteria from 
contaminants originated by the culture medium present at the bacterial surface and that would eventually 
cause interfering m/z peaks in the MALDI spectrum, a solution of chloroform and methanol was used  [72]. 
After the cleaning procedure, the bacteria were pelleted by centrifugation and then the pellet was re-
suspended in 0.1 % (v/v) of TFA. Before MALDI analysis, an equal volume of sample and matrix, α-CHCA 
or SA, was mixed. The mixture was then vortexed and 1 µL of this solution was spotted into the MALDI 
target in five different spots.  
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Influence of the type of matrix 
The matrix used to aid in the ionization process is of main concern in MALDI analysis. The most used 
matrices are α-CHCA, SA, 2,5-dihydroxybenzoic acid (DHB), or ferulic acid  [84]. Currently, there is no 
consensus about the most adequate matrix or which matrices should be used for a particular sample or 
analyte. In general, α-CHCA is used in those cases where the analytes are mainly peptides with molecular 
masses below 10 KDa, whilst SA is used for those cases where the analytes are high mass peptides or 
proteins, above 10 KDa  [84, 85]. DHB is considered a universal matrix for MALDI analyses although 
several studies have reported no peptide/protein signals due to low homogeneity of sample/matrix 
mixture, lower sensitivity, and difficulties in ionization of analytes of high-mass range. DHB is usualy used 
to study oligosaccharides, glycopeptides, and glycoproteins. Ferulic acid is usually used for ionization of 
analytes with higher molecular weigh up to 70 kDa. Several studies have reported good resolution of 
signal and reproducibility among shots  [73, 84].	   
Evidences have demonstrated that the use of different matrices causes significant alterations in MALDI 
spectra  [84]. In order to avoid the loss of potential significant information needed to obtain accurate 
fingerprints of morphotypes, this study included the two most used matrices, α-CHCA and SA. Figure 2.10 
shows spectra of different morphotypes of P. aeruginosa using both matrixes. From the results obtained it 
may be concluded that the spectrum obtained with α-CHCA had more m/z signals with higher intensity 
that the ones observed in the spectrum obtained with SA. In other words the best matrix for P. aeruginosa 
was anticipated to be α-CHCA, which was later confirmed by statistical assay. The richer is the spectrum 
in signals, the better classification is attained, as there is a higher chance to find differences between 
morphotypes.  
Although the method mentioned above had provided excellent spectra for the P. aeruginosa, it failed to 
obtain m/z signals for S. aureus. It was hypothesised that this was due to the low mass of bacteria 
transferred to the MALDI plate, since the size of the S. aureus colonies were considerably lower than P. 
aeruginosa colonies, and differences in the size and in the surface topologies of both types of bacteria. 
The cell walls of Gram-positive bacteria are usually more difficult to analyse using MALDI-TOF MS than 
the cell walls of Gram-negative bacteria which results in fewer peaks and lower peak intensities  [86]. In 
addition, colonies should be not grown for no more than 48 h because the excessive cultivation time can 
weaken and reduce the detection of characteristic peaks by MALDI-TOF MS  [3]. In this study, colonies 
were allowed to grow during 72 h to achieve complete colony morphogenesis, which may have affected 
the obtainment of MALDI-TOF MS spectra. Consequently, for the case of S. aureus a different approach 
was attempted. First, the cleaning step was avoided, as it was observed that some bacteria were lost 
during this step. However, again no signal was obtained. So an additional change was made. The 
crystallization process was modified. It is well known that in many cases the crystallization process 
severely affects the MALDI spectrum  [85]. According to Vaidyanathan et al. (2002)  [87], the deposition 
method that produces the best spectra in terms of number of detected signals and signal-to-noise ratio 
was first deposited bacterial suspension on MALDI plate, let it dry and after overlaid with the matrix 
solution. Therefore, it was applied the described method for S. aureus colonies. First, the bacterial 
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solution was spotted, let to dry and, then, the matrix solution (α-CHCA or SA) was spotted over the dry 
sample. Once the matrix was also dry, the MALDI analysis was performed. With such modifications, good 
spectra were obtained using either α-CHCA or SA, as shown in Figure 2.11.  As a matter of fact, the 
spectra were similar for both α-CHCA and SA, being difficult to distinguish through naked eye. So, for this 
case it was not possible to anticipate which matrix would provide the best results for classification 
purposes. 
 
 
Figure 2.10. MALDI-TOF MS spectra of the different colony morphotypes of P. aeruginosa obtained using (a) α-­‐CHCA and (b) SA 
matrices.   
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Figure 2.11. MALDI-TOF MS spectra of the different colony morphotypes of S. aureus obtained using (a) α-­‐CHCA and (b) SA 
matrices.   
 
Colony Morphology Classification 
In this work, the new standardising morphological characterisation system proposed in section 2.3 was at 
the base of the colony annotation process. Morphological criteria used include form, margin, sheath, type 
of surface, texture, size, elevation, opacity, consistency and colour. Based on the aforementioned criteria 
four morphotypes of P. aeruginosa and four of S. aureus (Figure 2.12) were classified as described in 
Table 2.6. As may be seen, in terms of morphology, P. aeruginosa morphotype A differs from B, C and D 
in 3 of the 10 parameters investigated. B differs from C and D in 2 parameters, and C differs from D on 
one parameter. In other words, the classification seems as follows A>>>B, C, D; B>>C, D; and C>D, 
where each “>” means one parameter of difference. 
For the case of S. aureus, the morphological classification was more troublesome. Non- and SCV 
morphotypes only differed in a maximum of two parameters (Figure 2.12 and Table 2.6).  Thus, 
morphotypes A and B differs in two parameters as well as B and C. A and B differs from C and D in one 
parameter whilst C and D differs between them in one parameter. In other words, A>>B; B>>C; A>C,D; 
B>D; C>D. 
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In an attempt to classify those morphotypes in a new, fast and straightforward way, we used MALDI mass 
spectrometry-based fingerprinting, as described below. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.12. Colony morphotypes of P. aeruginosa and S. aureus analysed by MALDI-TOF MS. 
  
Table 2.6. Comparison of the classification results obtained from morphological and MALDI-TOF MS categorization of P. aeruginosa and S. aureus colonies. Colonies were morphologically organized in 
four distinct groups according ten qualitative and one quantitative criteria.  
 
Morphotype 
designation 
Colony Morphotyping classification MALDI-TOF 
MS 
classification Form Margin Type of Surface Texture Sheath Opacity Elevation Consistency Size Colour 
Diameter 
(mm) 
P. aeruginosa             
A Circular Undulate Heterogeneous 
Rough 
and 
wrinkled 
Inexistent Opaque Flat Dry Large Green 9 
A = B 
B Circular Lobulate Homogeneous Rough Inexistent Opaque Flat Dry Large Green 7 
C Circular Undulate Homogeneous Rough Inexistent Opaque Flat Dry Large plusa Green 10 C 
D Circular Undulate Homogeneous Rough Inexistent Opaque Flat Dry Large Green 6 D 
S. aureus             
A Circular Entire Homogeneous Smooth Inexistent Opaque Flat Dry Large Yellow 3 
A = B 
B Circular Entire 
Homogeneous 
with 3 distinct 
zones 
Smooth Inexistent Opaque Flat Dry Large Yellow 4 
C Circular Entire 
Homogeneous 
with 2 distinct 
zones 
Smooth Inexistent Opaque Flat Dry Small Yellow 2 
C = D D 
Circular Entire 
Homogeneous 
with 3 distinct 
zones 
Smooth Inexistent Opaque Flat Dry Small Yellow 2 
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MALDI-TOF MS Classification 
The spectra obtained, a total of 140, were clustered using the methodology described in section 2.4.2.  
For the P. aeruginosa, a cluster was done with the data taken from the spectra that were obtained using 
α-CHCA (Figure 2.13A). As it may be seen, MALDI clusters the morphotypes into three main groups, two 
single groups constituted by the morphotypes C and D and a group constituted by morphotypes A and B. 
Morphotype D is clearly separated from the other morphotypes, while morphotype C appears slightly 
mixed with some samples of morphotype B. Although samples of morphotype A are also mixed with 
samples of morphotype B, there is a clear separation between morphotype A and morphotypes C and D. 
The same result was attained with the spectra obtained with SA. 
The characteristic peaks concerning the three groups (A/B, C and D) were compared with those reported 
in literature. It was found that this type of information is not abundant because the studies regarding 
species identification by MALDI-TOF MS are focused on specific parameters, such as the matching at 
genus and species level and non-matching percentages  [8, 88, 89]. Furthermore, peaks reported by 
those studies correspond to conserved domains expressed by the whole species, which do not apply to 
the present study. Therefore, no common peaks were found between the list of characteristic peaks 
reported by strain differentiation studies by MALDI-TOF MS and the list of peaks reported by this study. 
Typically, peaks obtained from strain differentiation studies are characteristic of each bacterial strain, 
whilst the present study was focused on intra-strain level differentiation. 
For S. aureus, the cluster done with the data taken from α-CHCA which is shown in Figure 2.13B reveals 
two main groups, one constituted by morphotypes A and B and another one formed by C and D. Although 
samples of morphotype D are grouped together, the number of peaks shared with samples of morphotype 
C indicates that both morphotypes are very similar. This group is more homogeneous than the groups A 
and B, where two samples (i.e. A_3_314 and B_2_60) were placed closer to the groups C and D than to 
their corresponding group. This classification was also obtained with SA although it was better attained 
with the α-CHCA, because for the case of SA one A and B morphotypes were mixed with the 
morphotypes C and D. 
The comparison of the characteristic peaks obtained for the two S. aureus groups with those reported in 
literature revealed that the 2646 of m/z signal was already noticed. Edward-Jones et al.  [90] pointed out a 
peak of 2647 m/z value as one of the characteristic peaks exhibited by methicillin-sensitive staphylococcal 
isolates. Such evidence suggests that C and D morphotype-associated bacteria may be susceptible to 
methicillin, in contrast to morphotypes A and B. 
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Figure 2.13. Heat map for the clustering of the (A) P. aeruginosa and (B) S. aureus spectra data generated using α-CHCA matrix. 
Vertical dendrogram shows the samples hierarchical clustering, while the horizontal dendrogram shows the m/z signals hierarchical 
clustering. 
MALDI-TOF MS versus morphological classification of bacterial colonies 
MALDI-TOF MS and conventional identification methods are both highly accurate for the identification and 
differentiation of isolated bacteria and yeast  [89, 91, 92]. However, minor discrepancies between 
conventional and MALDI-TOF MS-based identification and differentiation results have been observed  [86] 
and noticed in this study (Table 2.6). P. aeruginosa is oxidase positive, frequently mucoid, and produces 
green (pyoverdin) or blue-green (pyocyanin) pigments. These characteristics are present at least in 90% 
of CF isolates that MALDI-TOF MS has been shown to be able to accurately identify both non- and 
mucoid morphotypes of P. aeruginosa  [93, 94]. However, P. aeruginosa morphotypes can exhibit 
differential antibiotic resistance profiles that MALDI-TOF MS can or not distinguish them. Furthermore, 
distinct P. aeruginosa morphotypes may express different cell-associated virulence factors that also can 
interfere with MALDI-TOF MS classification. These facts could explain the discrepancies between MALDI-
TOF MS and colony morphology characterisation. For the case of P. aeruginosa, the morphological 
classification of colonies provides 4 phenotypes, whilst the MALDI classifies only into three phenotypes 
because morphotypes A and B seemed similar in terms of their MALDI fingerprintings. This group is 
different from the other two groups formed by C and D.  
The morphological classification done for S. aureus gave rise to four phenotypes whilst the clustering 
done with the MALDI spectra classified the morphotypes into two groups: A, B and C, D. Several authors 
have reported the accurate ability of MALDI-TOF MS to identify S. aureus bacteria and even to 
discriminate isolates in methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive 
Staphylococcus aureus (MSSA)  [90, 95, 96]. In fact, this study detected a peak of 2647 m/z value that 
was pointed out as one of the characteristic peaks exhibited by MSSA  [90]. Therefore, it was 
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hypothesized again that antibiotic susceptibility profile might be the cause of MALDI-TOF MS 
classification.  
Although the progressive advances demonstrated in microbial diagnosis field, the ability of MALDI-TOF 
MS to identify SCV has not been reported. This study reported for the first time evidences that MALDI-
TOF MS could discriminate colony morphotypes at least by their size. The two groups that MALDI-TOF 
MS classification originated were composed by non-SCV (A and B) and SCV (C and D). This ability of 
MALDI-TOF MS to distinct SCV is of great importance in clinical diagnosis. SCV could be detected from 
complex infecting populations more quickly. Even so, this ability to differentiate SCV should be more 
intensively studied with higher number of SCV samples, distinct SCV morphotypes and SCV of non-S. 
aureus. 
In short, the discrepancies observed between MALDI-TOF MS and colony morphology methods for P. 
aeruginosa and S. aureus may arise due to the differential antibiotic patterns exhibited by the colony 
morphotype-associated bacteria. Indeed, a number of studies have reported that MALDI-TOF MS may 
distinguish antibiotic resistant and susceptible strains of the same species  [90, 91, 95, 96, 97]. In addition, 
the expression of differential virulence factors may also contribute to discrepancies between both 
techniques. The hypotheses should be addressed in future works to disclose which criterion or criteria 
MALDI-TOF MS is using to group colony morphotypes. 
 
2.5. Conclusions 
An accurate identification and characterization of pathogens is crucial in disease management. The 
appropriateness and effectiveness of the microbial diagnosis method influence the choice of the 
antimicrobial agent to be used in the treatment of infection. Despite the great potential of colony 
morphology characterization in the context of clinical diagnosis, scarce improvements have been noticed 
in this method. This chapter aimed at improving the colony morphology characterisation method at 
different levels in order to achieve appropriate experimental procedures, more quickness in analysis and 
data standardisation, consistency and unambiguity. 
Although colony morphology characterisation method has a simple procedure to perform and analyse the 
colonies, there is great variability among experimental conditions, including colony growth time, colony 
density per plate and solid media. In this chapter, the impact of those parameters and also the impact of 
bacterial lifestyle (planktonic or biofilm) and bacterial genetic background were intensively studied. The 
results obtained demonstrated that all parameters had impact on colony morphogenesis and on detection 
of bacterial diversity. These results are extremely important because for the first time it is known which 
colony traits are affected by each experimental parameter. For instance, colony size was a trait highly 
dependent on solid media, which is of serious concern in the context of clinical diagnosis. Diagnosis could 
be distinct according the experimental procedure used, in this case solid medium, which consequently 
affects the antimicrobial therapy chosen. Inadequate diagnosis may lead clinicians to prescribe an 
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inadequate antibiotic for an infecting population that could encompass morphotypes that were no detected 
in that solid medium.  
Time of colony growth also revealed to be an important culturing condition because insufficient time of 
growth may cause overlook of some colony morphotypes, for instance morphotypes formed by bacteria 
with slower growth rates, or wrongly identify colonies that have not concluded their morphogenesis yet. 
Therefore, it is urgent to standardize the experimental parameters. In this logic, some guidelines were 
proposed that should be taken into account when performing colony morphology characterization. The 
general use of these guidelines will allow to accurately inferring about bacterial diversity of the infecting 
populations, a quite valuable input to clinical diagnosis, aiding the decision-making towards the selection 
of the most suitable antibiotic and supportive treatments. 
In addition to the morphological traits exhibited by the colonies which may be significantly affected by the 
procedures taken to grow the bacteria, colonies have been described using a panoply of vocabulary and 
morphological criteria. It is very important to establish the minimum set of information to be part of the 
morphotype description and to employ harmonised vocabulary in that morphological description. The 
standardisation of the colony morphology data was considered crucial to make the resulting knowledge 
more explicit, ensure data reliability and promote data interchange. In effect, standardization augments the 
global value of results leading to great advance of science knowledge. This advance is not limited to 
scientific purposes, as clinical diagnosis interests might gain serious advantages in eradication or, at least, 
control of bacterial infections.  
The second part of this chapter focuses on extensively reviewing and collecting all the terms used in 
literature and organising them in a structured way. However, a system just based on the vocabulary of the 
current descriptions has exhibited some constraints. Those constraints were overcome with few 
alterations in the characterisation system. At the end, the proposed system encompassed 10 
morphological criteria (form, margin, sheath, type of surface, texture, elevation, consistency, opacity, size, 
colour). Each criterion included detailed features that authors should use to describe bacterial colony 
morphologies (e.g. circular, wrinkled, opaque, small, green).  
A general use of this system leads to consistent and unambiguous descriptions of morphotypes and 
systematic comparison of morphotypes across experiments (and laboratories), species, diseases and 
clinical samples. Combining the standardisation of the experimental conditions with a general lexicon, the 
understanding about infection development, bacterial diversification, adaptation and evolutionary 
mechanisms may impressively advance.  
Among the current microbial diagnosis techniques, colony morphology is the method that returns the 
results later, normally 1-3 days, and with low-throughput. Therefore, any modification on this method 
reducing the time of analysis and to obtain the results is very welcome. In the third part of this chapter, 
MALDI-TOF MS was explored as a tool for bacterial colony morphotyping. MALDI-TOF MS approaches 
have been used to perform species identification and even strain differentiation but its ability to 
discriminate at colony morphology level has not been assessed yet. From the results obtained it was 
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verified that MALDI-TOF MS provided a different classification of the morphotypes in contrast to colony 
morphotyping, suggesting that MALDI-TOF MS of intact bacteria could, in some extent, be used to 
complement the classical morphological characterisation. It was hypothesized that MALDI-TOF MS could 
be used as criterion of classification the antibiotic resistance profile. Future studies should urgently 
address this issue to find out whether this was in fact the criterion of MALDI-TOF MS classification. The 
discovery of that criterion will allow the fast categorization of colony morphotypes, which represents a 
huge advance in colony morphology characterisation. The method will take advantage of the fast and 
high-throughput MALDI-TOF MS technology to test large amounts and complex clinical samples 
simultaneously, without the need of culturing steps, acquiring information about the infecting population 
diversity at species, strain and intra-strain level.  
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2.7. Supplemental Material 
 
Table S2.1. Definitions of the terms that composed the sub-categories of the last version of the colony morphology 
characterisation system. 
 
 
Sub-category 
name Definition 
Form  
Circular The external appearance or configuration of a colony by having a form of a 
circumference or a circle due to any point of the edge be equidistant from the centre. 
Elliptical The external appearance or configuration of a colony by having a oval form with two 
axes of symmetry, as produced by a conical section. 
Filamentous  The external appearance or configuration of the colony area by having a threadlike 
growth, i.e., extensions at the margin. 
Rhizoid The external appearance or configuration of the colony area by having extensions 
radiating from its centre. 
Spindle The external appearance or configuration of the colony area by having a long tapered 
rod that is wide in the middle and tapers at both ends. 
Irregular The external appearance or configuration of a colony by not having any distinguishable 
form. 
Margin  
Entire A margin quality of a colony by having a straight well-defined line border without 
toothing, irregularities or other projections. 
Undulate A margin quality of a colony by having a wavy indentation. 
Lobate A margin quality of a colony by having marked indentation-forming lobes. 
Erose A margin quality of a colony by having tooth-like indentation. 
Curled A margin quality of a colony by having parallel chains in undulate fashion on the border. 
Filiform A margin quality of a colony by having filaments.  
Sheath  
Present sheath The existence of a structure after the margin that surrounds a colony, the sheath. 
Absent sheath The lack of a structure after the margin that surrounds a colony, the sheath. 
Type of Surface  
Homogeneous  A surface quality of a colony by having only one type of texture. 
Heterogeneous A surface quality of a colony by having more than one type of texture. 
Texture  
Smooth A texture quality of a colony by having a surface free of roughness or vertical 
irregularities. 
Rough A texture quality of a colony by having small vertical irregularities. 
Wrinkled A texture quality of a colony by having large vertical irregularities. 
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Table S2.1 (continuation) 
 
Sub-category 
name Definition 
Consistency  
Brittle 
 
A consistency quality of a colony by shattering easily when touched by a loop. 
Dry A consistency quality of a colony by not being covered by a liquid. 
Moist A consistency quality of a colony by having humidity, not completely dry. 
Mucoid  
 
A consistency quality of a colony by having consistency of mucus. 
Viscous A consistency quality of a colony by having viscosity. 
Elevation  
Flat An elevation quality of a colony by having no discernable raise, being thin spread over 
the agar surface. 
Raised An elevation quality of a colony by being slightly elevated. 
Convex An elevation quality of a colony by having a dome-like raise. 
Pulvinate An elevation quality of a colony by being marked convex or having a convex cushion-
like raise form. 
Umbonate An elevation quality of a colony by having a rounded knob raised or knoblike 
protuberance. 
Crateriform An elevation quality of a colony by having a raise with a depression. 
Opacity  
Transparent An optical quality of the colony mass by full transmitting light. 
Translucent An optical characteristic of the colony mass by partial transmitting light. 
Opaque An optical quality of the colony mass by not transmitting light. 
Iridescent An optical quality of the colony mass by changing colour in reflected light as the angle of 
view changes. 
Size  
Small A size quality of a colony by having a physical dimension or extension or magnitude 
nearly one-tenth less than the size of the wild-type colony. 
Large A size quality of a colony by having a physical dimension or extension or magnitude 
higher than the size of the wild-type colony. 
Diameter A size quality which is equal to the length of any straight line segment from side to side 
through the centre of the circular colony or the average of the lengths of the longest and 
shortest line segments from side to side through the centre of the non circular colony. 
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3 
Understanding biofilm population diversity and  
functionality to prevent chronic infections development 
 
 
Abstract 
The extensive P. aeruginosa diversification in CF-adapted phenotypes allows bacteria to persist in CF lungs for long 
periods of time causing chronic infections hardly eradicated by antibiotics. Biofilms are the main cause of phenotypic 
heterogeneity, antibiotic resistance and persistence of these infections. Therefore, the early detection of biofilm 
formation is of upmost importance in CF disease management. Colony morphology variation had proven to be a 
reliable method to detect biofilm-phenotypes representative of the existent sub-populations (Chapter 2), however it is 
unknown the typical P. aeruginosa colony-biofilm variants. Being, this study aimed at determining one or more colony 
morphology variants characteristic of biofilm growth to better detect biofilm formation in further studies. This study also 
aimed to investigate the functionality of the distinct sub-populations within P. aeruginosa biofilms in order to gain 
insights into biofilm recalcitrance mechanisms. The results revealed that biofilm population diversity was strain-
dependent and a colony variant characteristic of P. aeruginosa biofilm growth was not found. Nevertheless, SCV 
seemed to be a strong hint of sessile lifestyle. This study highlighted as well that population diversity seemed to have 
no impact on augmented biofilm virulence potential and resistance to the antibiotic tested. In contrast, the absence of 
SCV within biofilm populations was associated with increase biofilm virulence potential, notably with increased amount 
of biofilm produced. This correlation was proven by robust statistical tests. In conclusion, the results obtained 
constituted a new perspective on P. aeruginosa biofilms, in particular on biofilm dynamics and functionally. 
 
 
 
 
 
 

Chapter 3 
 125 
3.1. Introduction 
The long-term persistence of P. aeruginosa infections in CF lungs is associated with clonal diversification 
into specialized phenotypes that causes chronic infections hardly eradicated  [1, 2, 3, 4]. Biofilms are the 
underlying cause of chronic infections and they provide a reservoir of high phenotypic diversity  [5, 6, 7]. 
This great variability of phenotypes is certainly one of the major contributors for sessile bacteria 
recalcitrance that it is not observed in planktonic state  [8, 9, 10]. CF chronic isolates of P. aeruginosa 
display a number of characteristics indicative of sessile lifestyle, including overproduction of alginate, slow 
growth rate, loss of motility and antibiotic resistance  [5, 11, 12]. Biofilm phenotypes could be also 
observed by a wide range of distinct colony morphologies as detected in Chapter 2, section 2.2. It is 
recurrent the isolation from biofilms colony morphologies such as mucoid variants, SCV and rough 
SCV  [7, 13, 14, 15]. As these variants are rarely observed in planktonic state, the phenotypic switching for 
mucoid and SCV has been pointed out as biofilm mechanisms against antimicrobial agents and survival in 
stressful environment as CF lungs  [16, 17, 18].  
It is thought that bacteria mode of growth at the early stage of CF disease is essentially the planktonic 
state because early CF isolates exhibited identical microbial characteristics of their wild-phenotypes 
species.  They displayed dry (non-mucoid) colony morphology, sensibility to antibiotics and have low 
bacterial density in lungs in contrast to chronic infections  [19, 20, 21]. Until now, it is not clear what time 
bacteria after CF airway colonization switch to sessile lifestyle and develop chronic infections. This 
temporal window until initiation of biofilm formation is of upmost importance to CF diagnosis and disease 
management. Before biofilm formation, bacteria are more sensitive and infections are thus more easily 
eradicated. Mature P. aeruginosa biofilms could be generally never be eradicated mostly due to be 
multidrug resistant  [22]. Early eradication avoids thus the biofilm formation and the establishment of 
chronic infections and consequently P. aeruginosa long-persistence in CF lungs. 
Based on the previous findings that colony morphology variants of biofilm cells were different from the 
planktonic counterparts (Chapter 2, section 2.2), it was hypothesized that these variants could be markers 
of biofilm formation and growth. Using a colony biofilm marker, it would be easier identify biofilm formation 
and gain knowledge about the time and the driven forces of bacteria switching to biofilms in CF sputum. 
As so, this study used seven P. aeruginosa strains to study biofilm diversity and to determine the typical 
P. aeruginosa colony biofilm variants. Phenotypic heterogeneity is one of the major contributors to biofilm 
persistence in human host, but the role of each subpopulation in biofilm pathogenesis is poorly 
understood. In this study, it was also aimed to verify the function of population diversity on biofilm 
pathogenesis potential.  
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3.2. Materials and Methods 
Bacterial strains and culture conditions 
Seven P. aeruginosa strains were used throughout this work and they are listed in Table 3.1. Four strains 
were laboratory strains (commonly named as reference strains) originally isolated from clinical patients 
and environment locations but have been used for laboratory study for decades. These strains were 
ATCC 10145 (from now on named as ATCC), PA01, PA14 and CECT 111. PAI1 strain was isolated from 
an endoscope, PAI2 and PAI3 were isolated from infected patients with no record of CF disease. These 
seven strains were used due to their distinct genetic background that ensure biofilm variability, based on 
previous results obtained in Chapter 2. 
Bacteria were routinely cultured on TSB or TSA at 37 ºC. All strains were preserved in criovials (Nalgene) 
at – 80 ± 2 ºC to minimise putative adaptation to the laboratory environment. Prior to each experiment, 
bacterial cells were grown on TSA plates for 24 h at 37 ºC.  
 
Table 3.1. Description of the P. aeruginosa strains used in this study. 
P. aeruginosa strain Description Reference 
ATCC 10145 Laboratory sequenced strain 
 
 [23] 
PA01 Laboratory sequenced strain 
 (pseudomonas.com) 
 [24] 
PA14 Laboratory sequenced strain  [25, 26] 
 [#1768] 
CECT 111 Reference strain  
PAI1  Isolate from an endoscope  [27] 
PAI2  Clinical isolated from non-CF environment  [28] 
PAI3 Clinical isolated from non-CF environment  [28] 
 
Planktonic growth  
Planktonic bacteria grew overnight in TSB at 37 ºC, 120 rpm. Cell suspension of each strain was washed 
twice in sterile water by centrifugation (9000 g, 5 min) and, further serial diluted and plated on TSA to 
perform colony morphology characterisation. The supernatants of cell suspensions were used to 
determine the pyocyanin produced.  
 
Biofilm formation 
Biofilms were developed as previously described by Stepanovic et al. (2000)  [29]. Planktonic cell 
suspension of each strain was diluted in TSB to obtain 107 CFU/mL as final concentration. Afterwards, 
200 µL of the bacterial suspension was transferred to a 96-well polystyrene microtiter plate where biofilms 
were developed aerobically on a horizontal shaker (120 rpm) at 37 ºC for 24 h. After that, biofilms were 
sonicated into sterile water to detach cells from biofilms, vortexed to homogenize and biofilm-cells were 
serial diluted with PBS and spread on TSA for viable and culturable cells counting and colony morphology 
characterisation. Other part of the biofilm cell suspension was used to determine the antibiotic 
susceptibility and virulence factors expression. 
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Counting the number of viable cells 
The number of viable cells obtained from biofilm cell suspensions was determined through colony-forming 
unit (CFU). Cell suspensions were serial diluted, plated on TSA and incubated overnight at 37 °C. After 
that, the number of colonies were counted and verified after more 24 h of growth. 
 
Observation and classification of colony morphology 
To inspect colony morphology, biofilm-bacteria were allowed to grown on TSA plates during 48 h at 37 ºC. 
This step was aimed to obtain complete and unchangeable morphotypes according the results obtained in 
Chapter 2, section 2.2. Colony morphologies were observed by directly placing the petri plates on a 
magnifying glass (Olympus SZ-CTV) and photographed in a CCD camera (AVC, D5CE; Sony, Tokio, 
Japan). The morphological features of the colonies were annotated using morphological criteria previously 
stipulated in Chapter 2, section 2.3. In brief, colonies were evaluated according their form, margin, type of 
surface, texture, size, sheath, elevation, opacity, consistency and colour. A phenotypic variant was 
considered when it differed in at least one of the referred morphological parameters and it was considered 
a member of the population when detected at least 3 in 5 independent assays.  
 
Antibiotic susceptibility assays 
The antibiotic susceptibility profiles were constructed determining the minimum inhibitory concentration 
(MIC) by microdilution assays following the recommendations of the Clinical and Laboratory Standards 
Institute (CLSI, formerly the National Committee for Clinical Laboratory Standards)  [30]. MIC was assayed 
using biofilm cells treated with different concentrations of antibiotics, ranging 0,125 to 16 mg/L of 
ciprofloxacin (Fluka) and colistin (Sigma Aldrich), 0,125 to 64 mg/L of amikacin and tobramycin (Sigma 
Aldrich), in Mueller Hinton Broth (MHB) at 37 ºC, 120 rpm for 24 h. After antibiotic treatment, MIC was 
determined by the concentration of antibiotic required to inhibit 90 % of growth measuring OD at 640 nm 
on a microtiter plate colorimeter (Bio-Rek Synergy HT, Izasa). The following clinical breakpoints for 
resistance were used: amikacin, MIC ≥ 64 mg/L; ciprofloxacin, MIC ≥ 4 mg/L; colistin, MIC ≥ 8 mg/L; 
tobramycin, MIC ≥ 16 mg/L  [30]. All tests were performed 5 times with 3 technical replicates. 
 
Characterisation of virulence factors expression 
• Total amount of biofilm biomass 
The total amount of biofilm produced (cells and exopolysaccharide matrix) was evaluated through a 
quantitative assay of total using crystal violet (CV) adapted from Stepanovic et al. (2000)  [29]. After 
biofilm formation during 24 h, the content of the plates was discarded and washed twice with sterile water 
in order to remove weakly attached cells and cell products that were in suspension. Afterwards 200 μL per 
well of methanol were added and plates were allowed to stand for 15 min in order to fix the biofilm-cells. 
Methanol was discarded and plates were left to dry at room temperature. Biofilms were stained with 200 
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μL of pure CV for approximately 5 min and were rinsed thoroughly and repeatedly with tap water. Finally, 
the amount of biofilm formed was quantified by solubilization of the CV in 200 μL of 33% (v/v) acetic acid. 
The optical density (O.D.) was measured at 590 nm using a microtiter plate reader (Bio-Rek Synergy HT, 
Izasa). 
 
• Motility determination 
Motility, including swimming, swarming and twitching, was assessed using the following procedures as 
described previously  [19]. Swimming motility: 108 CFU/mL of each biofilm cell suspension was inoculated 
in TSA plates with 0,3 % (w/v) of agar and incubated for 24 h at 37 ºC in air conditions. Swimming was 
assessed by measuring the circular turbid zone around the inoculation point. Swarming motility: 108 
CFU/mL of each biofilm cell suspension was inoculated in TSA plates with 0,5 % (w/v) of agar and 
incubated for 24 h at 37 ºC in air conditions. Swarming motility was indicated by irregular branching that 
appeared at the periphery of the colonies and this turbid zone was measured. Twitching assay: 108 
CFU/mL of each biofilm cell suspension was inoculated in TSA plates with 1,5 % (w/v) of agar and 
incubated for 24 h at 37 ºC in air conditions. Twitching motility was indicated by a hazy zone of growth at 
the interface between the agar and the polystyrene surface and this hazy zone of growth was measured.  
 
• Hemolysin production 
Hemolytic activity of biofilm cells was assessed using Columbia Agar (CA; agar, 15 g/L, Liofilchem; 
Columbia broth, 43 g/L, Liofilchem) with 40 % (v/v) of sheep blood (Probiologica) plates. CAB plates were 
incubated 24 h at 37 ºC in air conditions. Hemolysin negative production was defined when no clearing 
zones were observed around the isolated colonies  [19].  
 
• Pyocyanin production 
Pyocyanin production was determined for P. aeruginosa planktonic and biofilm populations. These assays 
were carried out on culture supernatants during growth in TSB as previously described  [31]. Bacteria 
were pelleted at 15 000 g for 15 min and the free-cell supernatants containing pyocyanin were carefully 
collected and mixed with the same volume of chloroform. Mixtures were vigorously vortexed and 
centrifuged at 17 000 g for 1 min. Afterwards the inorganic phase was discarded and added to the organic 
phase, containing the pyocyanin (blue-green coloured), the same volume of 0.2 M HCl. Mixtures were 
vortexed and centrifuged at 17 000 g for 1 min. The pyocyanin-containing phase (pink layer) was collected 
and OD was measured at 520 nm using microtiter plate reader (Bio-Rek Synergy HT, Izasa). 
Concentration of pyocyanin, expressed as micrograms per millilitre of TSB supernatant, was determined 
by multiplying the OD by 17,072  [31].  
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Statistical Analysis 
Results are reported in terms of population mean ± standard error of the mean (SEM). Values of biofilm 
formation (OD590 values), motility (zone diameters) and pyocyanin production (concentration values) 
represent means of 3 biological replicates and the value for each replicate is the average of 8 to 12 
technical replicates for biofilm formation and 3 for motility and pyocyanin production. The significance of 
the difference between virulence factors expression among biofilm populations was analysed by using the 
one-way ANOVA and post-hoc by Tukey Multiple Comparison Test. Association of population diversity 
and the presence SCV, with virulence factors expression and antibiotic resistance was analysed using 
bivariate correlation and Pearson correlation, respectively. The statistical analysis was performed using 
SPSS version 20.0 (Chicago, Illinois, USA), and p values < 0.05 were considered significant. 
 
3.3. Results 
Colony morphology diversity 
Planktonic and biofilm population diversity of the seven strains of P. aeruginosa (PA01, ATCC 10145, 
CECT 111, PA14 and 3 clinical isolates, PAI1, PAI2 and PAI3) was examined through colony morphology 
characterization. P. aeruginosa was grown overnight in planktonic state and in biofilms for 24 h and 
bacteria plated on TSA to evaluate population diversity. Prior to colony examination, knowing that reduce 
viable and culturable cell number could mask population diversity and lead to misinterpretations, the 
number of viable and culturable cells of each biofilm formed was determined. Figure 3.1A showed that all 
biofilms have identical number of cells (p > 0,05) indicating that further examinations could be done 
without an additional normalization step. 
 
 
 
Figure 3.1. (A) Number of viable and culturable cells recovery from the distinct P. aeruginosa biofilms. The bars and whisker 
represent mean values ± SEM; (B) Diversity of biofilm populations expressed in number of colony morphology variants. Population 
diversity was determined after at least 5 independent assays.  
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Planktonic and biofilm population diversity was determined based on the number of distinct colony 
morphologies identified. Each P. aeruginosa colony formed by planktonic and biofilm bacteria on the solid 
media was inspected in terms of form, margin, surface, texture, size, presence of sheath, elevation, 
opacity, consistency and colour as described in Chapter 2, section 2.3. All planktonic populations did not 
demonstrate diversity being each P. aeruginosa population composed by only one morphotype (Figure 
3.1B), called as wild-morphotype (WM). The WM of the majority of P. aeruginosa strains were large (~7,5 
mm of diameter after 48 h onto TSA), dry, flat and opaque colonies with homogenous surface and rough 
texture (Table 3.2 and Figure 3.2). In contrast, 24 h-biofilms exhibited variable number of colony 
morphologies. P. aeruginosa biofilms could include in their populations exhibiting only one colony variant 
such as PA01, CECT and PAI3 biofilms or to be composed by several colony variants such as ATCC, 
PA14, PAI1 and PAI2 biofilms (Figure 3.1B). Colony morphology of biofilm cells demonstrated alterations 
in size and sheath and, less frequent, in texture in comparison with WM (Table 3.2 and Figure 3.2).  
Among the colony biofilm variants, special focus was put in the inspection of mucoid variants and SCV 
due to their attributed importance related to biofilm resistance mechanisms. All morphotypes whose 
diameters were less than 3 mm were considered as SCV [18]. Results showed that all biofilms formed did 
not include in their populations mucoid variants, but SCV were frequently detected (never more than 20 % 
of frequency), with the exception of the biofilms formed by PA01, CECT111 and PAI3 (Figure 3.1B). 
Moreover, some biofilms were composed by more than one type of SCV, such as PAI1 and PAI2 (Figure 
3.2). Comparing these results with those of section 2.2 of Chapter 2 some incongruities were noticed. In 
section 2.2, it was reported that ATCC biofilm populations included 3 distinct large colonies and no SCV 
(Figure 2.3 in Chapter 2) and PAI1 included 8 SCV and 2 large colonies (Figure 2.4 in Chapter 2). The 
differences could be explained by the different preparation of TSA plates. To perform the present study, it 
was followed all the guidelines described in section 2.2, in particular, it was standardized the height of 
solid medium among TSA plates to 0,5 cm. The study of the section 2.2 was performed without that 
concerns of height of solid medium. This experimental parameter was only detected as a factor that 
influences colony morphology but was not study and no standardised in section 2.2. The different height of 
solid medium may have produced variations in detection of colony morphologies. From now on, the 
analysis of the results was performed considering the information of biofilm population diversity obtained 
in the present study. 
Despite the variable number and distinct colony morphologies, biofilm populations shared some 
characteristics. WM was present in all biofilm populations (Figure 3.2), with the highest prevalence, and 
rough SCV was frequently detected (Table 3.2), in 4 of 7 biofilms. Although these similarities, it was not 
found a colony morphology biofilm characteristic of P. aeruginosa sessile lifestyle, i.e., there was not a 
colony variant that has emerged in all P. aeruginosa biofilms. 
  
Table 3.2. Detailed morphological description of the colonies identified in P. aeruginosa biofilm populations. 
a smooth texture with several surface element as “craters” 
 
 Form Margin Sheath Type of Surface Texture Consistency Elevation Opacity Size Colour 
PA01           
planktonic circular undulate present homogeneous rough dry flat opaque large yellow 
biofilm circular undulate present homogeneous rough dry flat opaque large yellow 
           CECT111           
planktonic circular undulate present homogeneous rough dry flat opaque large green 
biofilm circular undulate present homogeneous rough dry flat opaque large green 
           ATCC 10145           
planktonic circular undulate absent homogeneous rough dry flat opaque large yellow 
biofilm circular undulate absent homogeneous rough dry flat opaque large yellow 
biofilm circular undulate present homogeneous rough dry flat opaque large yellow 
biofilm circular undulate absent homogeneous rough dry flat opaque small yellow 
           PA14           
planktonic circular erose present homogeneous rough dry flat opaque large brown 
biofilm circular erose present homogeneous rough dry flat opaque large brown 
biofilm circular undulate absent homogeneous rough dry flat opaque small brown 
           PAI1           
planktonic irregular undulate present homogeneous smootha dry flat opaque large yellow 
biofilm irregular undulate present homogeneous smootha dry flat opaque large yellow 
biofilm circular entire absent homogeneous smooth dry flat opaque small yellow 
biofilm circular entire absent heterogeneous rough and smooth dry flat opaque small yellow 
biofilm circular entire absent homogeneous rough  dry flat opaque small yellow 
biofilm circular entire present homogeneous rough dry flat opaque small yellow 
           PAI2           
planktonic circular entire absent homogeneous rough dry flat iridescent large blue-green 
biofilm circular entire absent homogeneous rough dry flat iridescent large blue-green 
biofilm circular entire absent homogeneous rough dry flat iridescent small blue-green 
biofilm irregular undulate absent homogeneous wrinkled dry flat iridescent small blue-green 
           PAI3           
planktonic circular undulate present homogeneous rough dry flat opaque large yellow 
biofilm circular undulate present homogeneous rough dry flat opaque large yellow 
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Figure 3.2. Appearance of colony morphology variants of P. aeruginosa planktonic and biofilm populations. Dashed line indicated 
SCV. Black bars = 1 mm. 
 
Pathogenic profiling of P. aeruginosa biofilms 
Because of the extensive colony variability within and among biofilms, the role of population diversity and, 
in particular, the SCV in biofilm pathogenesis was investigated. It was aimed to determine whether: 1) the 
population diversity was an indicator of augmented pathogenic potential of P. aeruginosa biofilms, i.e., 
whether biofilms with higher number of colony morphotypes exhibited more virulence potential and/or 
antibiotic resistance; and if so, 2) the presence of SCV was the responsible for the augmented biofilm 
virulence potential and/or resistance to antibiotics. To answer these questions, firstly the virulence factors 
expression and antibiotic resistance profiles of biofilm cells were determined to following perform the 
correlation among virulence and resistance profiles with population diversity and the presence of SCV. 
It is undeniable the impressive arsenal of virulence factors that P. aeruginosa possesses with increase 
ability to cause damage to host. In this study, it was only analysed some virulence factors that have 
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particular impact in the context of CF–associated infections. The ability to form biofilm is one of the most 
important virulence factors of P. aeruginosa and it can be an indicator of the adaptive capacity of a strain 
to survive and grow in new environments as CF lungs  [32, 33]. All P. aeruginosa biofilms demonstrated to 
be composed by identical number of viable and culturable cells (Figure 3.1A), but they can differ in the 
amount of matrix produced (Figure 3.3). Biofilm matrix has a crucial role in biofilm recalcitrance because 
act as protective barrier against antibiotics, host immune defences molecules, dehydration and ROS  [34, 
35]. Possible differences in the amount of matrix produced would be reflected in the total amount of biofilm 
biomass. Therefore, the CV staining method was used to determine the total amount of biofilm biomass 
(cells and matrix) and, thus, infer about the relative capacity of strains to form biofilms during 24 h. The 
results showed that P. aeruginosa strains formed biofilms with distinct total amount of biomass (p < 0,05, 
Figure 3.3), leading to conclude that they had produce different amounts of matrix.  
PA01, ATCC and PAI1 displayed significantly increased biofilm amounts in comparison to the other 
strains, suggesting that these biofilms had a ”better” physiological barrier, the exopolysaccharide matrix. 
This matrix represents an ecological advantage in persistence in challenging environments as CF lungs. 
Despite the differences among P. aeruginosa strains, it should be highlight the impressive ability that all P. 
aeruginosa strains showed to form biofilms.  
 
 
 
 
 
 
 
 
Figure 3.3. Total amount of biomass of 24 h P. aeruginosa biofilms measured by CV staining methods (biomass was quantified in 
terms of absorbance at 590 nm). The bars and whisker represent mean values ± SEM.  
 
In addition to the different amount of exopolysaccharide matrix produced by biofilm cells, P. aeruginosa 
biofilms seemed to be composed by bacteria with different abilities to swim, swarm and twitch. Although 
the wide range of swimming, swarming and twitching motilities observed, it was verified that all P. 
aeruginosa biofilms seemed encompass niches where it was allowed the three types of motility (Figure 
3.4A, B and C). The amount of pyocyanin produced by biofilm cells was also quite variable among strains 
(Figure 3.4D), but it was noticed a trend of P. aeruginosa to reduce pyocyanin production after switching 
to biofilm mode of growth.  
Regarding the biofilm resistance to antibiotics, P. aeruginosa biofilms exhibited slightly differences in MIC 
values of amikacin and tobramycin, but according to CLSI susceptibility interpretation criteria  [30] they 
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were equally categorised as sensitive to these antibiotics (Table 3.3). Ciprofloxacin and colistin MIC 
values were identical to all P. aeruginosa biofilms and categorised as resistant and sensitive, respectively. 
 
 
 
Figure 3.4. (A) Swimming, (B) swarming and (C) twitching motilities of biofilm-cells. Each point is the mean of the results from three 
biological replicates. (D) Pyocyanin production of planktonic and biofilm-cells of each P. aeruginosa strain. * p < 0,05; ** p < 0,01 
 
 
Table 3.3. Characterization of the susceptibility profiles to amikacin (AK), ciprofloxacin (CIP), colistin (COL) and tobramycin (TOB) of 
the P. aeruginosa biofilm-cells. 
 
 
 
 
 
 
 
 
Strain 
MIC (mg/mL) 
AK CIP COL TOB 
PA01 0,5 to 1 4 2 0,125 to 0,25 
CECT 111 0,5 4 2 0,125 
ATCC 10145 0,5 to 1 4 2 0,125 
PA14 0,5 4 2 0,125 
PAI1 0,5 to 1 4 2 0,125 to 0,25 
PAI2 0,5 to 1 4 2 0,125 to 0,25 
PAI3 1 4 2 0,25 
Chapter 3 
 135 
The role of diversity and SCV within biofilms 
To determine the role of population diversity and, in particular, SCV in the biofilm virulence potential, a 
statistical analysis of correlation (Pearson Correlation and Mann U Whitney test) was performed to ensure 
results reliability.  
From the statistical results obtained, the distinct abilities to form biofilms were not related to the number of 
colony variants constituent of biofilms (Table 3.4), but, interestingly, they were associated with SCV (Table 
3.5). That means populations without SCV tend to produce biofilms with increased biomass (Figure S3.1). 
Still regarding biofilm virulence potential, motility and pyocyanin production were not correlated with 
diversity of biofilm population and the SCV presence within biofilm populations (Table 3.4 and 3.5). In 
summary, the absence of SCV seemed to be associated with increased biofilm biomass. 
As antibiotic resistance profiles of P. aeruginosa biofilms were identical, the statistical analysis was not 
performed because the assumption of variability for these factors was not accomplished. 	  
 
Table 3.4. The association of diversity population with biofilm formation, swimming, swarming and twitching motilities, according 
Pearson correlation. Statistical significance was determined by two-tailed p value. 
 
 
 
 
Table 3.5. The association of SCV presence within populations with biofilm formation, swimming, swarming and twitching motilities, 
according Mann U Whitney.  Statistical significance was determined by two-tailed p value. 
 
 
3.4. Discussion 
P. aeruginosa infections in CF lungs generally persist despite the use of aggressive and long-term 
antibiotic treatments mainly because bacteria form antibiotic–resistant biofilms  [36, 37, 38, 39]. To form 
biofilms bacteria need to undergo several changes to adapt to so spatially structure environment 
producing several colony variants with altered morphology. This study aimed to determine which were the 
 Biofilm  formation Swimming Swarming Twitching 
Pyocyanin 
production 
 χ2 p-value χ
2 p-value χ
2 p-value χ
2 p-value χ
2 p-value 
Diversity -0,047 0,839 -0,039 0,868 0,153 0,509 -0,160 0,490 -0,148 0,522 
 Biofilm 
formation Swimming Swarming Twitching 
Pyocyanin 
production 
U p-value U p-value U p-value U p-value U p-value 
SCV 26,000 0,047 38,500 0,269 41,500 0,365 34,000 0,148 46,000 0,568 
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typical colony variants found in P. aeruginosa biofilms to better detect biofilm formation in further studies. 
To investigate the colony biofilm variants, isogenic populations of WM were allowed to form biofilms during 
24 h in TSB. The results demonstrated that planktonic populations were homogenous composed by only 
one morphotype - the WM - that shared several colony traits among the seven P. aeruginosa strains, 
including circular form, homogenous type of surface, dry consistency, opaque opacity and large size.  
Biofilm populations were much more complex indicating that biofilm mode of growth selected specific 
phenotypes. P. aeruginosa biofilm populations were not identical among the seven strains varying in 
number and colony morphological traits. The 24 h-biofilms were composed since only one morphotype 
until 5 distinct morphotypes. Although they shared the same genome that encodes the functional response 
of bacteria to external stimuli and the genes involved in regulation are highly conserved, the differences of 
biofilm population diversity among P. aeruginosa strains may be the result of the instability of the core 
elements that can function differentially  [40]. Consequently, P. aeruginosa strains produced different 
biofilms with singular niches. The diversity of niches encouraged adaptive radiation and the emergence of 
biofilm niche-specialist observed in this study by colony morphology variation. Therefore, the differential 
diversity of biofilm population observed among strains could be supported by biofilms were formed by 
niches with different environmental conditions. Despite the variability of P. aeruginosa biofilm populations, 
they shared some characteristics. The WM of each strain was observed in all biofilms studied as 
previously reported in Chapter 2, section 2.2. Furthermore, the different biofilms could shared some 
colony variants, such as SCV and rough SCV, indicating that distinct biofilms could include similar niches 
in their structures. Similar environmental conditions and selective pressures within niches generate similar 
colony variants. 
SCV have been intensively studied because of their particular characteristics, such as increased antibiotic 
resistance, twitching motility, increased fitness under stationary growth, biofilm formation ability, 
autoaggregative traits, auxotrophy and reduced respiration  [18, 41, 42, 43]. Such variants are often 
isolated from laboratory biofilms  [5, 7, 44], and more importantly from CF lungs  [13, 44, 45]. The isolation 
of SCV from biofilms in this study reinforced the hypothesis that biofilms are present in CF lungs. Some 
authors have pointed out that SCV could be one of the specific-biofilm phenotypes that bacteria switch on 
in order to better adapt to biofilm lifestyle  [16, 17, 18]. In this study, SCV was not detected in all biofilm 
populations, which could led to question whether SCV is indeed a specific-biofilm phenotype. But, it must 
be stressed that the observed diversification within biofilms is not necessarily indicative of sustained 
diversity and differences among populations could be transient. Population diversity could be dynamic 
changing over time, influenced by the surrounding environmental conditions and external factors 
exposure. More studies are needed to fully understand the biofilm population, its evolution and 
functionality over time and the influence of external factors over the population.  
In this study, it was observed that WM dominated and SCV never made up more than 20 % of the 
biofilms, which led to conclude that SCV was only able to grow in some niches of biofilms and thus it was 
considered a colony variant niche specialist. The variability of morphological traits exhibited by SCV found 
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in some biofilms could be an indicator of distinct SCV niche specialists. Isolation of distinct SCV from 
biofilms it was reported previously  [5, 13, 18, 41, 46].  
Although the frequent detection of SCV in P. aeruginosa biofilms, they were not observed in all P. 
aeruginosa biofilms and thus SCV was not considered a colony variant characteristic of biofilm growth, but 
a strong hint. WM was present in biofilm populations but was also not considered a candidate because it 
was present in planktonic cultures making discrimination between the two modes of growth not possible. 
Therefore, it was conclude based on the gathered results that there was not a colony morphology marker 
for 24 h-biofilms of P. aeruginosa.  
Although the inexistence of a colony morphology marker and given the distinct colony heterogeneity found 
among P. aeruginosa biofilms, it was sought to determine whether biofilms with increased population 
diversity and with SCV had augmented pathogenesis potential. Understanding the biofilm functionality, 
i.e., the role of population diversity and SCV within biofilms is crucial to CF-associated infections 
diagnosis, to improve the actual treatments of P. aeruginosa biofilm-associated infections and, 
consequently, to prevent chronic infections development. To test this hypothesis, it was characterized the 
virulence factors expression and antibiotic susceptibility profiles of the biofilm cells.  
The virulence factors provide to bacteria tools to persist and cause damages in the host usually necessary 
for infection or disease development  [32, 47, 48]. The ability to form biofilms, the production of 
extracellular (proteases and pyocyanin) and cell-associated (flagella and type IV pili) virulence factors are 
among the most important P. aeruginosa virulence determinants in CF context  [19, 49, 50]. The biofilm 
cells of the seven P. aeruginosa strains exhibited quite diverse abilities to form biofilms, to swim, swarm 
and twitch and to produce pyocyanin. Among so much variability, it was noticed that all 24 h-P. aeruginosa 
biofilms were composed by niches where flagella expression was conserved as swimming motility of 
biofilm-cells was verified. It is known that bacteria inside a biofilm do not require extensive motility until the 
time they detach to colonize another available surface  [19, 51, 52, 53]. However, biofilms are composed 
by stratified niches and conservation of flagella may be indicative of the niche localization inside the 
biofilms. These niches where flagella expression was conserved may be located at the top of biofilms 
where bacteria still conserved several planktonic-associated characteristics such as swimming motility. 
The results obtained from colony morphology characterisation supported this conclusion as the WM was 
detected in all biofilms. Therefore, WM could be the colony variant representative of this top biofilm niche.  
To determine the location of other biofilm niches, it would be interesting to individually characterize the 
remaining colony morphologies and predict the respective niche location. This issue should be addressed 
in near future since it could provide valuable insights about biofilms ecology, recalcitrance and exposure 
new target sites for antibiotics act on. 
All P. aeruginosa biofilm cells exhibited in this study similar susceptibility profiles to the in-use CF 
antibiotics. Given these findings population diversity and SCV seemed not play a role in antibiotic 
recalcitrance of biofilms. But, regarding the biofilm virulence potential, the absence of SCV in populations 
was related to biofilms with increased biomass. This result contradicts some of the traditional concepts 
held in literature. SCV are typically considered excellent biofilm formers and thus it would be expected that 
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biofilms with SCV would have more biofilm biomass. Bofilms with SCV may have other advantages that 
biofilm without SCV do not. For instance, SCV may play a crucial role when communities face stressful 
conditions, such as pH alterations, osmotic stress, starvation, host immune molecules action. SCV could 
be responsible to ensure community survival and regrowth when a stress vanish  [7, 54, 55, 56]. Under 
certain circumstances, subpopulations inside of biofilms might have a survival advantage over others 
resisting to the stressful conditions imposed. This question should be addressed in future studies to clarify 
the role of SCV in biofilms.  
Current management of CF airway infections includes the use of antibiotics that reduce patient morbidity 
and mortality, but could also led to collateral effects as the emergence of antibiotic resistant bacteria  [34, 
57, 58]. Although at early CF infection stage it is expected bacteria growing in planktonic stage, increased 
concentrations of antibiotics are typically needed due to the adverse environmental surrounding conditions 
that affect the antibiotic action, such as extracellular DNA and hypoxia. The antibiotic treatments are being 
more aggressive in attempt to early eradicate bacteria, in particular P. aeruginosa, and to avoid 
persistence of infection. This trend had raised the need to attain higher organism-specific MIC. 
Determination of MIC is the first line technique of discovery for indicators of antibiotic activity against 
bacteria and indicates the lowest concentration of an antimicrobial agent to inhibit the growth of a 
particular organism. In this study it was determine the MIC of most commonly used antibiotics in early CF 
infections treatment, including ciprofloxacin, colistin, tobramycin and amikacin  [57, 59, 60]. Based on the 
MIC values obtained in this study, it was hypothesized that early treatments could use concentrations of 4, 
2, 1 and 0,25 mg/L of ciprofloxacin, colistin, amikacin and tobramycin, respectively. According 
pharmacodynamics and pharmacokinetics studies these concentrations could be use without adverse side 
effects in patients  [61, 62, 63, 64, 65, 66, 67, 68]. The efficacy of antibiotic treatments using these 
concentrations was evaluated in Chapter 4. 
 
3.5. Conclusions 
Bacteria within biofilms are phenotypically different from their freely swimming counterparts. In this study, 
it was aimed to determine the characteristic colony morphologies of P. aeruginosa biofilm populations to 
enhance the detection of biofilm formation in further studies. The results revealed that biofilm populations 
varied in number of colony variants and in morphological traits. The increased diversity of colony variants 
inside biofilms resulted possibly due to bacteria be confronted with different selective pressures imposed 
in each biofilm-niche that favour optimized growth activities and thus the emergence of subpopulations 
with distinct colony morphologies. The variable colony variants among P. aeruginosa biofilms may be 
explained by the different ability of strains to form biofilms and with different regulatory responses despite 
belonging to the same species.  
SCV was studied with particular attention due their supposed contribution to biofilm resistance against 
antibiotics. It was detected SCV within biofilm populations in opposite to planktonic cultures. This lead to 
conclude that these variants may result from adaptations undergone by bacteria to the specific sessile 
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lifestyle, making SCV a potential candidate to colony-biofilm marker. However, SCV was not observed in 
all P. aeruginosa biofilms, being no possible to consider SCV as candidate colony marker of biofilm growth 
but only a strong hint. In fact, none of colony variants identified in biofilm populations seemed to be a 
marker of P. aeruginosa biofilm growth. 
The inconsistent diversity and presence of SCV among P. aeruginosa biofilms led to question the role of 
diversity and SCV in biofilm pathogenesis. Biofilm cells were characterized in order to understand the 
association between diversity and SCV with biofilm virulence potential and antibiotic resistance. 
Surprisingly, the increased diversity and the presence of SCV within biofilm populations was not found as 
an adaptive advantage in terms of antibiotic resistance. But, the absence of SCV was associated with 
increased biofilm formation ability. Anyway, population diversity and SCV could be an advantage in 
stressful conditions not tested in this study and be responsible for community survival and re-
establishment. In these conditions SCV and higher number of distinct sub-populations may play a crucial 
role.  
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3.7. Supplemental Material 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3.1. Boxplot of the total biofilm mass (cell and matrix) of biofilms with and without SCV. The black line within the box 
indicates the median of each dataset. The edges of rectangles correspond to the first and third quartile of the data set.	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Pseudomonas aeruginosa diversification at early infection 
stages in cystic fibrosis environment 
 
 
Abstract 
P. aeruginosa diversification has been pointed out as the major cause of chronic infections of CF patients, but little is 
known about the early stages of infection. The main goal of this study was to investigate the evolutionary processes 
associated with P. aeruginosa adaptation to the CF lungs and with early infection development. This study aimed to 
go further and intended to study P. aeruginosa evolutionary processes in relevant clinical scenarios for CF 
antimicrobial stewardship, such as different initiation timings of antibiotic treatments and antibiotic concentrations. 
Treatments could be initiated soon as first positive detection, called early antibiotic treatments, or could be initiated 
more lately, called delayed antibiotic treatments. The concentrations of the antibiotics administered to CF patients are 
variable which may impact on P. aeruginosa adaptation to the CF lungs and on the eradication success. To perform 
this study, bacteria were grown in artificial sputum medium (ASM) with and without early and delayed ciprofloxacin 
treatments with distinct concentrations. Population diversity was analysed through colony morphology sampled during 
ten days and mapped the temporal diversity variation within populations. The virulence factors expression and the 
antimicrobial resistance profiles of the distinct colony morphotypes were determined in order to identify the biological 
traits altered to P. aeruginosa achieve adaptation and/or to develop infection.  
The results revealed clearly that the timing of antibiotic treatment initiation and the antibiotic concentration play a 
crucial role in early P. aeruginosa eradication. Early antibiotic treatments using adequate antibiotic concentrations, 
correspondent to biofilm-cells inhibitory concentrations, had strong possibilities to achieve successful eradication. In 
contrast, delayed antibiotic treatments exhibited quite variable successful eradication rates that demonstrated to be 
highly dependent of the adaptive ability of the P. aeruginosa strain. The constructed temporal diversity maps 
disclosed: 1) a trend of P. aeruginosa for diversification after initial CF environment colonization promoted by the CF 
environmental conditions; and 2) a propensity of inadequate ciprofloxacin treatments (early and delayed) in promoting 
diversification into new “fitter” variants impacting on eradication. Interestingly, all P. aeruginosa evolution/adaptation 
pathways included a common alteration, the impaired swimming motility. As so, this alteration was considered a 
potential disease marker for early P. aeruginosa adaptation and infection development. Furthermore, it was found that 
colony morphology variation was a sign of evolution/adaptation of P. aeruginosa and, more importantly, colony traits 
could be used as useful indicators of antimicrobial resistance profiles to some antibiotics, as well as to indicate the 
expression of some virulence factors proven by several statistical tests. 
All these results will have soon impact on clinical diagnosis and will introduce great improvements in CF disease 
management. Such as, actual antibiotic treatments could be re-design adjusting the dosage of antibiotics take in 
account new standards, for instance the inhibitory concentration of biofilm-cells, early infections could me more easily 
detected using a impaired swimming motility as disease marker and resistance profiles and virulence factors 
expression could be anticipated by colony morphology observation.  
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4.1. Introduction 
P. aeruginosa is the most prevalent pathogen in chronic infection stages contributing to lung function 
decline and ultimate mortality in CF patients  [1, 2]. Although P. aeruginosa is the most common pathogen 
in adulthood, it is also frequently isolated from CF lungs of younger patients  [3, 4]. Patients infected with 
P. aeruginosa at younger age generally have numerous respiratory complications and slower growth 
resulting in decreased quality of life and decreased chances of survival  [5, 6, 7].  
It is known that during infection development in CF lungs, P. aeruginosa switch from an acute 
environmental virulent pathogen, characteristic from early infection stages, to a CF-adapted pathogen 
typical from chronic infection stages  [8, 9, 10]. Similar evolution and adaptation profiles were observed in 
distinct clonal lineages of CF-adapted strains suggesting parallel evolution of P. aeruginosa in CF airways 
driven by similar selective pressures  [11, 12]. Genome sequence analyses have substantiated this 
conclusion because of the recurrent mutational patterns detected in independent P. aeruginosa 
lineages  [13, 14, 15]. In addition to this parallel evolution, other studies have reported the evidences of 
intraclonal P. aeruginosa diversification  [16, 17]. A significant level of phenotypic diversity is commonly 
observed from P. aeruginosa clones that display distinct colony morphologies, differences in QS 
regulators, antibiotic resistance and expression of virulence factors  [8, 18, 19, 20, 21]. The specific 
causes and underlying mechanisms of intraclonal diversity are difficult to unveil and thus they are 
incompletely understood. Both pathways, parallel evolution and intraclonal diversification, seemed to be 
relevant in CF airway disease because ensure phenotypic diversity considered fundamental to the 
development of chronic infections. 
Although all this knowledge about P. aeruginosa adaptation to CF lungs, it is not clear: i) which are the P. 
aeruginosa early adaptive changes after CF lungs colonisation; ii) which those changes are associated 
with the early infection development and transition to chronic stages; iii) what time bacteria switch and 
which are the environmental conditions that trigger this switching. This situation undermines the 
development of rationales for the selection of accurate antibiotic treatment regimes and achieving 
successful rates of P. aeruginosa early eradication. Early eradication is a central part of CF management 
as it avoids infection establishment and its progression to chronic stages. Inappropriate initial antibiotic 
treatments in addition to causing initial adverse effects in patient outcome can compromise the success of 
future antibiotic treatments. Therefore, CF disease management will greatly benefit from the 
understanding of P. aeruginosa early adaptive changes and the underlying mechanisms. 
The ability to anticipate the bacterial pathogenic potential and the response to antibiotic treatments is also 
of interest. Predict antibiotic susceptibilities and the expression of virulence factors of the bacteria isolated 
from CF patients by, for instance, bacterial characteristics or colony features could made antimicrobial 
stewardship more assertive because it takes in account the particular characteristics of that specific 
infecting population. Therefore, to gain insights about the processes and mechanisms undergone by P. 
aeruginosa after initial colonization of CF lungs, this study investigated the early adaptation changes of 
three P. aeruginosa strains focusing on their phenotypic evolution, the environmental conditions that 
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trigger adaptation and the underlying mechanisms. Furthermore, it was attempted to correlate P. 
aeruginosa phenotypic characteristics (antibiotic susceptibilities and virulence factors expression), colony 
morphology traits, infection development and population diversity in order to determine putative disease 
markers and indicators of antibiotic failure.  
 
4.2. Materials and Methods 
Bacterial strains and culture conditions 
P. aeruginosa PA01, ATCC 39324 and a clinical isolated non-CF related, PAI2, were used throughout this 
study. P. aeruginosa ATCC 39324, from now on referred as ATCC, is a mucoid strain and PA01 and PAI2 
are dry strains. Bacteria were routinely cultured on TSB or TSA at 37 ºC. All strains were preserved in 
criovials (Nalgene) at – 80 ± 2 ºC to minimise putative adaptation to the laboratory environment. Prior to 
each experiment, bacterial cells were grown on TSA plates for 24 h at 37 ºC.  
 
Artificial sputum medium preparation and bacterial growth conditions 
Artificial sputum medium (ASM) was used to mimic the sputum of CF patients  [22]. The ASM was 
prepared following the protocol of Sriramulu, D. (2010)  [23]. ASM contained 5 g/L of mucin from pig 
stomach (Sigma-Aldrich), 4 g/L of DNA from salmon sperm (Sigma-Aldrich), 5,9 mg/L of diethylene 
triamine pentaacetic acid (DTPA, Sigma-Aldrich), 5 g/L of NaCl, 2,2 g/L of KCl and 5 g/L of casoamino 
acids (AMESRO). pH was adjusted to 7,0 with Tris base. ASM was sterilized in an autoclave at 110 ºC for 
15 min and, after cooled, 5 mL of egg yolk emulsion (Fluka) was added. Two mL of ASM were transferred 
to each well of a 24 well-plate and inoculated on the top with 5 µL of bacterial cell suspensions obtaining a 
final cellular concentration in each well of 107 CFU/mL. P. aeruginosa inocula were obtained by growing 
each bacterial strain overnight in TSB at 37 ºC and 120 rpm in air conditions. The resulting cell 
suspensions were washed twice in sterile water by centrifugation (9000 g, 5 min) and further serial diluted 
to a final concentration of 4 x 109 CFU/mL. 5 µL of these bacterial suspensions were used to inoculate 
ASM. ASM cultures were incubated at 37 ºC for 10 days in static and air conditions. Static conditions were 
used in this study because the cilliary movements in CF lungs are typically reduced or absent  [24, 25].  
As referred in Chapter 1, antibiotic treatments should be administered to CF patients as soon as P. 
aeruginosa is detected in order to early eradicate bacteria and avoid infection development or progression 
for chronic stages. However, in some cases, P. aeruginosa could be detected later and, consequently, 
antibiotic treatments are also initiated later. In this study these two antibiotic regimes were investigated 
and to distinguish them, the formers were named as early antibiotic treatments and the others named as 
delayed treatments. 
To mimic early antibiotic treatments, sub- and inhibitory concentrations of ciprofloxacin were added to the 
top of ASM cultures after 30 min of the bacterial inoculation. New antibiotic dosages were added to ASM 
every 24 h over 10 days. Delayed antibiotic treatments were mimicked adding sub- and inhibitory 
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concentrations of ciprofloxacin to ASM cultures after 5 days of bacterial growth. In this regime new 
antibiotic dosages were added to ASM every 24 h over the next 5 days. The concentrations of 
ciprofloxacin used in this study were based on the MIC of biofilm-cells of the three strains determined in 
Chapter 3. The inhibitory concentration of ciprofloxacin towards biofilm-derived cells was 4 mg/L and 0,5 
and 1 mg/L were chosen as sub-inhibitory concentrations. 
After 1, 3, 5, 7 and 10 days of bacterial growth in ASM, the content of wells was collected aseptically and 
was vigorously shaken to detach cells from the small aggregates and those adhered to mucin. From these 
cell suspensions that contained the whole population resident in ASM, called from now on as whole 
population, it was determined the number of viable cells, the population diversity through colony 
morphology diversity, the pyocyanin production, the mutation frequency and the antibiotic susceptibility. 
After numbering the viable cells, the whole resident population in ASM was divided in sub-populations 
according the colony morphologies identified. One colony morphotype represented one sub-population. 
The identified sub-populations were characterized in terms of virulence factors expression and antibiotic 
susceptibility. All experiments were performed at least 5 times.  
 
Counting the number of viable cells 
The number of viable cells obtained from ASM suspensions was determined through colony-forming unit 
(CFU). Cell suspensions were serial diluted, plated on TSA and incubated overnight at 37 °C. After that, 
the number of colonies were counted and verified after more 24 h of growth. Through the number of viable 
cells, it was constructed the growth kinetics of P. aeruginosa strains in ASM and the time killing curves of 
the P. aeruginosa strains grown in ASM and exposure to the different antibiotics treatments.  
 
Colony morphology diversity 
According the results obtained in Chapter 2, P. aeruginosa colonies should be grown at least 45 h to 
obtain complete and unchangeable morphotypes and to avoid that small colonies (slow growing bacteria) 
were overlooked. As so, to assess colony morphology diversity, bacteria were allowed to grow on TSA 
plates during 48 h at 37 °C in air conditions. Colony morphologies were observed by directly placing the 
petri plates on a magnifying glass (Olympus SZ-CTV) and photographed in a CCD camera (AVC, D5CE; 
Sony, Tokio, Japan). The morphological features of the colonies were annotated using the morphological 
criteria previously stipulated (Chapter 2). In brief, colonies were evaluated according their form, margin, 
type of surface, texture, size, sheath, elevation, opacity, consistency and colour.  
After morphological characterisation of colonies, it was evaluated the stability of the morphological traits 
spreading repeatedly colonies in TSA plates, at least 10 times, and after 48 h of growth re-evaluated their 
morphology. This procedure allowed to distinguish the non- from the revertant phenotypes. 
The distinct colony morphotypes were referenced with an identity number, for instance MT01. Identity 
numbers had not any correlation with the order of emergence or relationships with other colony 
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morphotypes within populations. It was used only to refer colonies with common features and 
distinguished them one from another.  
Through colony morphology characterisation over ten days, it was constructed maps of the evolutionary 
profiles of the three P. aeruginosa strains in the several ASM growth conditions. 
 
Characterisation of virulence factors expression  
The bacteria derived from the different morphotypes were characterized according the virulence 
determinants more relevant in the CF context, namely biofilm formation, motility, auxotrophy, pigments 
and hemolysin production. All the tests were performed at least 5 times and each test used colonies of the 
identified morphotypes from the different biological assay. Moreover, in all tests 3 technical replicates 
were performed to ensure precision. 
Pyocyanin production was the only parameter studied for both colony morphotypes and the whole 
populations collected after 1, 3, 5, 7 and 10 days of bacterial growth in ASM. 
 
• Biofilm formation  
The ability of colony morphotype-associated bacteria to form biofilms was assessed by the crystal violet 
(CV) method  [26]. Colony morphotypes were suspended and diluted in TSB to obtain a final concentration 
of 107 CFU/mL. The cell suspensions were transferred to 96-well microtitre plates (200 µL per well) being 
then incubated at 37 ºC for 24 h under agitation (120 rpm) in air conditions. After 24 h of biofilm formation, 
the content of the plates was discarded and the adhered biomass to the plates was washed twice with 
sterile water in order to remove weakly attached cells. Afterwards, 200 μL per well of methanol were 
added and plates were allowed to stand for 15 min in order to fix the biofilm-mass. Methanol was 
discarded and plates were left to dry at room temperature. Biofilms were stained with 200 μL of pure CV 
for approximately 5 min and then rinsed thoroughly and repeatedly with tap water. Finally, the amount of 
biofilm formed was quantified by solubilization of the CV in 200 μL of 33 % (v/v) acetic acid. The optical 
density (OD) was measured at 590 nm using a microtiter plate reader (Bio-Rek Synergy HT, Izasa). 
 
• Motility determination 
Swimming, swarming and twitching were assessed using the following procedures: i) swimming motility - 
108 CFU/mL of each colony morphotype-associated bacteria were inoculated in TSA plates with 0,3 % 
(w/v) of agar and incubated for 24 h at 37 ºC in air conditions. Swimming was assessed by measuring the 
circular turbid zone around the inoculation point; ii) swarming motility - 108 CFU/mL of each colony 
morphotype-associated bacteria were inoculated in TSA plates with 0,5 % (w/v) of agar and incubated for 
24 h at 37 ºC in air conditions. Swarming motility was indicated by irregular branching that appeared at the 
periphery of the colonies being this turbid zone measured; iii) twitching assay - 108 CFU/mL of each 
colony morphotype-associated bacteria were inoculated in TSA plates with 1,5 % (w/v) of agar and 
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incubated for 24 h at 37 ºC in air conditions. Twitching motility was indicated by a hazy zone of growth at 
the interface between the agar and the polystyrene surface and this hazy zone of growth was measured. 
 
• Auxotrophy testing 
This metabolic trait was investigated by determining the ability of colony morphotypes-associated bacteria 
to grow on glucose M9 media (AMESRO) with and without 0,2 % (w/v) of casoamino acids  [21]. Colony 
morphotypes were transferred to M9 medium plates with and without casoamino acids and incubated at 
37 ºC. Evaluations were performed at 24 and 48 h of growth. Absence of growth on M9 media without 
casoamino acids was indicative of auxotrophy.  
 
• Pigments production 
The pyocyanin production was performed for each cell suspension obtained from ASM cultures and for 
each colony morphotype identified to assess the ability of the whole resident population and specific sub-
populations to produce this pigment, respectively.  
To determine pyocyanin production of the whole population it was performed a quantitative approach. 
These assays were carried out on culture supernatants during growth in ASM as previously 
described  [27]. Bacteria from cell suspensions collected after 1, 3, 5, 7 and 10 days of growth in ASM 
were pelleted at 15000 g for 15 min and the free-cell supernatants containing pyocyanin were carefully 
collected and mixed with the same volume of chloroform. Mixtures were vigorously vortexed and 
centrifuged at 17000 g for 1 min. Afterwards, the inorganic phase was discarded and to the organic phase, 
containing the pyocyanin (blue-green coloured), was added with the same volume of 0.2 M HCl. Mixtures 
were vortexed and centrifuged at 17000 g for 1 min. The pyocyanin-containing phase (pink layer) was 
collected and OD was measured at 520 nm using microtiter plate reader (Bio-Rek Synergy HT, Izasa). 
Concentration of pyocyanin, expressed as micrograms per millilitre of ASM supernatant, was determined 
by multiplying the OD by 17,072  [27].  
Due to the high number of morphotypes and biological and technical replicates, the production of 
pyocyanin for each colony morphotype-associated bacteria was assessed using a qualitative approach. 
So, pyocyanin production was determined visually observing the colour of colonies and the surrounding 
agar medium. Colonies exhibiting blue-green colour on TSA plates were considered pyocyanin 
producers  [28].  
The production of other pigments was also determined using a qualitative approach because of the 
abovementioned reasons. Pyoverdine and pyomelanin production were determined visually from colour of 
colonies and the surrounding agar medium. Colonies exhibiting green and brown colours on TSA plates 
were considered pyoverdine and pyomelanin producers, respectively  [28].  
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• Hemolytic activity 
The hemolytic activity of colony morphotypes-associated bacteria was assessed using Columbia Agar 
(CA; agar, 15 g/L, Liofilchem; Columbia broth, 43 g/L, Liofilchem) with 40 % (v/v) of sheep blood 
(Probiologica) plates (CAB). CAB plates were incubated 24 h at 37 ºC in air conditions. Hemolysin 
production was considered negative when no clearing zones were observed around the colonies. 
	  
Antimicrobial susceptibility test 
Due to the large number of antimicrobial susceptibility analysis, including whole populations, colony 
morphotypes and the number of independent replicates (at least 5 replicates) for each whole population 
and colony morphotypes, it was selected the disk diffusion method for its simplicity and reproducibility in a 
high-throughput format. The antimicrobial susceptibility profile of each morphotype was determined using 
ten antibiotics commonly used to treat P. aeruginosa infections in CF context: amikacin (AK) 30 µg, 
aztreonam (ATM) 30 µg, ciprofloxacin (CIP) 5 µg, tobramycin (TOB) 10 µg, gentamicin (CN) 10 µg, 
ceftazidime (CAZ) 30 µg, cefepime (FEP) 30 µg, imipenem (IMI) 10 µg, piperacillin (PRL) 100 µg and 
ticarcillin /clavulanic acid  (TTC) 85 (75+10) µg, all obtained from Liofilchem. Disk diffusion susceptibility 
testing was performed in accordance with the recommendations of NCCLS document M100-522  [29]. The 
cartridges of antibiotic disks were stored at -20 ºC and allowed to come to room temperature prior to use. 
The inhibition zones were measured (mm) after 18-21 h at 37 ºC in air conditions. Whole population and 
colony morphotypes-associated bacteria were assigned as resistant (R), intermediate resistant (I) or 
sensitive (S) as defined by NCCLS guidelines. 
 
Determination of mutation frequencies 
Hypermutability was assessed through determination of spontaneous mutation frequencies on TSA agar 
containing 300 mg/L rifampicin (Sigma-Aldrich) following ASM collection as described by Oliver et al. 
(2000)  [30]. ASM cultures were plated on TSA plates with and without 300 mg/L of rifampicin and 
incubated at 37 ºC. The number of colonies growing after 24 h of incubation was counted and confirmed 
after more 24 h of incubation (48 h in total). The mutation frequency was calculated as the fraction of 
resistant mutant cells (median number of mutant cells/median total cell number). Colonies growing on TSA 
plates with 300 mg/L of rifampicin were streaked onto another plate with 300 mg/L of rifampicin in order to 
assess the stability of mutants and to avoid mutation jackpot (the recovery by chance of a vast number of 
mutants). These experiments were performed at least 3 times. 
 
Statistical analysis 
Four continuous variables (biofilm formation ability, swimming, swarming and twitching motilities) and 
twenty categorical phenotypic characteristics (10 antibiotic resistance profiles and 10 colony morphology 
traits) were analysed.  
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CFU data were analysed by Mann–Whitney test, a non-parametric procedure to assess a null hypothesis 
that two populations are the same. In vitro biofilm formation data (OD values) were analysed using Kruskal 
Wallis (assumption of normality was not verified). Differences in proportions of colony morphology traits 
per antibiotic susceptibility status were estimated by the Chi-square test or Fisher’s exact test when 
appropriated. Measures of association between colony morphology traits and bacterial phenotypic 
features were determined by Kolmogorov-Smirnov Z test. This test does much the same as the Mann-
Whitney U test, however it tends to have better power that the Mann-Whitney U in smaller samples as of 
this study  [31]. The independent factors were colony form, margin, sheath, consistency, opacity and size. 
As colony colour had more than two categories, a Kruskal-Wallis test was performed. All statistical 
analyses were performed in SPSS version 20.0 (Chicago, Illinois, USA) considering as level of statistical 
significance p < 0,05. 
	  
4.3. Results 
The initial adaptation and the intraclonal diversity of P. aeruginosa populations were monitored after in 
vitro initial CF environment colonisation and growth in ASM during 10 days. The intraclonal diversity of P. 
aeruginosa populations was studied with respect to colony morphology variation. Thus, the presence of 
distinct colony morphologies allowed supposing the existence of sub-populations within the whole 
populations grown in ASM. To characterize the ecology of the whole P. aeruginosa populations in early-
infected CF environment and to infer about the adaptive alterations undergone by bacteria, it was 
performed a phenotypic characterization of all sub-populations detected along the 10 days.  
This study used three P. aeruginosa strains, two dry (non-mucoid) strains (PA01 and PAI2) and one 
mucoid (ATCC 39324) strain. The mucoid strain was included in this study to assess whether initial 
colonisation by a mucoid strain represents indeed a risk factor for the development of faster and worse 
infection. Early colonisation of the CF airways with these strains is associated with an accelerated rate of 
decline in pulmonary function  [32]. 
	  
4.3.1. Intraclonal diversification of P. aeruginosa after initial colonization 
The three P. aeruginosa strains used in this study demonstrated identical growth profile in ASM without 
the presence of ciprofloxacin (Figure 4.1). After one day of exponential growth, the three populations 
achieved the stationary phase with no difference in the number of viable cells between all the populations. 
However their microevolution profiles were dependent on the strain (Figure 4.2). P. aeruginosa PAI2 and 
ATCC populations exhibited colony morphology diversity after 3 days of growth in ASM, contrary to PA01 
strain that demonstrated no population diversity. P. aeruginosa PAI2 population exhibited the highest 
diversity since it generated 4 new distinct morphotypes all catalogued as SCV, while ATCC strain 
generated only one new morphotype, a dry variant. (Table 4.1) In terms of colony morphology alterations, 
ATCC wild-morphotype (WM), MT01, generated colonies with dry consistency (MT12). Regarding PAI2 
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strain, WM generated colonies with small size and/or with irregular form and/or with mucoid consistency 
(Table 4.1). Interestingly, the coexistence of several morphotypes within planktonic/inoculum populations 
was not observed previously (Chapter 3), which may mean that bacteria switch to new phenotypes 
possibly to adapt to CF environmental conditions, for instance new nutritional conditions, pH, DNA and 
salts concentration.  
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Growth kinetics of P. aeruginosa populations in ASM.  
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Figure 4.2. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM. Arrows represent the 
continuous presence of colony morphotypes within populations. 
 
  
 
 
Table 4.1. Detailed morphological description of the colonies identified in P. aeruginosa populations grown from ASM with and without ciprofloxacin. 
ª MF10 was observed in both PA01 and PAI2 populations. 
 
 
 
 
 
 Form Margin Sheath Type of Surface Texture Consistency Elevation Opacity Size Colour 
PA01           
MF02 circular undulate present homogeneous rough dry flat opaque large yellow 
MF17 circular undulate present homogeneous rough moist flat opaque large yellow 
           
PAI2           
MF14 circular entire absent homogeneous rough dry flat iridescent large Blue-green 
MF04 circular undulate absent heterogeneous smooth/rough dry flat iridescent small Blue-green 
MF05 irregular undulate absent homogeneous wrinkled dry flat iridescent small Blue-green 
MF07 circular entire absent homogeneous rough dry flat iridescent small Blue-green 
           
ATCC            
MF01 circular undulate present homogeneous smooth mucoid flat opaque large beige 
MF03 circular undulate present homogeneous rough dry flat opaque large beige 
MF12 circular undulate present homogeneous rough dry flat transparent large beige 
MF15 circular undulate present homogeneous rough dry flat opaque pinpoint beige 
MF19 circular undulate present homogeneous rough dry flat opaque small beige 
           
PA01 and PAi2           
MF10ª circular entire absent homogeneous smooth mucoid flat opaque small yellow 
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Given the population diversity found in these CF populations, further research questions have emerged: 
was the population diversification indeed an indicator of P. aeruginosa adaptation to CF conditions and 
infection development? If so, which bacterial phenotypic traits could be considered indicators of initial 
adaptation and infection development? To answer these questions, the antibiotic resistance profiles and 
the expression of virulence factors of all colony morphotype-associated bacteria, representative of sub-
populations, were investigated.  
The P. aeruginosa PAI2 population demonstrated diversity either in antibiotic resistance and virulence 
factors expression. Two PAI2 morphotypes (MT04 and MT10) had an antibiotic resistance profile different 
of the WM, the MT14 (Table 4.2). MT04 and MT10 did not exhibit intermediate resistance against 
aztreonam and ticarcillin/clavulanic acid as MT14. Furthermore, MT10 exhibited intermediate resistance 
against ciprofloxacin in opposite to MT14 that was resistant. The distinct phenotypic features of MT04 and 
MT10 seemed influence the whole population response to ciprofloxacin and aztreonam (Figure S4.1 in 
Supplemental Material). The emergence of the sensitive morphotypes MT04 and MT10 within PAI2 
populations at day 5 and 7, respectively, made populations more sensitive to antibiotics. For instance, the 
sensitivity of PAI2 population to ciprofloxacin and aztreonam increased from resistant to intermediate and 
intermediate to susceptible, respectively. 
In terms of virulence potential, all the new PAI2 morphotypes exhibited impaired swimming motility (Figure 
4.3A) and notable ability to form biofilms with exception of MT10 (Figure 4.3B). The expression of the 
other studied virulence determinants seemed to be unaltered (Table 4.3). Defective swimming motility and 
biofilm formation are characteristics typically associated with chronic isolates  [24, 33], which may mean 
that PAI2 population had initiated its adaptation to CF conditions and started expressing some bacterial 
features fundamental to develop an infection.  
 
 Table 4.2. Antibiotic susceptibility profiles of PAI2 colony morphotypes-associated bacteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 CIP CN TOB AK IMI ATM CAZ FEP TTC PRL 
MT14 (WM) R S S S S I S S I S 
MT04 R S S S S S S S S S 
MT05 R S S S S I S S I S 
MT07 R S S S S I S S I S 
MT10 I S S S S S S S S S 
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Figure 4.3. Phenotypic characterisation of the PAI2 colony morphotypes-associated bacteria: (A) swimming, swarming and twitching 
motilities and (B) ability to form biofilms. WM – wild-morphotype. 
 
 
Table 4.3. Phenotypic profile of PAI2 colony morphology-associated bacteria related to hemolysin, pyoverdine, pyocyanin and 
pyomelanin production and auxotrophy. 
 
 
 
 
 
 
 
 
 
a  colonies exhibited blue-green colour when were grown surrounding each other. 
b colonies exhibited brown colour when were grown in plates with lower colony concentration. 
 
Concerning ATCC population, very little diversity was observed since the only one new morphotype, the 
MT12 (Figure 4.2), exhibited an antibiotic susceptibility profile identical to the WM, MT01 (Table 4.4). 
Moreover, no differences in overall population resistance against antibiotics were noticed (Figure S4.1 in 
Supplemental Material). Regarding virulence factors expression, some phenotypic heterogeneity was 
detected. MT12 exhibited impaired swimming motility (Figure 4.4A), better ability to form biofilms (Figure 
4.4B) and pyocyanin production (Table 4.5) in comparison with ATCC WM, the MT01. Despite MT12 was 
a pyocyanin producer, the amount of pyocyanin found in the surrounding environment of the whole ATCC 
population was still very reduced in comparison with the whole PAI2 and PA01 populations (Figure 4.5). 
The reduced amounts of pyocyanin might be caused by the presence of only one sub-population 
pyocyanin producer and its reduced prevalence within population. Similarly to PAI2 population, it seemed 
that ATCC population had initiated its adaptation and started to develop infection.  
 
  
Hemolysin Auxotrophy 
Pigments production 
 Pyoverdine Pyocyanin Pyomelanin 
MT14 (WM) - - - ++ - 
MT04 - - - +a +b 
MT05 - - - + a + b 
MT07 - - - + a + b 
MT10 - - - -  + b 
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Table 4.4. Antibiotic susceptibility profiles of ATCC colony morphotypes-associated bacteria. 
 
 
 
 
 
 
 
 
Figure 4.4. Phenotypic characterisation of the ATCC colony morphotypes-associated bacteria: (A) swimming, swarming and 
twitching motilities and (B) ability to form biofilms. WM – wild-morphotype. 
 
 
 
 
Table 4.5. Phenotypic profile of ATCC colony morphology-associated bacteria related to hemolysin, pyoverdine, pyocyanin and 
pyomelanin production and auxotrophy. 
 
 
 
 
 
 
 
 
 CIP CN TOB AK IMI ATM CAZ FEP TTC PRL 
MT01 (WM) S S S S S S S S S S 
MT12 S S S S S S S S S S 
 
Hemolysin Auxotrophy 
Pigments production 
 Pyoverdine Pyocyanin Pyomelanin 
MT01 (WM) - - - - + 
MT12 - - - ++ - 
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Figure 4.5. Pyocyanin production of PA01, PAI2 and ATCC populations grown in ASM along 10 days. 
 
Concerning PA01 strain, its population did not exhibit diversification during all the 10 days, as only the 
WM, MT02, was observed (Figure 4.2). This event may mean that population did not start its adaptation 
and no infection was developed.  
Taking together the results obtained for the three strains, it was verified that diversification can occur at 
early stages of disease and diversified populations was associated with P. aeruginosa adaptation and in a 
real scenario could be associated with infection development. This clonal diversification, however, was not 
caused by increased spontaneous mutations (Table S4.1 in Supplemental Material).  
 
4.3.2. Effects of early ciprofloxacin treatments on P. aeruginosa populations 
Typically, CF patients are subjected since first P. aeruginosa detection to extended antibiotic treatments in 
order to early eradicate infection and avoid progression to chronic stage. However, antibiotics generally do 
not reach the maximum (inhibitory) concentration in CF lungs due to, for instance the presence of mucin 
and extracellular DNA that interfere in antibiotic action. As so, bacteria are just exposed to sub-inhibitory 
concentrations. In this study, the impact of sub- and inhibitory concentrations of ciprofloxacin in P. 
aeruginosa growth, population diversity and evolution and response to ciprofloxacin treatment was 
evaluated. The inhibitory concentration of ciprofloxacin corresponded to the MIC of biofilm cells, 4 mg/L, 
previously determined (Chapter 3). Biofilm formation is characteristic of CF chronic stages and typically 
biofilm cells exhibited increased levels of antibiotic resistance [37, 74]. Therefore, the MIC of biofilm cells 
seemed a suitable therapeutic reference for early ciprofloxacin treatments. The sub-inhibitory 
concentrations tested were 0,5 and 1 mg/L. 
The results obtained demonstrated that sub-inhibitory concentrations of ciprofloxacin were clearly 
inefficient to eradicate P. aeruginosa (Figure 4.6A and B). Some bacterial load reduction was indeed 
observed but only significant for the ATCC strain, where a 3 log reduction was attained using 1 mg/L of 
ciprofloxacin. Regarding the early ciprofloxacin treatment using 4 mg/L, it was observed PA01 and ATCC 
eradication, after three days of growth, and no interference in PAI2 growth (Figure 4.6 C).  
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Figure 4.6. Time-killing curves of P. aeruginosa populations grown in ASM exposed to: (A) 0,5 mg/L; (B) 1 mg/L; and (C) 4 mg/L of 
ciprofloxacin.  
	  
The greatest impact of ciprofloxacin treatments seemed to be on population diversity. The exposure to 
sub-inhibitory concentrations, 0,5 and 1 mg/L, has changed the colony morphology diversity as new 
morphotypes have emerged (Figure 4.7 and 4.8). The WM of PA01 and ATCC switched to other variants 
with distinct colony traits giving rise to populations with distinct dynamics and structures in comparison 
with homologous populations grown only in ASM. In contrast, population diversity of PAI2 did not differ 
with ciprofloxacin treatment, as the same morphotypes were detected. However, these morphotypes 
emerged later, at day 7 and 10. It should be noted the negative selective pressure of 1 mg/L of 
ciprofloxacin that seemed to exert on PA01 and PAI2 populations. This selection was noticed because the 
no emergence of MT10 in PAI2 and PA01 populations (Figure 4.7 and 4.8). Among all the sub-populations 
within PAI2, this sub-population was the one who had exhibited intermediate resistance to ciprofloxacin.   
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Figure 4.7. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM exposed to 0,5 mg/L of 
ciprofloxacin. Arrows represent the continuous presence of colony morphotypes within populations. 
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Figure 4.8. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM exposed to 1 mg/L of 
ciprofloxacin. Arrows represent the continuous presence of colony morphotypes within populations.  
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Among the new morphotypes emerged in PA01 and ATCC populations, it was observed moist variants 
(MT17), dry- and mucoid-SCV (MT19 and MT10, respectively) and pinpoint variants (MT15) (Figure 4.7 
and 4.8 and Table 4.1). Through the emergence of these morphotypes, the respective populations 
became more diverse in terms of antibiotic resistance and virulence factors expression. In effect, all new 
morphotypes, with exception of MT03, exhibited distinct antibiotic resistance profiles in comparison with 
the respective WM (Table 4.6). Furthermore, the emergence of these new morphotypes altered the 
susceptibility of the whole population against the antibiotics (Figure S4.2, S4.3 and S4.4 in Supplemental 
Material).  
Concerning the virulence factors expression, all new morphotypes, with exception of MT17, exhibited 
defective swimming motility (Figure 4.9A) as observed previously. Although the excellent biofilm formation 
ability of the new morphotypes, they did not revealed enhanced capacity than the respective WM (Figure 
4.10). Interestingly, the treatment with sub-inhibitory concentrations of ciprofloxacin almost abolished the 
pyocyanin production of PA01 and ATCC populations (Figure 4.11).  
 
Table 4.6. Antibiotic susceptibility profiles of colony morphotypes-associated bacteria. Grey shading marks the new morphotypes 
identified. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 CIP CN TOB AK IMI ATM CAZ FEP TTC PRL 
PA01           
MT02 (WM) S S S S S S S S S S 
MT17 S S S S S S S S I S 
MT10 I S S S S S S S S S 
           
ATCC           
MT01 (WM) S S S S S S S S S S 
MT03 S S S S S S S S S S 
MT19 S S S S S S S S I S 
MT15 R S S S S S S S I S 
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Figure 4.9. (A) Swimming, (B) swarming and (C) twitching motilities of colony morphotypes-associated bacteria. 
 
 
 
 
 
Figure 4.10. Biofilm formation abilities of colony morphotypes-associated bacteria of (A) PA01, (B) ATCC strains. 
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Figure 4.11. Pyocyanin production of PA01, PAI2 and ATCC populations grown in: (A) ASM with 0,5 mg/L of ciprofloxacin; (B) ASM 
with 1 mg/L of ciprofloxacin. 
 
Negative selective pressure seemed to be exerted with the use of 4 mg/L ciprofloxacin (inhibitory 
concentration) because MT05 and MT07 were not observed within PAI2 population and MT10 within PA01 
population (Figure 4.12). This negative selection seemed to be directed to sub-populations with 
intermediate resistance to aztreonam and/or to ticarcillin/clavulanic acid within PAI2 populations and 
directed to sub-populations with intermediate resistance to ciprofloxacin within PA01 populations (Table 
4.2). 
To investigate the mechanisms underlying the appearance of the new morphotypes within population 
under stressful conditions (exposure to sub- and inhibitory of CIP), the presence of mutators was 
assessed. The results obtained demonstrated that phenotypic heterogeneity was not caused by increased 
spontaneous mutations (Table S4.1 in Supplemental Material).  
Taken together the results obtained, it was possible to conclude that treatments using sub-inhibitory 
concentrations of ciprofloxacin based on MIC of biofilm cells were ineffective to early eradicate P. 
aeruginosa and may trigger phenotypic switching to better “fitter” variants. Furthermore the emergence of 
the new variants, negative selection of less “fitter” variants within populations may enhance the ability of 
the whole population to survive in CF lungs. These events highlight that inadequate concentrations of 
antibiotics could be the driven force of P. aeruginosa diversification and adaptation. From the new 
emergent morphotypes it was verified that all of them exhibited impaired swimming motility.  
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Figure 4.12. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM exposed to 4 mg/L of 
ciprofloxacin. Arrows represent the continuous presence of colony morphotypes within populations.  
	  
4.3.3. Effects of delayed ciprofloxacin treatment on P. aeruginosa populations 
Delayed detection of P. aeruginosa is associated with the worsening of patient prognosis because 
bacteria may have initiated its adaptation to CF lungs and developed infection. Whether adaptation has 
been initiated, the changes undergone by P. aeruginosa might perturb the efficacy of antibiotic treatments. 
So, it is important to determine the window of opportunity to eradicate P. aeruginosa from CF lungs after a 
delayed detection that often leads to a delayed onset of an antibiotic treatment. Based on the previous 
results (described on section 4.3.1), it can be pointed out that P. aeruginosa populations started their 
adaptation at day 3. To mimic delayed antibiotic treatments, 5-day early-adapted populations were 
exposed to different ciprofloxacin treatments (using sub- and inhibitory concentrations of, respectively, 1 
and 4 mg/L) to evaluate their efficacy and, in case of failure, the response of populations. The 
ciprofloxacin treatment using 0,5 mg/L was not tested at this stage because of the evident unsuccessful 
results in eradication of the three P. aeruginosa populations (described in section 4.3.2). 
The results demonstrated that delayed antibiotic treatments using sub-inhibitory concentrations could 
have unpredictable results: complete inefficacy, bacterial load reduction or eradication as observed for 
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PAI2, PA01 and ATCC populations, respectively (Figure 4.13A). Similar time-killing curves were obtained 
when using the inhibitory concentration, even though slight differences were observed (Figure 4.13B).  In 
effect, PA01 strain was eradicated after 48 h of antibiotic treatment and PAI2 underwent a little load 
reduction in the number of viable cells, approximately 1 log, but with no significant microbiological effect. 
 
 
Figure 4.13. Time-killing curves of P. aeruginosa populations grown in ASM and exposed at day 5 to ciprofloxacin treatments of (A) 
1 mg/L and (B) 4 mg/L and along the remaining 5 days. 
 
Concerning the population diversity, sub- and inhibitory concentrations of delayed ciprofloxacin treatments 
have changed the dynamics and structure of the whole populations that survive (PA01 and PAI2 strains 
when using 1 mg/L and PAI2 when using 4 mg/L). PA01 population responded to 1 mg/L of delayed 
ciprofloxacin treatment identically to the early treatments because the same new morphotypes MT10 and 
MT17 had emerged again (Figure 4.14). MT17 variants still appeared after the application of 4 mg/L of 
ciprofloxacin (Figure 4.15), but they were eradicated in the course of the treatment. PAI2 population 
underwent also alterations in population diversity. Both ciprofloxacin treatments reduced greatly 
population diversity as happen in early treatments, but only for a few days (Figure 4.14 and 4.15). At day 
10 populations were able to restore part or the whole diversity. ATCC population composed by the WM, 
the MT01, and MT12 did not survive to both delayed treatments. 
No mutators were detected within populations under delayed ciprofloxacin treatments (Table S4.1 in 
Supplemental Material). 
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Figure 4.14. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM and exposed at day 5 to 1 
mg/L. Arrows represent the continuous presence of colony morphotypes within populations. Black points represent the end of the 
morphotypes presence within populations and black squares re-emergence of morphotypes. 
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Figure 4.15. Evolutionary profiles of the three P. aeruginosa populations during 10 days of growth in ASM and exposed at day 5 to 4 
mg/L. Arrows represent the continuous presence of colony morphotypes within populations. Black points represent the end of the 
morphotypes presence within populations and black squares re-emergence of morphotypes. 
 
4.3.4. Association between colony morphology traits and antibiotic susceptibility 
The significant association between mucoidy and antibiotic resistance described in literature  [34] 
prompted to verify whether colony morphology traits were related to resistance against the antibiotic used 
in this study. As so, the results related to antibiotic susceptibility of all colony morphotypes identified and 
the colony morphotyping information were analysed following a statistical approach, in particular using 
correlation tests (Fisher’s Exact test and Pearson Chi-square, when appropriate). The results obtained 
showed that the absence of sheath, iridescent opacity, small size and green-blue colour were significantly 
associated with resistance to ciprofloxacin (Table 4.7). The same colony traits with exception of small size 
were significantly associated with intermediate resistance to aztreonam. No colony traits were significantly 
associated with intermediate resistance or sensitivity to ticarcillin/clavulanic acid (Table S4.2 in 
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Supplemental Material). Therefore, based on this statistical approach sheath, opacity, size and colour 
were considered potential candidates to indicators of antibiotic susceptibility to aztreonam and 
ciprofloxacin. 
 
Table 4.7. Categorical data analysis between ciprofloxacin resistance and colony morphology traits. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* significant at level 0.05  a 8 cells have expected count less than 5. The minimum expected count is 0,45. 
b 6 cells have expected count less than 5. The minimum expected count is 0,45. 
c 6 cells have expected count less than 5. The minimum expected count is 0,91. 
d 7 cells have expected count less than 5. The minimum expected count is 0,25. 
e 5 cells have expected count less than 5. The minimum expected count is 0,25. 
f 6 cells have expected count less than 5. The minimum expected count is 0,75. 
 
4.3.5. Association between colony morphology traits and bacterial phenotypic 
features 
It was hypothesized that colony morphologies could serve also as indicators of some bacterial virulence 
characteristics, as biofilm formation ability, swimming, swarming and twitching motilities. As so, a 
statistical approach was followed to verify the existence of correlation between these virulence factors 
expression and colony traits. From the statistical results obtained, using Kolmogorov-Smirnov Z test and 
Chi-square tests when appropriate, it was verified that swimming motility was significantly augmented in 
large colonies (Table 4.8 and Figure S4.5 in Supplemental Material) and twitching motility was significantly 
increased in colonies with sheath and in large colonies (Table 4.8 and Figure S4.6 in Supplemental 
Material). Regarding biofilm formation, significant differences in blue-green colour colonies in contrast with 
 Statistical test χ2 df p-value 
Co
lo
ny
 m
or
ph
ol
og
y 
tra
its
 
Ciprofloxacin resistance     
Form Fisher’s Exact Test   0,455 
Margin Fisher’s Exact Test   0,182 
Sheath Fisher’s Exact Test   0,015* 
Type of surface Fisher’s Exact Test   0,455 
Texture Person Chi-Square 3,437 a 3 0,329 
Consistency Person Chi-Square 2,037 b 2 0,361 
Opacity Person Chi-Square 7,639 b 2 0,022* 
Size Person Chi-Square 7,543 b 2 0,023* 
Colour Person Chi-Square 7,773 c 2 0,021* 
     
Aztreonam resistance     
Form Fisher’s Exact Test   0,250 
Margin Fisher’s Exact Test   0,250 
Sheath Fisher’s Exact Test   0,045* 
Type of surface Fisher’s Exact Test   1,000 
Texture Person Chi-Square 4,000d 3 0,261 
Consistency Person Chi-Square 1.333e 2 0,513 
Opacity Person Chi-Square 8,000e 2 0,018* 
Size Person Chi-Square 2,095e 2 0,351 
Colour Person Chi-Square 8,000f 2 0,018* 
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yellow and beige colonies were detected (Table 4.6 and Figure S4.7 in Supplemental Material). In fact, 
blue-green colonies exhibited increased biofilm formation ability.  
It seemed that beyond indicators of antibiotic susceptibility, sheath, size and colour revealed to be as well 
putative candidates for indicators of P. aeruginosa phenotypic characteristics. 
 
Table 4.8. Differences of colony morphology traits in biofilm formation ability, swimming, swarming and twitching motilities using the 
Kolmogorov-Smirnov Z test (K-S Z). 
 
* significant at level 0,05 
 
 
Table 4.9. Differences of colony colour in biofilm formation ability, swimming, swarming and twitching motilities using Kruskal-Wallis. 
 
 
 
 
 
 
* significant at level 0,05 
a degrees of freedom 
	  
 
4.3.6. Association among phenotypic traits 
In this study, the association among phenotypic traits was evaluated in order to verify whether the 
expression of a phenotypic trait could be an indicator of another. To verify this association, it was used the 
Pearson Correlation test. The results demonstrated that there was a strong positive association between 
swarming and twitching motilities and also a positive association between swimming and swarming 
motilities (Table 4.10). No phenotypic trait was significantly associated with biofilm formation ability. 
The results obtained seemed thus pointed out that augmented swarming motility could predict augment 
swimming and twitching motilities.  
 
 Biofilm 
formation 
Swimming Swarming Twitching 
K-S Z p-value K-S Z p-value K-S Z p-value K-S Z p-value 
Co
lon
y 
m
or
ph
olo
gy
 
tra
its
 
Margin 0,667 0,766 0,500 0,964 0,667 0,766 1,000 0,270 
Sheath 0,976 0,297 0,878 0,423 0,976 0,297 1,464 0,028* 
Consistency 0,667 0,766 0,833 0,491 0,667 0,766 0,667 0,766 
Opacity 1,140 0,149 0,513 0,955 0,684 0,738 1,140 0,149 
Size 0,969 0,305 1,368 0,047* 0,969 0,305 1,368 0,047* 
 
Biofilm 
formation 
Swimming Swarming Twitching 
dfa 
χ2 p-value χ2 p-value χ2 p-value χ2 p-value 
Colour 0,425 0,021* 1,478 0,809 3,005 0,478 7,753 0,223 2 
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Table 4.10. Pearson correlation between biofilm formation and swimming, swarming and twitching motilities. 
 
 
 
 
 
 
 
* significant at level 0,05 
** significant at level 0,0001 
 
4.4. Discussion 
The understanding of P. aeruginosa evolution and diversification during the course of infections in CF 
lungs is of upmost importance regarding the antibiotic treatments to administer to patients, nevertheless 
these processes are poorly understood. Remain thus unknown what happens immediately after P. 
aeruginosa lungs colonization. The less amount of information regarding early infection stages is mainly 
due to the needed of continuous sampling the sputum, which is very uncomfortable for patients. The 
impossibility of serial sputum sampling limits the ability to determine the exact timing of the initiation of P. 
aeruginosa adaptation and the emergence of new phenotypes. Therefore, in vitro studies have a crucial 
role to start investigating what occurs to P. aeruginosa after enter in CF lungs.  
Diversification of the infecting populations has been intensively studied, however limited to species 
identification and richness and anaerobic pathogen quantification mainly focused on chronic infections. 
Intraclonal diversification has been reported as a source of phenotypic heterogeneity with a role in 
bacteria adaptation to new environments  [16, 35, 36, 37]. Despite these evidences, it remains unclear the 
causes of intraclonal diversity, how stable are the variants generated, their function within the population, 
which niche variants grow and their response to antimicrobial action of antibiotics. To address these 
issues, this study deeply analysed the diversity of three distinct populations of P. aeruginosa after 
simulated initial colonization of CF lungs.  
The data obtained provided evidences of early P. aeruginosa diversity after ASM colonization. P. 
aeruginosa evolved generating diverse populations determined by the distinct colony morphotypes 
identified along 10 days of the experiment. The diversity of the P. aeruginosa populations of the three 
strains was distinct which may be explained by the different function of the central elements in genome, 
despite the genes involved in regulation were highly conserved. For instance, concentrations of sigma 
factors can vary according environmental conditions and across strains. This instability of the core 
elements of regulation is sufficient to generate distinct clonal diversification and adaptive pathways among 
strains  [38]. Moreover, it was observed that these populations were also dynamic since colony 
morphotypes-associated bacteria exhibited divergent phenotypic characteristics that coexisted for 10 
days. The results emphasized the role of intraclonal diversification in P. aeruginosa adaptation, in 
 Biofilm  formation Swimming Swarming Twitching 
Swimming -0,156 - 0,632* 0,534 
Swarming 0,473 0,632* - 0,864** 
Twitching -0,277 0,534 0,864** - 
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particular at early stage, leading to conclude that a single clone in sputum may not represent the whole 
infecting population resident in CF lungs.  
Phenotypic diversity is traditionally associated to adaptation to chronic infections  [20, 21, 34], but some of 
colony morphotypes typically associated with chronic infections were observed at early stage, for instance 
mucoid- and rough-SCV, pinpoint and moist variants were detected in early populations. There is no 
single colony morphotype dominating at early stages of infections, but several morphotypes can evolve 
with distinct characteristics and not restricted to mucoid morphotypes.  
In addition to the early diversity noticed in P. aeruginosa populations, results also demonstrated that such 
diversity could have long-term stability as pointed out during the 10 days of growth. The existence and co-
existence of distinct variants suggested that they all play a role in infection development and progression 
to chronic stages. Furthermore, those earlier morphotypes maintained their colony features as well as 
their biological characteristics in subsequent cultures, at least 10 cultures, highlighting the stability of these 
variants, as previously reported by Markussen et al. (2014)  [37]. 
The determination of the driven forces and the underlying mechanisms of intraclonal diversification of P. 
aeruginosa in ASM was considered of upmost importance and addressed in this study. The absence of 
mutators in populations grown in ASM seemed indicate that hypermutability was not the underlying 
mechanism of intraclonal diversification and suggested that spatial organisation in distinct niches in CF 
lungs might play a major role in the generation and maintenance of intra-population diversity. The rapid 
diversification of P. aeruginosa after initial ASM colonization was indicative of the existence of several 
niches within ASM that bacteria fill in leading to several sub-populations. This theory was previously 
proposed and named as adaptive radiation  [18, 39]. The results of this study supported the adaptive 
radiation theory and reinforced the assumption that CF sputum is intrinsically a heterogeneous, complex 
and dynamic environment  [40] highlighting the importance of spatial organisation and niche partitioning 
since early stages of infection. Other in vitro evolution studies have established this correlation between 
heterogeneous environments, evolution and maintenance of population diversity  [41, 42]. However, 
conclusions about the characteristics of CF niches related to intraclonal variation are very difficult to reach 
because most of the studies analysed bacterial diversity from sputum or bronchoalveolar lavage fluid 
samples with lack of spatial resolution or intraclonal diversity concerns. Among the scarce studies that 
address these niches partitioning issues, Markussen et al. (2014)  [37] found quite similar results as those 
reported in the present study. The authors showed that the initial infecting strain diverged into distinct 
sublineages immediately after initial lungs colonization possibly caused by niche partitioning. Both studies, 
Markussen et al. (2014)  [37] and the present work, highlight the relevance of better understanding the 
interactions that take place between P. aeruginosa and the CF environment. The knowledge about those 
initial P. aeruginosa interactions could provide important insights into colonization, infection development 
and progression to chronic stages. 
Biofilms are also heterogeneous environments and they are typically found in chronic infections  [25, 33, 
43]. After discarded the hypothesis of hypermutability to be the underlying mechanism of intraclonal 
diversification in ASM, it was considered interesting to verify whether population diversity was linked to the 
Chapter 4 
 177 
presence of small aggregates or immature biofilms at this in vitro early stage of infection. Comparing the 
colony morphotypes derived from ASM cultures with those obtained in biofilm assays in Chapter 3, it was 
verified that some of new ASM morphotypes were identical to the colony morphotypes-biofilm associated. 
This evidence suggested that at early infection stages the P. aeruginosa mode of growth in CF lungs 
could be the aggregate mode (without or with very reduced amount of matrix) or immature biofilms that 
may further evolve to mature biofilms. Therefore, beyond niche partitioning the formation of small 
aggregates or immature biofilms in ASM seemed promote P. aeruginosa diversification.  
Much attention has been directed towards the development of new drugs targeting biofilm formation, 
motility and QS-signals  [44, 45, 46, 47, 48]. However, the answer for early eradication failure could pass 
in changing the design of the actual antibiotic treatment regimes, in particular, the dosage administered to 
patients. There is a continuous debate about antibiotics, combinations of antibiotics, concentrations and 
modes of administration that should be applied in the treatment of CF-associated infections  [49, 50]. It is 
urgent to establish some guidelines about antibiotic therapy and this study aimed to gain insights about 
the most adequate concentrations of early treatments. In this study, the therapeutic dosage reference was 
established based on the MIC of biofilm cells previously determined in Chapter 3. Antibiotics commonly do 
not reach the expected maximum inhibitory concentration in CF lungs due to interferences in their action, 
such as the presence of mucin and extracellular DNA. To reach biofilm cells, antibiotics face similar 
obstacles and therefore the MIC of biofilm cells seemed an adequate therapeutic reference. From the 
results obtained, the MIC of biofilm cells demonstrated to be an accurate and useful reference for the 
antibiotic dosage for early treatments using ciprofloxacin monotherapy. Concentrations around MIC of 
biofilm cells have produced better bacterial eradication results than sub-MIC doses. Nonetheless, PAI2 
strain survival to inhibitory concentrations of ciprofloxacin weakened the generalization of that assumption.  
The survival of PAI2 could be due to its culture history before the CF adaptation process implemented. 
Some authors advocated that the understanding of bacteria adaptations and their regulatory responses 
requires the contextualization of the culture history of bacteria, in particular of clinical isolates, such as the 
stress exposure, growth rate and mode of growth before the adaptive transition that is under studied  [38]. 
PAI2 strain is a clinical isolate obtained from a non-CF environment that could have faced several 
unknown stresses and/or acquired some genetic material and/or mutations that provided to bacteria better 
fitness and greatest ciprofloxacin resistance and thus its success against ciprofloxacin MIC of biofilm cells. 
Transposing to real scenario, inefficacy of early ciprofloxacin treatments using MIC of biofilm cells could 
be verified whether CF patients acquire pathogens with pre-developed resistance to antibiotics, for 
instance from other patients. 
The results related to early ciprofloxacin treatments using sub-MIC doses demonstrated that beyond 
contributing to the failure of bacteria eradication, inaccurate concentrations were the driven forces for P. 
aeruginosa diversification into better “fitter” variants. Furthermore, sub-MIC ciprofloxacin pressure has 
exerted selection within populations persisting the antibiotic resistant clones. Similar findings were also 
reported by Macia et al. (2006)  [51] that found selection of populations with distinct antibiotic resistance 
levels in response to different ciprofloxacin concentrations.  
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Moreover, sub-inhibitory concentrations of antibiotics can function as signalling molecules regulating gene 
transcription, physiology and virulence potential  [52, 53, 54, 55] and that alterations could be reflected on 
colony morphology variation. This regulation impacts on bacterial fitness increasing the survival in 
stressful environments. PA01 and ATCC populations under ciprofloxacin treatments greatly decreased 
their pyocyanin production. Pyocyanin production is under QS regulation and the sub-inhibitory 
concentrations of ciprofloxacin seemed to modulate QS networks in populations. This result challenges 
the traditional view of antibiotics action limited to reduce bacterial fitness and virulence potential and 
interestingly several authors previously described it  [52, 56, 57, 58]. However, this result could be not 
verified in all P. aeruginosa populations. PAI2 population even under ciprofloxacin treatments maintained 
its pyocyanin overproduction. Similar feature was reported to the hypervirulent Liverpool epidemic CF 
strain of P. aeruginosa and correlated with periods of pulmonary exacerbations in some CF patients  [20, 
59]. The distinct pyocyanin production among P. aeruginosa populations in this study reflects that CF 
environments can comprise the coexistence of QS-positive and – defective bacteria  [20, 60, 61]. QS-
defective bacteria could be fitter facing other stressful conditions due to the biological cost of QS.  
The importance of the antibiotic dosage boosts whether P. aeruginosa is detected later and antibiotic 
treatments are as well initiated later. The results obtained in this study evidenced that sub-MIC 
ciprofloxacin dosages of delayed treatments could have unpredictable results, since successful 
eradication to bacteria persistence. This range of antibiotic treatment results was highly dependent of P. 
aeruginosa strain ability to adapt to ASM. Some bacterial resistance to the treatments using reduced 
concentrations of ciprofloxacin was expected because P. aeruginosa is intrinsically resistant to the most 
fluoroquinoles  [62].  
The development of resistance to other unrelated antibiotics (antibiotics belonging to other classes) is a 
risk of antibiotic treatments and it has been particularly reported for ciprofloxacin  [63]. The results 
obtained in this study demonstrated that ciprofloxacin could be used as an early antibacterial agent but 
some intermediate co-resistance emerged for aztreonam, monobactams antibiotic, and 
ticarcillin/clavulanic acid, a combination of β-lactam antibiotic with β–lactamase inhibitor. It should be 
addressed more studies to confirm if in fact ciprofloxacin treatments could induce co-resistance. 
Nevertheless, the whole P. aeruginosa populations analysed in this study demonstrated to be susceptible 
to almost antibiotics. From the clinical point of view, this result is very welcome meaning that P. 
aeruginosa could be easily eradicate at this stage of infection. Although these satisfactory results of 
susceptibility, the antibiotic susceptibilities of colony morphotypes-associated bacteria were determined to 
monitored possible changes undergone by bacteria to achieve adaptation. From this analysis it was 
observed that antibiotic susceptibilities of the some colony morphotypes-associated bacteria were not 
identical to the antibiotic susceptibilities of the whole populations. For instance, PA01 populations grown in 
ASM under 0,5 mg/L of ciprofloxacin treatment exhibited sensitivity to ticarcillin/clavulanic acid, but MT17 
and MT10 were intermediate resistant to this antibiotic. These results demonstrated that in fact some sub-
populations have altered their susceptibility profile, which is of serious concern because it is unknown 
what happen after day 10. It is known through this study that whole populations are sensitive until day 10 
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but there is a possibility that the intermediate resistant or resistant sub-populations gain expression in 
number within populations after day 10 and the overall sensitive could be lost. These situations highlight 
the importance of testing the antibiotic susceptibility of colony morphotypes and the whole population 
separately. A sensitive population does not mean that resistant or intermediate resistant variants are not 
present and that soon, with or without antimicrobial treatment stimuli, population became resistant.  
From the microbiological perspective, the distinct susceptibility profiles exhibited by whole populations and 
their derived morphotypes highlight the relevance of sub-populations interactions. However, so far, there 
is no relevant information on this matter, namely on the role that the distinct sub-populations may play on 
the different aspects of CF disease, as infection development, transition to chronic stages, bacteria 
persistence and exacerbations occurrence. In attempt to collect some information about the role of sub-
populations in CF disease and to identify the alterations undergone by P. aeruginosa at this early stage of 
infection, all colony morphotypes were phenotypically characterised in terms of virulence factors 
expression. In this study, it was found that early clonal isolates varied in motility (swimming, swarming, 
twitching), biofilm formation ability and pigments production. Impaired swimming motility was a common 
feature among the all new clonal variants, seeming thus that bacteria lack flagella in order to adapt and 
survive to CF conditions and to antibiotic treatments. Motility in CF sputum is mechanically inhibited due to 
the presence of mucin as the FliD flagellar cap protein at the tip of the flagella binds to hitch cells and 
inhibits rotation  [64]. Therefore, at one adaptation step swimming motility is inhibited and adherence 
promoted. Furthermore, defective swimming motility facilitates further adaptations, such as aggregation 
(biofilm formation), which confer protection against to antibiotics and host immune molecules, as 
described previously  [65, 66] and reinforced by this study as some colony morphotypes-biofilm 
associated were detected. Data led to the hypothesis that impaired swimming motility could be associated 
with initial P. aeruginosa adaptation and early infection development. This premise is reinforced by Mayer-
Hamblett et al. (2014)  [28] that found an association between defective swimming ability and pulmonary 
exacerbations, worsening symptoms and declining lung function, the common signs of infection 
development  [20, 67, 68] and by several other studies that described defective swimming ability as a 
characteristic of CF chronic isolates  [28, 65, 66, 69]. 
The hypothesis that impaired swimming motility could be associated with initial P. aeruginosa adaptation 
and infection development contradicted some traditionally held concepts that mucoidy and/or emergence 
of SCV are the characteristic associated with infection development and transition to chronic stages and 
thus contributors to disease  [70, 71]. Conversion to mucoid phenotype in this study was limited to one 
colony morphotype (MT10), susceptible to negative selection by exposure to ciprofloxacin and thus not 
considered a relevant feature at this infection stage. The detection of SCV was limited to one P. 
aeruginosa strain that did not allow considering as an infection development feature. As motility measures 
can be performed in a reproducible and quantitative way and it was a common trait among all new 
emergent colony morphotypes identified, defective swimming was considered a potential disease marker, 
as also proposed by Mayer-Hamblett et al. (2014)  [28].  
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Acquisition of mucoid phenotypes even at early stages of infection development is typically associated 
with worsening of prognosis. Data obtained in this study did not support that assumption since the mucoid 
clones switched to dry variants after ASM colonization and were easily eradicated by early and delayed 
treatments using biofilm cells inhibitory concentrations of ciprofloxacin. Initial clearance of mucoid 
phenotypes was also reported by Troxler et al. [72].  
Diversification of P. aeruginosa grown in ASM without ciprofloxacin seemed to be caused by phenotypic 
plasticity of P. aeruginosa and supported by the absence of mutators. It is well known the impressive 
ability of P. aeruginosa to adapt to so different environments diversifying into several phenotypes  [8, 73, 
74]. Changes in diversification during and after exposure to sub-inhibitory concentrations of antibiotics 
could result of mutagenesis induction, which causes variation and/or promotes hypermutability. Antibiotics 
can induce mutagenesis because trigger SOS response and thus increasing the expression of error-prone 
DNA polymerases leading to diversity within populations  [75, 76]. Ciprofloxacin is a fluoroquinolone 
antibiotic that acts in DNA replication by interacting with DNA gyrase and with DNA topoisomerase IV  [77, 
78] that sub-inhibitory concentrations can induce mutations and recombinations and supporting the 
emergence of phenotypic variants and mutators  [60, 79, 80]. Although the distinct phenotypic diversity of 
P. aeruginosa populations observed during the treatments with sub-MIC dosages of cirpofloxacin, no 
hypermutable phenotypes were detected. Therefore, there was no evidence that hypermutability was the 
underlying mechanism for diversification under antibiotic treatments. The absence of hypermutable 
phenotypes was similarly reported by other previous studies  [42, 60, 81, 82].  
As previously described, P. aeruginosa exhibited several different colony morphologies and it was 
hypothesized whether they could serve as indicator of antibiotic resistance and virulence factors 
expression. Due to the importance of these indicators in clinical diagnosis, it was used a statistical 
analysis to ensure results reliability. It was found that the absence of sheath, iridescent opacity and blue-
green colour could be potential candidates to indicate antibiotic resistance. The small size revealed to be 
a good indicator but only for ciprofloxacin resistance. Concerning the virulence factors expression, the 
colony size revealed to be an indicator of swimming and twitching motilities, colony sheath demonstrated 
to be an indicator of twitching motility and colony colour an indicator of biofilm formation. These results 
emphasize the importance of colony morphology characterisation in the context of clinical diagnosis and in 
monitoring of P. aeruginosa adaptation and evolution. Despite the promising results, these colony traits 
need to be extensively studied to validate them. 
	  
4.5. Conclusions  
The adaptive changes undergone by P. aeruginosa after initial colonisation of CF lungs are poorly studied. 
P. aeruginosa diversity is greatly associated with chronic stage infections and mucoidy remains the risk 
factor for the development of chronic infections and exacerbations. This study demonstrated the 
occurrence of P. aeruginosa diversification after in vitro initial colonisation and provided evidences that 
such diversification played a role in bacterial adaptation to the CF environment and early infection 
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development. These findings have great impact on CF disease management as they highlighted that “real” 
diversity can be underestimated when it is assumed that single or few isolates represent the entire 
population. Diversity underestimation can contribute to erroneous diagnosis with serious implications in 
antibiotic therapy efficacy. Moreover, it can also have implications in the information about P. aeruginosa 
adaptation to CF lungs provided by genomic, transcriptomic, metabolomic, proteomic and phenotypic 
studies. In effect, these studies are based on population diversity that, if poorly estimated, may provide 
defective information that not represents the true scenario about the infecting populations.  
It is consensual that the delay of P. aeruginosa infection in CF patients is fundamental to avoid chronic 
infection establishment that is greatly associated with rapid lung function deterioration and increased 
antibiotic resistance. This study demonstrated that the antibiotic doses used in the early treatments have 
impact on P. aeruginosa populations. In fact, dosage of ciprofloxacin equivalent to the MIC of biofilm cells 
was able to eradicate bacteria in ASM. Conversely, sub-inhibitory concentrations were ineffective in 
bacterial eradication and constituted the driven forces for diversification towards better “fitter” variants and 
infection progression. Inadequate concentrations of antibiotics could even exert selection over population 
leading to only remain the resistant variants and boosting antibiotic resistance and persistence of the 
infecting population. This outcome is of upmost importance in clinical decision making, in particular, to re-
design tailored antibiotic treatment regimes using accurate concentrations. Results also pointed out that 
MIC of biofilm cells seems to be an adequate therapeutic reference for early antibiotic treatments regimes.  
Early intraclonal P. aeruginosa diversification seemed not be caused by hypermutability but by bacteria 
plasticity and niche specialization. In effect, the diversification of P. aeruginosa grown simply in ASM could 
result from niche partitioning reinforcing the assumption that CF lungs is one of the most complex 
environment within human host, highly structured with temporal and spatial variations, different 
environmental conditions (the niches), multiple connections among compartments and microorganism 
(intra- and interspecies interactions). Bacterial survival in ASM with ciprofloxacin seemed also not be 
caused by hypermutability but by the impressive versatility of P. aeruginosa to face stressful conditions 
triggering stress responses. 
Bacteria resident in CF lungs undergone alterations that may have profound effects on disease status and 
clinical outcome specially whether these alterations have impact on bacterial fitness and resistance to 
antibiotics. Those alterations may represent useful tools for monitoring infection development and 
bacterial response to treatments. Therefore, in the present study, a substantial effort was directed towards 
finding early disease markers to enable prompt diagnosis and tailored antibiotic treatment before chronic 
infection development. Results showed that P. aeruginosa undergone multiple in vitro phenotypic changes 
after ASM colonization, but impaired swimming motility was the phenotypic trait most associated with CF 
adaptation instead of mucoidy as traditionally referred. Therefore, impaired swimming motility was 
considered a potential disease marker of early P. aeruginosa adaptation and infection development. It 
must be stressed that these results were obtained from in vitro experiments that could not exactly 
represent the in vivo scenario, so impaired motility should be assessed through ex vivo experiments and 
thus validated as disease marker.  
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In the present study, several colony morphologies usually associated to chronic stages were observed in 
early P. aeruginosa populations, such as SCV, rough, iridescent and moist variants. The presence of 
these colony variants in this in vitro study seems to indicate that CF lungs could be potential reservoirs of 
antibiotic resistant and increased virulent variants since the early stages of disease able to persist and to 
cause chronic infection.  
Given the increased colony morphology diversification resulting from P. aeruginosa bacterial adaptation it 
was hypothesized that colony traits could be useful bacterial indicators of virulence factors expression and 
antibiotic susceptibility. It was found that some colony traits such as absence of sheath, iridescent opacity, 
small size and blue-green colour were indicative of ciprofloxacin resistance and aztreonam intermediate 
resistance. Likewise, the presence of sheath and large size were indicative of twitching motility and blue-
green colour of increased ability to form biofilms. These findings highlight the relevance of colony 
morphology observation as an auxiliary and complementary diagnosis method. 
The overall results achieved with the present work provide valuable insights about initial adaptation of P. 
aeruginosa in CF lungs, intraclonal diversity and disease markers. However, the results obtained could be 
strengthened if more strains of P. aeruginosa from non- and –CF environment were included. In effect, as 
observed, the genetic background of the strains plays a crucial role in bacteria adaptation. Despite strains 
belong to the same species and the genes involved in regulation are highly conserved, central elements in 
genome can function in different ways. Therefore, more P. aeruginosa strains should further be studied in 
order to broaden and generalise the main findings obtained. It must also be stressed that, in contrast with 
the described in literature, some virulence factors seemed not to be expressed in this experiment. This 
could be attributed to the lack of stimulus similar to those played by host cells and host immune 
molecules. The practicality of assessing several colony morphotypes limited the number of phenotypic 
traits evaluated. The lack of expression of some described virulence factors could be also caused by the 
reduced period of time of this study in the context of “real” CF infection development. Despite to be a 
considerable period of time for an in vitro study, ten days could not be the sufficient period of time to 
observe other P. aeruginosa alterations in virulence factors expression, as well as in antibiotic resistance. 
An early stage of infection in CF disease could last weeks to months.  	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4.7. Supplemental Material 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.1 – Antibiotic susceptibility profiles of colony morphotypes that composed PA01, PAI2 and ATCC populations and 
antibiotic susceptibility profiles the respective whole populations (represented by (-) grown in ASM without ciprofloxacin. 
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Table S4.1. Rifampicin mutation frequencies of P. aeruginosa populations of PA01, U14 and ATCC grown in ASM without 
ciprofloxacin treatment; grown in ASM with 0,5 mg/L of ciprofloxacin; grown in ASM with 1 mg/L of ciprofloxacin; grown in ASM with 4 
mg/L of ciprofloxacin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Mutation frequency (mutants per cell) 
 PA01 U147016 ATCC 39324 
Without treatment    
Day 1 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 3 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 5 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 7 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 10 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
    
0,5 mg/L    
Day 1 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 3 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 5 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 7 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 10 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
    
1 mg/L    
Day 1 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 3 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 5 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 7 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 10 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
    
4 mg/L    
Day 1 < 5 x 10
-11
 < 5 x 10
-11
 < 5 x 10
-11
 
Day 3 - < 5 x 10
-11
 - 
Day 5 - < 5 x 10
-11
 - 
Day 7 - < 5 x 10
-11
 - 
Day 10 - < 5 x 10
-11
 - 
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Figure S4.2 – Antibiotic susceptibility profiles of colony morphotypes that composed PA01, PAI2 and ATCC populations and the 
overall population (-) grown in ASM with 0,5 mg/L of ciprofloxacin. 
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Figure S4.3 – Antibiotic susceptibility profiles of colony morphotypes that composed PA01, PAI2 and ATCC populations and the 
overall population (-) grown in ASM with 1 mg/L of ciprofloxacin. 
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Figure S4.4 – Antibiotic susceptibility profiles of colony morphotypes that composed PA01, PAI2 and ATCC populations and the 
overall population (-) grown in ASM with 4 mg/L of ciprofloxacin. 
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Table S4.2. Categorical data analysis of between ticarcillin/clavulanic acid resistance and colony morphology traits. 
 
 
 
 
 
 
 
 
 
 
 
 
a 8 cells have expected count less than 5. The minimum expected count is 0,5. 
b 6 cells have expected count less than 5. The minimum expected count is 0,5. 
c 6 cells have expected count less than 5. The minimum expected count is 1,5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.5 – Boxplots that display swimming motility data for colony size. The black bars in the boxes represent the median values. 
 
 
 
 
 Statistical test χ2 df p-value 
Co
lo
ny
 m
or
ph
ol
og
y 
tra
its
 
Ticarcillin/clavulanic 
acid resistance  
    
Form Fisher’s Exact Test   1,000 
Margin Fisher’s Exact Test   1,000 
Sheath Fisher’s Exact Test   1,000 
Type of surface Fisher’s Exact Test   1,000 
Texture Person Chi-Square 4,500 a 3 0,212 
Consistency Person Chi-Square 3,111 b 2 0,211 
Opacity Person Chi-Square 2,143 b 2 0,343 
Size Person Chi-Square 1,143 b 2 0,565 
Colour Person Chi-Square 1,533 c 2 0,465 
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Figure S4.6 – Boxplots that display twitching motility data for (A) colony size and (B) sheath. The black bars in the boxes represent 
the median values. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S4.7 – Boxplots that display biofilm formation data for colony colour. The black bars in the boxes represent 
the median values. 
 
 
Chapter	  5	  
Morphocol:	  an	  ontology-­‐based	  knowledgebase	  for	  
the	  characterisa8on	  of	  clinically	  signiﬁcant	  
bacterial	  colony	  morphologies	  

  
 
 
 
 
5 
MorphoCol: an ontology-based knowledge for the 
characterisation of clinically significant bacterial  
colony morphologies  
 
 
Abstract 
To transform the findings of this project and upcoming results into a valuable clinical decision making tool, 
colony morphology characterisation should be standardised. Notably, it is important to establish the minimum 
experimental information necessary to contextualise the environment that originated the colony morphology, 
and describe the main morphological features associated unambiguously. This chapter presents MorphoCol, a 
new ontology-based tool for the standardised, consistent and machine-interpretable description of the 
morphology of colonies formed by human pathogenic bacteria. MorphoCol, publicly Web-accessible 
knowledgebase, is an end-user means to search and compare annotated colony morphotypes using the 
Colony Morphology Ontology (CMO). CMO is the first controlled vocabulary addressing the specificities of the 
colony morphology of clinically significant bacteria. The ultimate aim of this work is to help correlate the 
morphological alterations manifested by colony-forming bacteria during different infections and disease stages 
with their response to the antimicrobial treatments administered, antibiotic resistance profiles and the 
expression of virulence factors. MorphoCol is the first tool to address bacterial colony morphotyping 
systematically and deliver a free of charge resource to the community. Hopefully, it may introduce interesting 
features of analysis on pathogenic behaviour and play a significant role in clinical decision making. Database 
URL: http://morphocol.org 
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5.1. Introduction 
Colony morphology observation and characterisation is still today among the most used microbial 
identification methods by scientific and clinical laboratories because it can be performed through a 
simple procedure and it is fairly easy to integrate into the analytical pipeline of any laboratory 
(Figure 5.1). Although it disregards phenotypic variations that are not observable macroscopically 
as MALDI-TOF MS analysis demonstrated (Chapter 2), it points out those features that are 
observable macroscopically and keep emerging in association with antimicrobial susceptibility, 
virulence and persistence profiles. Clinical decision making applications can thus make use of these 
key morphological features as immediate indicators of microbial behaviour while reasoning about 
the most adequate antimicrobial therapies. However, colony morphologies vary widely, depending 
on the particular behaviour of the microbial species under different growth conditions, for instance 
different colonisation sites (lungs, bloodstream, urinary tract), or exposure to antibiotic agents with 
different modes of action. Also, the morphological traits exhibited by the colonies may be 
significantly affected by the procedures taken to isolate and grow the bacteria as demonstrated in 
Chapter 2, section 2.2. Colony morphology data management is thus a complex task because there 
is not available a structured and standardized formats, common terminology to describe colonies 
and minimum information standards for colony morphology origin (e.g. solid media, temperature, 
time of growth, agar concentration). Computer applications in assistance of phenotypic annotation 
and systematically analysis of morphotypes are therefore pivotal to manage and integrate data in an 
amenable, systematic and accurate way. It is very important to establish the minimum set of 
information to be part of the morphotype description and to employ harmonised vocabulary in both 
the biological contextualisation and the morphological characterisation of the observed colony.  
Scientific literature is the main source of morphotypes, where they are often presented as 
exemplificative figures of what the researchers observed and are described informally. The fact that 
the description of colony morphologies does not yet follow predefined rules of annotation nor makes 
use of controlled vocabulary further hampers the automated classification, integration and 
interpretation of such data. In particular, biomedical ontologies are the key to standardise 
terminology and unambiguously describe relevant morphological features well as discretise the 
corresponding values (or establish some range of threshold, in the case of continuous features). 
Ontologies are a formalism to describe entities and their relationships and they attempt to replace 
the free-text descriptions of colony morphologies with equivalent computable descriptions  [1]. 
Ontologies have become an important tool for structuring biological information since the 
introduction of Gene Ontology (GO)  [2] and nowadays they are the standard to support knowledge 
representation of any scientific field. Through these computable descriptions it is able to draw 
inferences about the data and provide a practical way to capture the biologically relevant 
information about, for instance associations with antibiotic resistance, virulence factors expression 
and gene expression.   
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Because the collection and ability to compare existing data is imperative to move forward in colony 
morphology analysis, the present work had addressed the development of systematic computer-
amenable approaches to colony morphology data organisation and standardisation. This chapter 
presents the rationale of a novel ontological framework in support of the characterisation of the 
colony morphology of clinically significant bacteria. The ontology created will be an integrative 
resource for the systematic, transparent and unambiguous characterisation of colony morphology 
traits in support of clinical diagnosis. The ontology will support a public Web repository of colony 
morphologies specially created to enable the macroscopic observation of morphotypes and the 
comparison of the morphological “output” of the species in different scenarios (e.g. antibiotic 
therapeutics and body localisation).  
 
Figure 5.1. General workflow of bacterial profiling. Bacteria provided from samples are cultivated and further characterised 
using several methods in which colony morphology is included.  
 
5.2. Design and Implementation 
5.2.1. Considerations in ontology design 
Harmonised and manual annotation guarantees the high quality of the colony morphotypes in 
MorphoCol repository. Likewise, it enables the search and comparison of morphotypes according to 
various aspects of morphological and biological characterisations. Ontologies are at the backbone 
of bioinformatics providing a significant contribution to the annotation of databases and high-
throughput data analysis. Till date, no ontology has covered for the specifics of colony phenotypic 
traits. Therefore, CMO aims to characterise the main features of the morphology of bacterial 
colonies.  
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The design of CMO was based on the classification system of colony morphologies proposed in 
Chapter 2 section 2.3 (Figure 2.6) because this system was constructed following similar principles 
of an ontology design, including: 1) the revision of literature; 2) collection of the terms commonly 
used by authors of clinical, microbiological and medical studies in the characterisation of colony 
morphology; 3) analysis of these textual descriptors, evaluating the appropriateness of the 
associated semantics and identifying the common name and synonyms of each concept according 
to overall concordance and our expertise in the field; 4) manual validation of the descriptive ability of 
the set of concepts gathered against published descriptions of morphotypes. Furthermore, CMO 
was developed following other basic principles of the Open Biomedical Ontologies (OBO) 
Foundry  [3], in particular: 
- CMO is restricted to the morphological characterisation of bacterial colonies and, 
therefore, it contains just model concepts and relations that are relevant to the representation of 
colony data; 
- CMO should be used for annotating data in databases and for textual documentation and 
as such, it should be understandable to people and unambiguously interpreted by software; 
- CMO development follows a pragmatic approach that grants the ability to integrate new 
morphological descriptors as they arise without affecting the existing ontological structure; 
- any bacterial colony morphology should be comprehensively described by a combination 
of CMO instances; 
- whenever possible, CMO terms are cross-referenced to entries on other ontologies 
covering for phenotypic characterisation. 
The ontology was constructed using the OBO-Edit editor, an open source platform that allows the 
editing of OBO-alike ontologies (http://oboedit.org/)  [4]. Five pre-defined OBO tags were used to 
represent the CMO terms, including id, name, synonym, def and xref (Figure 5.2).  
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Figure 5.2. CMO viewed in OBO-Edit editor. OBO- Edit editor has multiple panels that can be used to display the overall 
graph structure of an ontology, id, name of the terms, definitions, external references (xrefs) and alternative names 
(synonyms). 
 
5.2.2. MorphoCol knowledgebase 
MorphoCol is a publicly Web-accessible knowledgebase that documents bacterial colony 
morphotypes, as comprehensively as possible, in order to enable the search and comparison of 
morphotypes across species (and strains) and conditions (namely, diseases and colonisation sites). 
Currently, the main source of information is scientific literature and manual curation grants the high 
quality of the data available. The curation pipeline (Figure 5.3) will be gradually incorporating 
automatic procedures, namely text mining processes, now that we have in hand an appropriate 
terminological resource and the minimum set of information necessary to comprehensively describe 
a morphotype. Likewise, the knowledgebase will enable the direct submission of morphotype data 
by authors, promoting a close interaction with the community.  
MorphoCol server runs on a CentOS platform (version 5.6) with Apache HTTP server (version 
2.2.22), MySQL Community Server (version 5.1.58) and PHP 5.5.3. Apache, MySQL and PHP 
technology are open-source and platform-independent software. Moreover, MySQL supports multi-
threading and multi-user environments, and thus it is well-suited to support (increasing) real-world 
database usage. Currently, the Web server and all parts of the database are hosted at the Centre of 
Biological Engineering of the University of Minho, Portugal. 
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Figure 5.3. An overview of the information curation pipeline of MorphoCol. Colony morphotype curation starts with document 
retrieval via PubMed. Once all relevant information has been flagged, curators annotate the morphotypes using 
morphological features of colonies using CMO and PATO controlled vocabularies, and link morphotypes to the 
corresponding phenotypic and molecular data. MorphoCol search engine enables users to retrieve and compare 
morphologies, ranking results according to keywords of interest and grouped by bacterial species. 
 
5.3. Results and Discussion 
5.3.1. CMO structure and contents 
Hierarchical ontologies, such as CMO, hold information about the structure of specific knowledge 
domain at varying degrees of detail allowing thus to have different levels of resolution. An important 
issue while defining the organisation of the CMO was the ability to perform updates without causing 
major changes in the structure. To this end, the high level nodes of the ontology represent the 
general concepts behind the morphological features more frequently discussed in literature, 
including ‘form’, ‘margin’, ‘type of surface’, ‘texture’, ‘sheath’, ‘opacity’, ‘elevation’, ‘consistency’, 
‘size’ and ‘colour’ (Figure 5.4). CMO encompassed thus a total of 10 main categories and 45 sub-
categories. Table 5.1 presents the definitions of the main concepts. 
The CMO ontology files, including terms, definitions and relationships, are freely available at the 
MorphoCol Web knowledgebase for bacterial colony morphotypes (http://morphocol.org) and the 
portal of the international consortium Minimum Information About a Biofilm Experiment (MIABiE) 
(http://miabie.org). 
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Figure 5.4. Structure of the CMO with definitions of some terms directly imported or adapted from the PATO. 
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Table 5.1 Conceptual definitions of the main categories of CMO. Each term is represent by an unique id (CMO:00000) and a 
name.  
Entity Description 
colony form 
(CMO:0000001) 
A morphological quality inhering in a colony by virtue of having a configuration. 
colony margin 
(CMO:0000002) 
A morphological quality inhering in a colony by virtue of having a limit zone. 
Colony sheath 
(CMO:0000005) 
A morphological quality inhering in a colony by virtue of having a closely 
enveloping part or structure after the margin and around the colony. 
Type of surface 
(CMO:0000003) 
A morphological quality inhering in a colony by virtue of having morphological 
features present on its outer layer. 
colony texture 
 (CMO:0000004) 
A morphological quality inhering in a colony by virtue of having a characteristic 
physical structure or composition or representation of the appearance, 
organization and distribution of its surface elements. 
Colony elevation 
(CMO:0000007) 
A positional quality inhering in a colony by virtue of vertical distance of a point 
above or below a reference surface. 
Colony consistency 
(CMO:0000008) 
A physical quality inhering in a colony by virtue of having density, firmness, or 
viscosity. 
Colony opacity 
(CMO:0000006) 
An optical quality which obtains by virtue of the ability of the mass of the colony 
to absorb visible light. 
Colony size 
(CMO:0000009) 
A morphological quality inhering in a colony by virtue of having a physical 
magnitude. 
Colony colour 
(CMO:0000010) 
A composite chromatic quality composed of hue, saturation and intensity parts. 
 
5.3.2. PATO as ontological reference 
Multiple ontologies have been proposed in the domain of phenotypes. Some are specialised in the 
characterisation of species (typically, model organisms), such as the Mammalian Phenotype 
ontology (MP)  [5], the Worm Phenotype ontology (WPO)  [6], the Plant Trait ontology (PO)  [7] and 
the Human Phenotype ontology (HPO)  [8]. Others, like the Phenotype and Trait ontology 
(PATO)  [9], are focused on integrating phenotypes across species, and reuse anatomy and 
process ontologies.  
The analysis of existing phenotypic ontologies, such as PATO, MP, WPO, PO and HPO, revealed a 
number of terms in common. However, PATO is the only ontology that provides taxon-independent 
and general phenotypic descriptors, which is one of the main requirements of the CMO design.  
No CMO term is defined identically to a PATO term. A total of 43 terms of PATO (Figure 5.4) were 
adapted to fit the CMO domain. For example, the term ‘circular’ (PATO:0000411) in PATO is 
defined as "a shape quality inhering in a bearer by virtue of the bearer's being such that every part 
of the surface or the circumference is equidistant from the center" and in CMO is defined as "a form 
feature inhering in a colony by virtue to present a configuration of a circumference or a circle due to 
any point of the edge be equidistant from the center". So, the labels of the CMO terms were altered 
to prevent any confusion about the CMO and PATO terms and their definitions. For example, 
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‘circular colony form’ (CMO:0000011), ‘smooth colony texture’ (CMO:0000025), ‘transparent colony 
opacity’ (CMO:0000030), ‘flat colony elevation’ (CMO:0000034), ‘viscous colony consistency’ 
(CMO:0000041), and ‘colony colour’ (CMO:0000010). The adaptation of terms and definitions was 
also motivated by differences in the organisation of the PATO and the CMO, and affected 14 terms. 
For instance, the term ‘lobate’ (PATO:0001367) in the PATO is “a surface feature shape quality 
inhering in a bearer by virtue of the bearer's having deeply undulating edges forming lobes” whilst 
the term ‘lobate colony margin’ (CMO:0000019) in the CMO is not a surface feature shape quality, 
but rather a margin feature quality.  
A total of 10 CMO terms did not find any correspondence with PATO due to semantics differences. 
For example, the term ‘small’ (PATO:0000587) is described in the PATO as “a size quality which is 
relatively low”, but in the scope of bacterial colonies the definition of ‘small colony size’ 
(CMO:0000045) is more specific, i.e. “a physical magnitude 10 times smaller than the diameter of 
the wild-morphotype”. 
 
5.3.3. Web application – MorphoCol knowledgebase 
The volume of phenotypic data on bacterial colonies is growing considerably due to the use of high-
throughput experimental procedures and analytical methods, and the impressive ability of bacteria 
to diversify under several environmental conditions. The variety of morphotypes within and across 
species is great, and requires expert knowledge on the formation of colonies and on the pathogenic 
bacteria under study in order to describe the observed morphological features comprehensively. It 
is of upmost importance that experimental design and morphological annotation must be consistent 
in order to allow the systematic comparison of morphotypes across experiments (and laboratories), 
species, diseases and clinical samples. Currently, free-text description and searching is the basic 
form to report and retrieve information, which is extremely limited because of the inherent ambiguity 
and lack of accuracy and specificity. Researchers are in need of new resources and tools geared to 
systematically analyse morphotypes, across infections, body locations, antimicrobial treatments and 
a number of other conditions of clinical relevance. Web-knowledgebase and biomedical ontologies 
are the key to organise and standardise terminology and describe relevant morphological features 
unambiguously. 
Concerning data organization in the MorphoCol repository, it should be made simple and intuitive so 
that the complexity of the studies would not affect the clear and unambiguous presentation of the 
colony morphology traits, the related results and biological contextualisation. In the scope of this 
bioinformatics initiative, a novel ontology on colony morphology was prepared to describe the 
overall concept of morphological traits of bacterial colonies. The immediate application of the CMO 
is the sharing of current understanding of the variation of colony morphology in microbial infections 
among domain experts, both clinicians and researchers. Furthermore, the CMO may be of help to 
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information retrieval applications, providing vocabulary and taxonomy that can be used for query 
expansion and semantic searching in this domain.  
The MorphoCol knowledgebase is supported by the CMO and aims to help manage the fast 
proliferation of information about colony morphology. The description of colony morphotypes using 
CMO provides a practical way to capture the biologically relevant information about the 
morphotypes in a machine-readable form. Moreover, it allows to compare, combine and analyse 
different colony morphotypes obtained from different species, strains, patients and laboratories. 
Currently, documentation efforts are focused on morphotypes exhibited by pathogenic bacteria 
causing respiratory infections, one of the most prevalent types of infection worldwide. Typically, 
respiratory human pathogens, such as P. aeruginosa, S. aureus, Klebsiella pneumoniae and 
Dolosigranulum pigrum. The identification of clinically significant colony morphotypes is of 
tremendous importance because colony observation is quite immediate and costless when 
compared to state-of-the-art identification methods. Even without pinpointing the strains involved, 
morphotypes comparison may provide insights on, for instance, the stage of infection (early, 
intermediate or chronic) and the resistance and virulence levels to be expected from the bacteria. 
To achieve those goals, colony morphology signatures should be self-contained, i.e. there should 
be enough information about the purpose and execution of the experiment as well as the analysis of 
results. As such, colony morphologies are to be documented with various descriptive metadata 
(Figure 5.5), that is data of data, including information about the experimental conditions. 
Experimental information is related to the “circumstances” in which colonies were formed since 
bacteria collection (in case of clinical samples, e.g. lungs, blood, urine, wounds, catheters), in vitro 
growth conditions (e.g. the type of culture - planktonic or biofilm -, type of solid media, temperature, 
pH, colony growth time, oxygen concentration), a posteriori bacterial characterisation (e.g. MIC and 
MBC determination, virulence factors expression and metabolomics, proteomic and transcriptomic 
profiles) and the statistical validation (i.e. the number of replicates and reproductions performed). 
The description of such information is of upmost importance because morphotypes are fully 
comparable only for similar methods under identical conditions. Also to effectively search, analyse 
and compare data performed in the same conditions it is need that metadata will be well organized 
and semantically integrated. Thus, the lexicon used should be universal, familiar and unequivocal. 
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Figure 5.5 The flowchart of the MorphoCol annotation process. Colony data annotation consists of the curation of 
morphological, experimental metadata and details followed by manual confirmation. After validation, morphotype data record 
is available online for information retrieval and formulation of new hypotheses. 
The major challenge to be faced in documenting colony morphology characterisation experiments 
and results is the complexity and variability of studies. The management of such heterogeneous 
metadata is complicated and raises several quality issues, such scarcity of standardised protocols, 
poor metadata quality and incomplete data sets, which affects significantly the quality of the results 
being stored in MorphoCol. This problem is not exclusive of colony morphology knowledge domain. 
Biofilm community has already detected difficulties of manage their heterogeneous data and 
metadata and has initiated efforts to overcome such barriers. The international Minimum 
Information	   About a Biofilms Experiment (MIABiE) initiative (http://miabie.org) is working on the 
harmonisation of biofilms procedures and associated data. To overcome some difficulties MIABiE 
initiative developed as well an ontology on biofilms and their study – the Biofilm Ontology (BO)  [10] 
– and a web-repository – BiofOmics  [11]. BO was designed to develop shared, structured and 
accurate vocabularies for the annotation of the general biofilm experimental workflow. For those 
colonies coming from biofilms MorphoCol is supported by BO. However, to accomplish the main 
goal of MorphoCol, to be a relevant auxiliary clinical decision making tool, information related to 
morphotypes must be indexed using whenever possible ontologies or controlled vocabulary 
accepted by scientific communities. Table 4.2 presents some of the intended ontologies and 
controlled vocabularies that will support MorphoCol in near future. 
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Table 5.2. Some predicted ontologies and controlled vocabularies that may support MorphoCol. 
 
Some efforts had been initiated in indexing experimental information to colony morphotypes related 
to microorganism description, conditions of morphotype observation, in vitro growth conditions and 
phenotypic characterisation of morphotypes, in particular antimicrobial resistance profiles (Figure 
4.5). Related to the conditions in which colonies are observed it is discriminate the solid media, 
temperature and oxygen availability used to originate the morphotype. At the colony source level, it 
is describe the origin of bacteria that form the morphotype. For instance, for in vitro studies it should 
be describe whether bacteria coming from a planktonic culture or biofilms. For clinical samples or 
others it should be describe all known characteristics of the sample, for instance, patient status 
(normal or infected), infection name, body location or fluid. Phenotypic data was also indexed to 
morphotypes and it was started integrating the antimicrobial susceptibility data due to the impact on 
clinical field. At this level authors should describe the agent, the method used to determine 
susceptibility (E-test, microdilution, disk diffusion method), the international standards used to 
categorize bacteria (e.g. EUCAST or CLSI) and the value of susceptibility (S – susceptible or 
sensitive, I – intermediate or R - resistant). 
Ontology/ 
controlled vocabulary Source Reference 
Chemical entities of biological 
Interest (CHEBI) 
http://obo.cvs.sourceforge.net/obo/obo/ontology/ch
emical/chebi.obo 
 [12] 
Infectious Disease Ontology (IDO) http://www.bioontology.org/wiki/index.php/Infectiou
s_Disease_Ontology 
 [13] 
Gene ontology (GO) http://obo.cvs.sourceforge.net/obo/obo/ontology/ge
nomic-proteomic/gene_ontology.obo 
 [2] 
Functional Genomics  
Investigation Ontology (FuGO) 
http://sourceforge.net/projects/fugo/  [14] 
MALDI imaging ontology (IMS) http://www.maldi-
msi.org/download/imzml/imagingMS.obo 
 [15] 
PSI-Mass Spectrometry (MS) http://psidev.cvs.sourceforge.net/viewvc/psidev/psi/
psi-ms/mzML/controlledVocabulary/psi-ms.obo 
 [16] 
PSI-Sample Processing and 
Separations (SEP) 
https://psidev.svn.sourceforge.net/svnroot/psidev/p
si/sepcv/trunk/sep.obo 
 [15] 
PRIDE controlled vocabulary http://code.google.com/p/ebi-
pride/source/browse/trunk/pride-
core/schema/pride_cv.obo 
 [17] 
Protein ontology (PRO) http://obo.cvs.sourceforge.net/obo/obo/ontology/ge
nomic-proteomic/pro.obo 
 [18] 
Phenotypic And Trait Ontology  
(PATO) 
http://obo.cvs.sourceforge.net/obo/obo/ontology/ph
enotype/unit.obo 
 [9] 
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The morphotype data record is manually verified in order to ensure its quality and thus allow 
clinicians and researchers to consider such data in their analyses and the formulation of new 
hypotheses. 
MorphoCol also “credits” information. The experiment is profiled in terms of authorship (institution 
and person of contact), the data scope, the date of execution, a summary of its main findings 
(produced by the authors), eventually other notes of interest and derived publications.  
 
 
Figure 5.6. Different levels of information associated to a colony morphotype. (A) Morphological data: description of colour, 
consistency, diameter, elevation, form, margin, opacity, sheath, size, surface, texture; (B) Authorship; (C) Description of the 
microorganism; (D) Conditions in which morphotype was observed; (E) Colony source: description about the bacterial origin; 
(F) Antimicrobial susceptibility profile: discrimination of the bacterial response against antimicrobial agents.  
 
5.4. Conclusions 
Several authors have documented colony morphologies in clinical settings and have shown that 
morphological features may be indicative of underlying microbial cues, and most notably, of 
resistance and virulence responses  [19, 20]. Nowadays, it is demand the clear association 
between morphological features and antibiotic resistance, virulence factors expression and the 
identification of biomarkers. The key to satisfying this need is the ability to describe different colony 
morphotypes in a consistent and structured way and also to sharing the clinical findings regardless 
source of the clinical samples. This led to the development of a specialised method of analysis that 
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aims to deliver useful inputs to more elaborated (and costly) studies, and assistance to clinical 
decision making.  
The originality of this work lays on addressing colony morphotyping in a systematic, harmonised 
and computerised way. The development of the CMO, the first ever controlled vocabulary on colony 
morphology, and the MorphoCol knowledgebase are considered an important step forward for 
enabling the standardised and systematic annotation of morphotypes. For the first time, there is a 
knowledgebase dedicated to the management of data related to colony morphotypes, including 
morphological data and experimental metadata. This knowledgebase provides the basic means to 
enquire and compare the visual manifestations of bacterial evolution and adaptation processes 
across pathogenic microorganisms and infections. Although still in its infancy, MorphoCol aims to 
pave the way to the development of advanced clinical decision making applications, which may use 
morphological features as immediate indicators of microbial behaviour. These indicators can be 
used to guide more sophisticated (time-consuming and costly) analyses, such as proteome and 
transcriptome analyses. Also, they may be used to construct decision support models that help 
clinicians in determining or anticipating what may be expected in terms of a given microbial species 
resistance and resilience in a clinical incident. To the best of our knowledge this is the first public 
repository documenting bacterial colony morphology systematically. 
In the short term, efforts will be focused on extending the description of the pathogenic potential of 
colony-forming bacteria, particularly regarding the expression of virulence factors, such as the 
ability to form biofilms, the production of toxins and quorum-sensing molecules. Moreover, the query 
tool will be complemented by a customisable comparison tool that looks for morphological 
similarities across species, infection sites and diseases. Therefore, the tool will provide insights on 
the most relevant traits of colony morphology under a given clinical scenario, which may be useful 
as predictive features of the virulence potential and resistance profile of bacteria causing the 
infection.  
Currently, the system documents respiratory infection traits, but in the future it will cover other major 
infections regarding the urinary tract, bloodstream, chronic wounds, osteomyelitis and biomaterial-
associated infections. MorphoCol will be thus of aid to the wider community of researchers and 
clinicians working in clinical microbiology. 
MorphoCol welcomes contributions from any research group working on the characterisation of 
clinically relevant morphotypes, crediting data authorship and associated bibliographic references.  
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6.1. General conclusions 
While CF community awaits the development of effective therapies targeting CFTR mutations, the 
management of microbial infections remains the primary focus. CF lungs shelter an impressive 
number of microbial species, but P. aeruginosa has excelled due to the association with rapid poor 
lung function and impressive persistence in CF lungs despite the long and aggressive antibiotic 
courses. P. aeruginosa long persistence is mainly due to clonal diversification into well-adapted 
phenotypes to CF environmental conditions with diverse phenotypic traits altered. This phenotypic 
diversity is observed when isolates from CF lungs are plated on solid medium and exhibited diverse 
colony morphology variations, for instance mucoid consistency and small size. Furthermore, some 
colony morphological traits are also associated with altered virulence factors expression and 
antibiotic resistance. Therefore colony morphology variation is considered an indicator of clonal 
diversification.  
The key factor to avoid clonal diversification, bacteria adaptation and chronic infections 
development is the early eradication of P. aeruginosa. To achieve a successful early eradication, it 
is need understanding the adaptation mechanisms used by P. aeruginosa so that effective 
antimicrobial strategies could be design and prevent antibiotic resistance, re-infection episodes and 
progression to chronic stages. As so, this study aimed to provide to CF community valuable insights 
about the early adaptation mechanisms used by P. aeruginosa, the respective driven forces and the 
early adaptation and infection development markers. 
Colony morphology characterization is an old microbial technique that usually complements the 
microbial diagnosis. Despite its long use, it is not clear the impact of the experimental procedures 
on colony morphogenesis. Moreover, the vocabulary and concepts used to describe colonies is 
inconsistent among reports and it is not updated for years. Since P. aeruginosa clonal diversification 
and evolution would be evaluated based on colony variation, it was considered fundamental to 
verify first which parameters affect colony morphogenesis and the detection of colony diversity. All 
experimental factors analysed, including solid medium, time of colony growth, number of colonies 
per plate, bacteria mode of growth (planktonic and biofilm) and genetic background demonstrated to 
have impact on colony morphology definition. The perception of colony morphologies dependence 
of experimental conditions allowed fitting the actual performance of clinical diagnosis culture-based 
approaches and a set of guidelines was proposed for authors, clinicians and technicians to 
implement when performing colony morphology characterization. CF community will great benefit 
with similar experimental procedures of colony morphology characterisation when comparing results 
with other centres and studies, leading to a better comprehension of bacterial adaptation and 
evolution.  
Some improvements at colony lexicon level were also performed. The vocabulary used to describe 
bacterial colony morphologies was updated and organized in a structured way. At the end, a 
classification system was proposed to unambiguously characterise colonies. This system was 
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deeply tested using several bacterial species and demonstrated to be adequate for colonies of any 
bacterial species. Modifications and updates to this classification system suggested by 
microbiological community are very welcomed. The system was constructed to be easily modified 
without structural constrains. 
Colony morphology characterisation is a culture-dependent method and this significantly delays 
results delivery. Currently, microbial diagnosis demands high-throughput analysis and automated 
systems that can return rapid and reliable results. Therefore, culture-independent methods present 
an attractive approach to detect, identify and characterize pathogens. As colony morphology 
characterization has great potential in clinical diagnosis some efforts were performed to make 
colony morphology characterization an advanced method using MALDI-TOF MS. It was verified the 
capability of MALDI-TOF MS provide similar colony categorisation to the manual morphotyping. The 
results obtained revealed that MALDI-TOF MS did not return similar results than manual colony 
morphotyping. The distinct results obtained may due to the MALDI-TOF MS criteria were based on 
molecular profiles that could be not analysed by naked eyed as in colony morphology 
characterisation. As so, MALDI-TOF MS was not able to “replace” manual colony morphology 
characterisation, but it could be used as complementary method.  
The extensive P. aeruginosa diversification in CF-adapted phenotypes could be also caused by the 
presence of biofilm growth within CF sputum. Biofilms are the underlying cause of chronic infections 
and thus their early detection is of upmost importance to CF disease management. Classically, 
there is a temporal window for successful eradication until bacteria switch to sessile lifestyle. Before 
biofilm formation, bacteria are more sensitive to antimicrobial agents and infections are thus more 
easily eradicated. After biofilm formation, P. aeruginosa is hardly eradicated mostly due to 
multifactorial resistance mechanism of biofilms. Therefore, the determination of the timing and the 
driven forces of bacteria switching mode of growth is upmost importance for early eradication 
treatments. As colony variants of biofilm cells were distinct from their planktonic counterparts as 
previously evidenced, the determination of the timing and the driven forces of bacteria switching to 
biofilms could be facilitated through a colony marker of biofilms. Therefore, it was verified whether 
P. aeruginosa biofilm cells had characteristic colony morphology. The results revealed that P. 
aeruginosa strains produced biofilms with distinct population diversity and a biofilm colony variant 
marker was not found. SCV was found as a strong indicator of biofilm growth.  
Given the distinct P. aeruginosa biofilm populations with different number of colony variants with 
different morphological traits, it was investigated the role of population diversity in biofilm 
pathogenesis potential. Population diversity seemed to have no impact on biofilm pathogenesis, but 
the absence of SCV was associated with increased biofilm virulence potential, notably in the 
amount of biofilm mass produced.   
To design effective early treatments for P. aeruginosa eradication, it is important the investigation of 
the adaptation mechanisms that P. aeruginosa uses when colonizes new environments and when 
challenges by antibiotic treatments. To closely mimic CF lungs environment, it was used ASM, an 
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experimentally determined composition of CF sputum that can support similar P. aeruginosa growth 
and adaptations as found in real CF lungs. Furthermore, different antibiotic regimes were simulated. 
Early and delayed ciprofloxacin treatments using different dosages, correspondent to sub- and MIC 
of biofilm cells, were tested to investigate the P. aeruginosa response. From the results obtained, it 
was concluded that substantial phenotypic diversity is likely to be present in P. aeruginosa 
populations shortly after CF lungs colonization. Ciprofloxacin concentrations had impact in success 
rates of the treatments. Early treatments using sub-inhibitory concentrations were ineffective in 
bacteria eradication and triggered population diversification into phenotypes better “fitter” to CF 
conditions. Delayed antibiotic therapies could have unpredictable results being the eradication 
results dependent of the adaptive ability of P. aeruginosa strains. Impaired swimming motility was 
the initial adaptation noticed in all P. aeruginosa strains exposure or not to ciprofloxacin treatments. 
This adaptation seemed to be driven by the environmental CF conditions, possibly by the presence 
of mucin. It was thus concluded that defective swimming motility is a potential disease marker of 
early stages. Colony morphology traits revealed to be promising indicators of antibiotic resistant and 
virulence expression.  
Given that the ultimate aim is to rationalise morphological and biological associations within and 
across species, and across infections, molecular, proteomic, transcriptomic and genomic profiles, it 
was developed the first knowledgebase dedicate to bacterial colony morphologies, called 
MorphoCol. MorphoCol attempts to standardise annotation of morphotypes and, in addition, 
manage data related to colony-forming bacteria, such as phenotypic, transcriptomic and proteomic 
information. Although still “younger”, MorphoCol in near future will provide the correlation of 
morphotypes to resistance and virulence cues, and enhance the understanding about the different 
responses of bacteria to antimicrobial therapies in acute and chronic infections. Altogether, these 
data will provide valuable inputs to clinical research and decision-making. 
In summary, progresses were made in the identification of the initial P. aeruginosa adaptations and 
their driven forces, in identification of a promising disease marker and lastly in identification of new 
indicators of altered virulence potential and antibiotic resistance. These results will certainly impact 
on the diagnosis of CF-associated infections and in the antimicrobial stewardship of those 
infections.  
 
6.2. Future research lines 
The current challenge for clinicians and researchers is to translate the stages of P. aeruginosa 
adaptation steps and infection stages into clinical markers in order to perform adequate and 
effective clinical interventions that will significantly improve the therapeutic outcomes. In this project, 
some putative clinical markers of early stage of CF disease and promising indicators of altered 
virulence potential and antibiotic resistance were pointed out, but more work has to be done to 
validate these outcomes.  
FINAL REMARKS 
 220 
P. aeruginosa is remarkably plastic in its ability to colonize and growth in so different environments. 
This success needs an explanation and an overall picture of the adaptive and evolutionary pathway 
will be always valuable. CF lungs are extraordinary complex habitats where there are quite diverse 
environmental (pH, oxygen, DNA, amino acids, mucin concentrations, different antibiotic 
treatments) and biological conditions (other bacterial species, fungi and virus). To draw an adaptive 
and evolutionary profile of P. aeruginosa, it is essential to reflect the full complexity of this habitat in 
order to encompass all the adaptive possibilities. Nevertheless, it must be aware that evolution is 
somewhat unpredictable. 
From an experimental point of view, it is a hard task to integrate all the environmental and biological 
ingredients into a single experiment. Clinical and microbiological studies are mainly based on 
cause-and-effect approach that helps to identify a likely cause of a problem. With such amount of 
possible clinical scenarios, it would be need to add a lot of variables at the same time resulting in a 
very hard task to find out the significant mechanisms used by P. aeruginosa to face certain clinical 
scenario and their driven forces. Therefore, P. aeruginosa evolutionary pathway and adaptation 
must be constructed “piece by piece” as a “puzzle”. The results obtained with this project are the 
first pieces of this quite complex puzzle. In fact, in this project, P. aeruginosa was studied alone, 
grown in common CF sputum conditions and in the presence and absence of ciprofloxacin, 
conditions that are a bit away from the real scenario. One of the most remarkable features of CF 
lungs is the impressive number of microbial species that can reside and co-exist. This feature is of 
upmost importance in the context of infections control and, in particular, P. aeruginosa-associated 
infections. It is thus paramount the detailed investigation of how P. aeruginosa diversity, 
pathogenesis and stress response are influenced by the presence of other pathogens and vice-
versa. It is important determine 1) which are the organism or combinations of pathogens that 
augment the pathogenic potential of P. aeruginosa; 2) what is the impact of antibiotic therapies on 
mixed populations; 3) what are the interactions established among pathogens; and 4) what is their 
impact on antibiotic resistance. To answer these questions, it is important to previously know the 
adaptive mechanisms used by P. aeruginosa when grown alone in CF sputum in order to better 
identify the differential adaptive behaviour of P. aeruginosa when grown with other species.  
After the development of this project and still regarding early CF infections, it would interesting to 
study the interactions between P. aeruginosa and S. aureus. The prevalence of S. aureus is mainly 
observed in younger patients with few years and frequently precedes P. aeruginosa colonization. 
Some evidences have pointed out that S. aureus somewhat prepare the CF environment for P. 
aeruginosa colonisation. During colonization, S. aureus secrete several exoproducts that could 
influence P. aeruginosa colonization and growth in CF lungs. These factors must be identified and 
their role in P. aeruginosa adaptation and microevolution understand. Furthermore, it would be 
important to determine the clinical implications of interspecies interactions concerning the efficacy of 
the antibiotic treatments. Through these experiments, more “pieces” could be added to the P. 
aeruginosa adaptation/evolution “puzzle”. 
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In chronic stages of CF disease, Bcc bacteria colonises CF lungs sharing the habitat with P. 
aeruginosa and sometimes also with S. aureus originating a polymicrobial community commonly 
found in CF patients. There is scarce information about the impact of the presence and interactions 
with Bcc on P. aeruginosa pathogenesis. The study of these mixed communities will bring out 
information helpful to construct the P. aeruginosa network with other bacteria and to understand 
how it is used to persist in CF lungs. Through the expected results of this project with those 
obtained with the previous experiments it could be possible to detect the (differential) mechanisms 
used by P. aeruginosa to persist in CF environment. All these experiments will help to assemble the 
quite complex “puzzle” of P. aeruginosa adaptation to CF lungs. Furthermore, these experiments 
with mixed communities (P. aeruginosa and S. aureus and P. aeruginosa, S. aureus and Bcc) will 
allowed gaining a temporal perspective of an infection course in CF patients.  
Other pathogens could be successively added to the experiments in order to closely mimic the real 
microbiome including H. influenza, S. maltophilia and, most important, anaerobic species. Few 
published clinical reports have studied the impact of mixed communities containing anaerobic 
species and thus it is still unknown their clinical significance and the impact of the in-use antibiotic 
therapies on those species and communities.  
In the study of P. aeruginosa adaptation of CF lungs, it could not be forgotten the influence of 
airway mammalian cells. To more closely mimic the real CF lung scenario, P. aeruginosa should be 
co-cultured with airway mammalian cells to simulate the signals that bacteria receive from airway 
cells immediately after CF lungs colonization. About this issue, it should be noted that still lacks an 
adequate animal model to study bacterial infections in CF context and by this reason the 
identification of the adaptation mechanisms is an hard task. 
To construct the adaptive and evolutionary pathway of P. aeruginosa since initial CF colonization 
until chronic infection development based only on phenotypic data is important but it is not enough. 
The evolutionary pathway of P. aeruginosa is distributed to phenotypic, structural, metabolic, 
proteomic, regulatory and genomic rearrangements to culminate in optimized growth rate [#1325]. 
All the research lines afore described should follow a phenotypic approach, but integrating also 
metabolomic, proteomic and transcriptomic approaches. None of these approaches are powerful 
enough to provide a real picture of P. aeruginosa evolutionary pathway, but combined it would be 
possible to obtain a global picture about what happen to P. aeruginosa at several cellular levels. 
Therefore understanding interspecies and bacteria-host interactions, the “adaptomic” description of 
P. aeruginosa will be complete and effective and tailored therapies could be design to eradicate 
bacteria from CF lungs.  
